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Abstract
We have addressed the role of Fyn in T cells using two different transgenic mouse 
systems. Using the class I-restricted F5 TCR transgenic model, we found that Fyn 
CD8 cells showed normal triggering and entry into cell division over a range of 
peptide concentrations, but subsequently proliferated more than WT CD8 cells. 
Increased proliferation of F5 Fyn cells was driven by their ability to produce more 
IL-2. which occurred only after cross-linking TCR and CD8 molecules with 
antibodies or pMHC, not by triggering through the TCR alone. Additionally, F5 Fyn 
cells showed differences in the induction of specific AP-1 members that could 
influence IL-2 production. F5 F yn ' cells required only 1 hr stimulation with Ag to 
commit to IL-2 production, whereas F5 WT cells needed -5  hrs, and yet IL-2 
production by Fyn cells remained sensitive to the Src-inhibitor PP2, added after 3 
hrs. These data suggest that loss of Fyn uncouples Lck activity from the need for 
sustained exposure to antigen and therefore, that Fyn acts as a negative regulator to 
limit IL-2 production in CD8 T cells. Not only was proliferation of F5 Fyn ' cells 
increased compared to WT controls, but so was the CTL response as judged by 
effector molecule expression and also specific killing activity. Like the increase in 
proliferation, the improved generation/function of Fyn7 CTL compared to WT was 
dependent on the levels of IL-2 produced by these cells.
In our second transgenic model, Fyn7 mice expressing reduced amounts of Lck were 
generated. These animals develop a fatal lymphoproliferative disorder, characterized
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by gut pathology and weight loss, an expansion of effector-memory like CD4*CD44" 
cells, and the appearance of anti-nuclear antibodies (ANA). Disease was ameliorated 
by turning off Lck expression, suggesting that an appropriate balance of Lck and Fyn 
activity is required in vivo to achieve cell survival without stimulating autoimmunity. 
Our data provides functional in vivo and in vitro evidence for a regulatory role for 
Fyn in both CD4 and CD8 T cells.
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Chapter 1: Introduction
1.1 The branches of the immune system
Our immune system wages a constant battle against infectious agents present in the 
environment and is composed of several cell types that eliminate bacteria, viruses and 
other foreign agents from our bodies. This response can generally be subdivided into 
two branches called the innate and adaptive immune systems. Successful immunity 
from an invading pathogen is often achieved by the independent and synergistic 
functions of both these two systems.
1.1.1 The innate immune system
Innate immunity is considered to be the first line of defence against an invading 
pathogen. It functions by recognising the conserved features that are generally 
referred to as pathogen-associated molecular patterns (PAMPS), which are 
components of bacteria, fungi, protozoa and viruses. Due to its generalised nature, 
innate immunity can respond almost instantaneously to challenge and does not 
require prior exposure to the invading organism.
1.1.2 Protective barriers
The epithelium is the first component of the innate system that an infectious agent 
must overcome to gain a foothold in the body. Pathogens often cross the epithelium 
at internal sites such as the lungs or gastrointestinal (GI) tract as the outer skin is
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relatively tough and impermeable. At the inner epithelial sites, a number of 
generalised mechanisms exist to prevent pathogen access. These include the 
secretion of mucus that can coat microorganisms preventing them from crossing the 
epithelial barrier, and chemicals such as lysozyme, present in tears and saliva, that 
inhibit microbial growth. Furthermore, epithelial cells are also bathed in a fluid 
containing anti-microbial agents such as surfactant proteins A and D. These bind 
pathogens and facilitate their removal by specialised cell types such as macrophages.
1.1.3 Macrophages and neutrophils
Macrophages are mononuclear cells that are present in tissues including the lung and 
GI tract. In contrast, neutrophils normally reside in the blood and migrate to the site 
of infection in response to soluble factors. Both cell types act by recognising and 
ingesting pathogens by virtue of receptors expressed on their cell surface. 
Phagocytosis is an active cellular process that involves the enclosure of the pathogen 
within the phagocytic membrane to form a structure called a phagosome. This then 
becomes fused with the cellular destructive machinery termed lysosomes, forming a 
phagolysosome. These structures contain enzymes such as lysozyme that mediates 
destruction of the pathogen. Macrophages and neutrophils also directly mediate the 
destruction of invading microorganism by the secretion of toxic molecules such as 
H20 2 and NO. Furthermore, macrophages can also secrete cytokines such as IL-1, 
IL-6, IL-12, and TNFa, and chemokines such as IL-8. The cytokines serve to activate 
other cells involved in the immune response such as T cells and DCs. However 
chemokines act by bringing other cells types including neutrophils and more
26
macrophages to the site of immune challenge. This massive tissue infiltration leads 
to localised inflammation. Moreover the macrophage-derived TN Fa increases 
vascular permeability allowing access of blood born immune cells to the site of 
infection. Furthermore, TN Fa, IL-1 and IL-6 can also raise body temperature 
slowing the rate of pathogen growth, as well as induce the production of acute-phase 
proteins that have properties similar to antibodies without the specificity. It should 
also be noted that activated macrophages upregulate the expression of specific surface 
molecules that enable them to act as professional APC and present antigen to T cells. 
Therefore, macrophages can also greatly influence the adaptive immune response.
1.1.4 Natural killer (NK) cells
NK cells are bone marrow derived cells that contain lytic granules much like the 
cytotoxic T cells of the adaptive immune system, however they are able to eliminate 
cells without prior antigen exposure. They are activated by macrophage-derived 
cytokines such as IL-12, and also by IFN secreted by virally infected cells. NK cells 
are also able to produce IFNy that can help to suppress viral infection. Therefore, it is 
considered that NK cells act to suppress a viral infection for the period of time 
required to mount an adaptive immune response. It is thought that NK cells are able 
to distinguish self from non-self by virtue of the receptors they express. An example 
of an NK inhibitory receptor is Ly49 that will be able to recognise normal self-MHC 
class I molecules and prevent killing from occurring. If however viral infection has 
modified the MHC class I on the cell surface then these inhibitory receptors fail 
recognise the MHC as self and fail to prevent NK mediated lysis. In the mouse there
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are also Ly49 NK receptors that recognise non-self MHC and have a pro-lytic effect. 
Therefore NK activity relies on an intricate balance of positive and negative signals. 
Furthermore, tumour cells often escape immune detection by CTL as they have lost 
MHC class I expression, however this makes them more susceptible to NK mediated 
lysis as there is no self-MHC molecule to prevent NK activation.
1.1.5 Mast cells
Mast cells are also components of the innate immune system and are found near 
surfaces in the body that are in contact with the environment, such as the GI tract, 
skin and airways. They express a number of receptors that enable them to respond to 
the presence of a pathogen, one of the most prominent being the high affinity IgE 
binding FCeRI receptor. Specific IgE produced by B cells during a Th2 immune 
response binds to the FCsRI receptor on the Mast cell. When the bound IgE 
encounters and binds its specific antigen this triggers the release of preformed 
granules containing pro-inflammatory mediators such as histamine (Galli et al., 
2005).
1.1.6 The complement system
One way in which foreign microbial agents are eliminated is through the complement 
system that is, in part, coupled to the expression of complement receptors on the 
surface of innate immune cells. In general the complement system is composed of 
multiple proteins that can opsonise pathogens for phagocytosis, activate inflammatory 
responses and also act directly on the invading organisms as proteases. In a resting
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cell, the complement proteins are present in an inactive state and become activated 
through proteolyitic cleavage. There are three pathways that can activate 
complement. Firstly, binding of the C lq complement protein to the pathogen surface 
activates the so-called classical pathway. Secondly, when the mannan-binding lectin 
serum protein binds to mannose-containing carbohydrates on the pathogen surface, 
the mannan-binding lectin pathway can be triggered. Lastly, the alternative pathway 
of complement activation occurs when spontaneously activated complement 
components bind to the pathogen surface. All pathways then activate the C3 
convertase protein that also binds to the pathogen surface and cleaves the C3 
complement protein to form C3a, a pro-inflammatory mediator, and C3b that induces 
opsonisation. C3b-mediated opsonisation is regulated by the presence of complement 
receptors on the surface of macrophages and also mast cells, these include CR1 and 
CR3. Furthermore C3b also induces the formation of membrane attack complexes 
that create pores in the cell membrane of the pathogen, inducing death.
1.1.7 Pattern recognition receptors (PRR)
Although generally thought to recognise general pathogenic structures or compounds 
present early in an infection, the innate immune system does possess some elements 
of target specificity. An example of a PRR expressed by phagocytic cells is the 
macrophage mannose receptor that can bind specific sugar residues found on the 
surface of viruses and bacteria, aiding recognition. Moreover, phagocytic cells also 
express scavenger receptors able to recognise anionic polymers and acetylated low- 
density lipoproteins that would normally be shielded from recognition by the
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presence of sialic acid modification on host derived cells. A further class of surface 
molecules important to innate immunity are the Toll-like receptors (TLR) that 
recognise the presence of various microbial constituents. For example TLR-4, in 
concert with macrophage receptor CD 14, has been shown to signal the presence of 
LPS by switching on the expression of cytokine genes that include TN Fa. 
Furthermore, TLR-2 has been shown to signal the presence of proteoglycans derived 
from gram-positive bacteria. These observations indicate that different TLR have 
different specificities for various pathogen products. Interestingly, TLR signalling 
may also assist the adaptive immune system by induces the expression of co- 
stimulatory molecules on APC that are required for T cell activation.
1.2 Adaptive immunity
While in most cases the innate immune response will be sufficient to prevent an 
infection from establishing a foothold, there are certain intrinsic failings associated 
with this response. Firstly, pathogens are constantly evolving and thus may escape 
the surveillance mechanisms of the innate immune systems due to major alterations in 
the PAMP. Secondly, some pathogens have natural mechanisms to evade recognition 
by the innate immune system. For example certain bacterial strains can secrete a 
thick polysaccharide that prevents recognition by PRR. Adaptive immunity 
overcomes many of the problems associated with the limited diversity of innate 
immunity in that it relies on the random generation of antigen receptor repertoires 
that are able to recognise almost any pathogen-derived peptide. The adaptive
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immune response requires more time than the innate as it requires a given clone that 
is initially present at low frequencies, to encounter specific antigen and undergo 
clonal expansion and differentiate into an effector cell. Therefore it can take 
anywhere between 4-7 days until the adaptive immune system is able to mount an 
effective primary response against a pathogen. The adaptive immune system confers 
immunological memory, as upon a secondary encounter with the same antigen, the 
response is much more rapid due to elevated numbers of specific clones generated by 
the primary encounter and their pre-differentiated phenotype. In contrast, the innate 
immune response will be the same regardless of the number of times antigen is 
encountered. Therefore, it is clear that the initial response against a pathogen is 
mediated by the innate system, however even if this proves insufficient the delay 
allows for the preparation of an adaptive response. Moreover, several cells and cell 
products of the innate immune system have been shown to influence the function of 
adaptive immune cells, helping to improve pathogen clearance.
1.2.1 The generation o f lymphocyte immune receptor diversity 
B cells are generated in the bone marrow, whereas T cells are generated within the 
thymus, but are both thought to originate from a common lymphoid precursor. The 
individual receptors that they express have a unique antigen specificity determined by 
the sequence of the antigen-binding site. This is made up of variable (V) regions that 
are themselves composed of a V gene segment and a joining (J) segment, and in 
certain cases the diversity (D) segment also. These separate gene segments can be 
randomly assembled in order to generate V regions, that when fused to a number of
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possible constant (C) regions form antigen receptors with almost unlimited 
specificities. Furthermore receptor diversity is also increased by other mechanisms 
including the random addition of nucleotides in the join between J and D segments by 
the TdT enzyme.
1.2.2 BCR diversity
The B cell antibody is formed from two separate polypeptide chains, heavy and light. 
There are two possible classes of light chain, X and k . In humans, the X gene locus 
contains 30 V segments and 4 J segments as well as 4 possible C segments. In 
contrast, the k  locus contains 40 V, 5 J but only 1 C segments. The heavy chain is 
not only made up of 40 V and 6 J segments, but also includes 27 D segments. Once 
the full V region is assembled it can fuse with any of the possible C regions, 
generating more diversity. This dictates the nature of the Ig formed and also its 
subsequent function. For example fusion of the Ce region to the V region generates 
IgE but if the V region associates with Cp, IgM is formed. The recombination of 
these gene segments is driven by the family of RAG enzymes. Further BCR diversity 
is promoted by somatic hypermutation, which involves the introduction of random 
point mutations into the V regions of the assembled heavy and light chains. During a 
B cell immune response, clones are preferentially selected that have improved antigen 
recognition through somatic hypermutation. This is called affinity maturation and 
occurs in the germinal centre regions. The possible combination of gene segments 
and other mutational mechanism that generate sequence diversity is thought to 
generate a possible ~1014 Ig receptor antigen specificities.
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1.2.3 B cell development
Initial B cell development occurs in the bone marrow, and can be subdivided into a 
number of different stages depending on the transitional phenotype of the cells. 
During the pro-B cell stages, the rearrangement of the D, H and J gene segments of 
the heavy chain locus occurs. Proliferation and survival of the pro-B cell is 
dependent upon cytokines such as IL-7 and also stem cell factor, both of which are 
derived from the bone marrow stromal matrix. Successful rearrangement of the 
heavy chain VDJ locus lead to the expression of the p heavy chain that, in 
combination with a surrogate light chain, forms the pre-BCR. Cells expressing the 
pre-BCR are termed pre-B cells, and can signal for the heavy chain rearrangement to 
stop. After several rounds of pre-B cell proliferation, light chain assembly begins. 
The successful assembly of a light chain VJ segment leads to the expression of a 
completed IgM molecule on the B cell surface, generating an immature B cell. At 
this stage, any B cell expressing a self-reactive BCR is thought to be removed by the 
process of negative selection, thus ensuring that autoreactive B cells are eliminated. 
However, it has been suggested that B cells expressing an autoreactive BCR have 
further chances to rearrange the light chain and no longer be self-reactive, escaping 
deletion (Gay et al., 1993). Immature B cells are then exported to the periphery, 
where they begin to express both IgM and IgD on the cell surface and recirculate till 
encountering antigen.
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1.2.4 TCR diversity
The TCR, like the BCR, is composed of two separate protein chains, a  and (3, that are 
also the product of RAG mediated gene rearrangement events. In humans the a  chain 
locus is composed of ~70 V segments and 61 J segments, whereas the p locus has 52 
V, 13 J and 2 D segments. As for B cells, the addition of random nucleotides occurs 
in the join between V and D segment, contributing to diversity. However, in T cells, 
random nucleotide addition also occurs between the V and J segments of the TCRa 
gene. Furthermore, the TCRa chain locus contains many more J gene segments than 
the BCR locus, as this region has been shown to code for the CDR3 loop of the TCR 
that forms the antigen-binding region. While the BCR can undergo mutational 
changes outside the CDR3 region, this would be unfavourable to a TCR as it is 
required to bind to the conserved features of MHC molecules, thus greatly restricting 
the sites of mutational diversity.
1.2.5 T cell development
T lymphocytes are generated from pluripotent haematopoietic stem cells (HSC) that 
are found in adult bone marrow and foetal liver. It is thought that the HSC become 
common lymphoid precursors (CLP) that can become either T, B or NK cells 
(Ardavin et al., 1993). Once inside the microenvironment of the thymus, interactions 
with the stromal cells and differentiating progenitor cells drive T cell development. 
For example Notch-1 ligation has been shown to play possible role in directing T cell 
development versus B cell formation as Notch-1'7' mice have B cell development in 
the thymus (Wilson et al., 2001). Furthermore, it has been shown that the stromal
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cells in the thymus express Notch ligands such as Delta-1 (Pui et al., 1999; Radtke et 
al., 1999). The stromal cell-derived cytokine IL-7 also plays an important role in 
driving T cell development as IL-7 '' mice show a block at the DN stage of T cell 
development (Maeurer and Lotze, 1998). In terms of in vitro B cell development it 
is possible to simply mimic this using a bone-marrow-derived stromal cell line and 
defined cytokines, however in vitro generation of T cells requires that the intricate 
microenvironment of the thymus is preserved. This has led to the use of whole foetal 
thymic organ cultures (FTOC) systems. Using this model it has been possible to 
analyse several aspects of thymocyte development, including the differentiation 
potential of various progenitors within the thymus, the importance of different 
stromal cell types in supporting this, and also it has been possible to manipulate the 
nature of signals being delivered (Zuniga-Pflucker, 2004).
The first stage of T cell development is the DN population, which can be subdivided 
into 4 populations based on the CD25 and CD44 expression profiles. During CD25 
upregulation at the DN1 stage, cells will begin to rearrange and express the TCR 
genes. Cells that successfully rearrange y and 6 genes express the y5 TCR and 
become cells of the y5 lineage. Interestingly, IL-7 may also play a role here as 
overexpression of IL-7 seems to preferentially drive cells to the y8 lineage (Maeurer 
and Lotze, 1998). However those cells that successfully rearrange the p chain locus 
are able to form a functional pre-TCR with the pre-Ta chain and undergo (3 selection, 
making the transition from CD25' CD44+ DN3 cells to CD25' CD44' DN4 cells. At 
the DN2 to DN3 stage, the TCRj3 chain locus is thought to undergo allelic exclusion
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and is no longer able to rearrange, ensuring that only one TCR specificity is 
generated per-cell, and the rearrangement of the a  chain begins at the DP stage.
During the next stage of T cell development after successful TCR assembly 
thymocytes express both CD4 and CD8 co-receptors to form DP cells. These 
thymocytes are then subjected to positive and negative selection by testing the 
recognition capabilities of the TCR repertoire on self-pMHC complexes. The process 
of positive selection involves the selection of those cell bearing TCR able to 
recognise and bind self-MHC. In contrast cells expressing a TCR that either interacts 
with self-pMHC with extremely low affinity or not at all fail to signal these cells to 
survive and they die by neglect (Huesmann et al., 1991). However, cells that 
recognise and bind self-pMHC with very high affinities may represent autoreactive T 
cells, therefore negative selection also exists to trigger these cells to undergo 
apoptosis. The net result of positive and negative selection is that only cells 
expressing a TCR that recognise a self-MHC with a relatively weak affinity are 
selected. It was considered that the self-peptide repertoire expressed within the 
thymus would be limited, and that antigens expressed by extra-thymic tissue sites in 
the body may not be present. This would have a dangerous outcome, as this model 
would predict that potentially autoreactive T cells clones specific for these tissue 
antigens would escape deletion and exit the thymus. However, a recently identified 
transcription factor termed AIRE has been shown to regulate the ectopic expression 
of peripheral tissue antigens in thymic stromal cells (Anderson et al., 2002). 
Furthermore it has been possible to visualise the movement of progenitor cells
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through the microenvironment of the thymus. This work has shown that HSC enter 
via the cortico-medullary junction, where they then undergo DN transition in the 
outer cortex and enter the medulla for the final stages of maturation (Lind et al., 
2001). Moreover, it seems that the specialised cells in these thymic areas may be 
essential to the particular developmental stages that occur there (Porritt et al., 2003; 
Prockop et al., 2002).
1.2.6 Lineage commitment
The final decision that a developing thymocyte has to make is whether to become a 
CD4 or CD8 cell. Early models of lineage commitment suggested that it was largely 
a stochastic event, in that the decision to downregulate CD4 or CD8 was random, and 
survival of the subsequent T cell relied on the fact the TCR was matched to the 
particular co-receptor (Jameson et al., 1995). However recent studies have suggested 
that the nature of signal delivered to the developing T cell may actually regulate the 
lineage decision, and not simply the class of MHC it is able to recognise. For 
example, expression of chimeric molecules composed of the extracellular portion of 
CD8 fused to the cytoplasmic region of CD4 diverted a MHC-class I restricted TCR 
to the CD4 lineage (Itano et al., 1996).
1.2.7 Peripheral lymphocyte functions
After development within their respective niches, mature lymphocytes patrol the 
periphery to detect the presence of infectious agents. Lymphocyte clones with unique 
antigen specificities are normally present at low frequency, however upon
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encountering the specific antigen they undergo clonal expansion in order to expand 
the number of antigen-specific cells. During this period of proliferation, lymphocytes 
acquire a number of cell-type specific effector functions that serve to attack and 
neutralise the infecting agent.
1.2.8 B cell functions
When a B cell encounters specific antigen, it differentiates into a plasma cell and 
begins to secrete antibodies that are able to carry out several important immune 
functions. B cell activation can occur in one of two ways. Firstly, if a B cell binds its 
antigen, it can internalise and process the protein in order to express antigenic 
fragments on surface bound MHC class II molecules. The B cell is then able to 
present this peptide antigen to activated Th2 CD4 cells, which can then contribute to 
the activation status of the B cell. This kind of B cell activation is known as a T cell 
dependent stimulation. The Th2 CD4 cells expresses CD40L that can bind to CD40 
on the B cell surface and, in conjunction with the CD4-derived cytokines IL-4 and 
IL-13, induce B cells to switch the Ig isotype they produce. This is an important 
mechanism as each type of Ig class has very different immunological function. For 
example, IgA is a potent neutralising antibody as it is soluble in body fluids and can 
bind to pathogens to block entry into cells. In contrast IgGl is a powerful opsonising 
antibody as it can bind to the surface of the pathogen and aid phagocytic recognition 
through Fc receptors expressed by macrophages. Antibodies such as IgM are potent 
activators of the complement system and also mediate pathogen destruction. These B 
cell-T cell interactions occur in specialised structures called germinal centres (GC)
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and facilitate the process of somatic hypermutation. B cells can also become activate 
independently of T cells by pathogen-derived polysaccharides, and these are called T 
cell independent antigens.
1.2.9 Naive, effector, and memory CD4 T cells
T cells that express the CD4 co-receptor normally recognise extracellularly derived 
peptides in the context of MHC class II molecules only expressed by professional 
APC. It is thought that naive T cells are located primarily in secondary lymphoid 
sites, including the LN, and Spleen. The number of naive T cells is maintained by a 
balance between cell loss, homeostatic proliferation and new thymic emigrants 
(Rocha et al., 1989). Upon encountering antigen, CD4 cells begin to differentiate 
into two different effector subsets (Seder and Ahmed, 2003). Thl cells are important 
for protection against intracellular pathogens, and are characterised by their ability to 
produce cytokines such as IFNy. At the transcriptional level, Thl differentiation is 
thought to be controlled by STAT4 and T-bet. It is thought that Thl cells are 
generated, in part, by the influence of the APC. For example an APC activated by a 
bacterial product such as LPS binding to the CD 14 / TLR4 complex will induce high 
levels of IL-12. IL-12 has been shown to favour Thl differentiation as it can induce 
IFNy production in T cells. Thl cells can also express surface molecules such as 
CD40L that can activate macrophages to become antimicrobial by producing NO and 
help to clear intracellular pathogens. In contrast to Thl cells, Th2 CD4 cells produce 
cytokines such as IL-4, IL-5, and IL-13. IL-4 has been shown to silence the IFNy 
locus, thus promoting Th2 development. Furthermore, the transcription factors
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STAT6 and GATA-3 have been shown to be important to Th2 development. Th2 
CD4 effector cells are often found in B cell rich areas of the body, such as the spleen, 
and are able to induce B cells to undergo Ig class switching to IgE by virtue of IL-4 
and IL-13, as well as CD40L binding to CD40 on the surface of the B cell (Vercelli, 
1995). The differentiation of CD4 cells to the Thl or Th2 lineage is probably 
influenced by the initial cytokine milieu as a result of a specific antigen interacting 
with components of the innate immune system including DCs, macrophages and also 
possibly NK cells. After successful clearance of the pathogen, it is considered that a 
proportion of antigen experienced CD4 cells survive and become resting memory 
cells, which are able to mount a more rapid response upon secondary challenge It is 
thought that the long-term survival of memory CD4 cells relies on signals delivered 
to the T cell via IL-7, which also maintains memory cell numbers by driving 
homeostatic proliferation (Seddon et al., 2003).
1.2.10 Naive, effector and memory CD8 T cells
T cells that express the CD8 co-receptor normally recognise intracellularly derived 
peptide fragments that are presented by ubiquitously MHC class I molecules. On 
encountering antigen CD8 cells undergo a more rapid proliferation programme that 
CD4 cells (Seder and Ahmed, 2003), and begin to express a number of specialised 
genes that turn them into potent antiviral cells. The general function of CD8 effector 
CTL is to recognise and bind to any cell that is expressing cognate antigen and 
facilitates their destruction. To do this the CTL uses a protein called Perforin to 
punch holes in the target cell membrane and then deposits potent pro-apoptotic
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molecules into the interior. CTL also express death receptor ligands such as FasL 
that bind to Fas on the surface of target cells and also induce apoptosis. As for CD4 
cells, antigen experienced CD8 cells also form resting memory cells that are able to 
respond vigorously to antigen re-encounter. It is thought that IL-7 and IL-15 can 
contribute to CD8 memory generation and survival (Schluns and Lefrancois, 2003). 
There has also been some suggestions that the presence of CD4 cells greatly 
influences the quality of CD8 memory cells generated by immune challenge (Janssen 
et al., 2003; Shedlock and Shen, 2003; Sun and Bevan, 2003). It is thought that 
memory CD8 cells are derived from effector cells as it has been suggested that the 
resulting memory pool size can be related back to the size of the effector pool (Hou et 
al.t 1994) and also gene chip profiling has also suggested a linear developmental 
pathway from naive to effector then to memory CD8 cells (Kaech et al., 2002).
1.2.11 Other thymically derived lymphocytes
As well as conventional a|3 T cells, the thymus also supports the development of NK 
T cells and yb T cells. NK T cells are also a p  TCR+ but express a limited receptor 
diversity and also express the NK1.1 marker. Their development and activation is 
supported by an MHC class I variant molecule called CD Id, which is expressed on 
DC and monocytes and present glycolipid antigens to the NK T cells. NK T cells 
have been implicated in influencing the polarisation of CD4 cells to Thl or Th2 
differentiation, as they can produce polarising cytokines after activation (Godfrey and 
Kronenberg, 2004). T cells from the yb lineage arise from DN cells that successfully 
rearrange the yb T cell locus. It is thought that the first wave of yb T cells become
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dendritic epidermal T cells and are found in the epidermis, and the second wave of 
yb T cells populate the reproductive tract. Both of these early waves have limited 
receptor diversities, however in later waves this changes. The role of yb T cells is not 
clear, however some subsets may be responsible for removing damaged gut epithelial 
cells.
1.2.12 MHC structure and function
MHC molecules are effectively the focal point of the adaptive immune system as they 
can provide both survival and stimulatory signals to T cells. MHC molecules are also 
able to bind and display an amazing repertoire of peptide fragments derived from 
many sources.
1.2.13 MHC gene loci
The genes encoding the MHC class I and II molecules are highly polygenic as they 
are encoded by several different sets of genes arranged into clusters in the genome. 
Secondly, these MHC genes are highly polymorphic and two molecules from the 
same MHC genotype can differ by up to 20 amino acids. Therefore any given 
individual can produce and express a diverse repertoire of MHC molecules, as they 
are also normally heterozygous for any given MHC haplotype. The polymorphisms 
have been shown to occur at specific sites responsible for forming the peptide- 
binding cleft and also the T cell recognition sites, and are able to increase the possible 
number of peptides any given MHC genotype can bind. This is an important 
contribution to an immune response, as specific T cell clones are only able to
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recognise peptides expressed by specific MHC genotypes; this is called MHC 
restriction. Without the polymorphisms, immune recognition may be less effective as 
the T cell clone may not be able to recognise the MHC genotype that was able to bind 
its cognate antigen.
1.2.14 MHC structure, loading and presentation
MHC class I molecules are almost ubiquitously expressed, reflecting the fact that 
almost any cell may require elimination by CTL. The MHC class I molecule is 
formed from two polypeptide chains. The a  chain is derived from the MHC gene 
locus and is folded into 3 domains and is associated with the non-variant |3 micro­
globulin protein. The a l  and o2 regions form the peptide binding cleft and can bind 
peptide of 8-10 amino acids in length. In general, these peptides are derived from the 
cytosol and are often viral-based products that are degraded in proteosomes. 
Interestingly, two components of the proteosome, LMP2 and LMP7 are encoded 
within the MHC gene cluster, and like MHC class I molecules, can be induced by 
IFN. Newly produced MHC class I polypeptides are found within the ER in an 
unfolded state and a number of chaperon proteins then assist in the assembly of the a  
chain, ^  micro-globulin and peptide. These chaperons include calnexin, which helps 
to retain the partially assembled MHC molecules in the ER allowing the (32 micro- 
globulin to bind and calreticulin, which is a chaperon that keeps the MHC class I 
stable to then receive the peptide. The TAPI and TAP2 proteins are then responsible 
for loading the MHC with peptide. Only when the MHC class I molecule is 
assembled with peptide can it be expressed on the cell surface.
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The MHC class II molecule is formed from two polypeptide chains called a  and P, 
both of which are encoded by the polymorphic MHC loci. The peptide-binding cleft 
is formed from the a l  and p i domains. Unlike class I molecules, MHC class II 
molecules are not restricted in the size of peptide they can bind, possibly because the 
peptide binding domain is comparatively in a more open conformation. These 
peptides are often derived from endosomes that degrade certain intracellular proteins 
and also protein that enter cells by endocytosis. While in the ER and undergoing 
assembly, MHC class II molecules are prevented from binding peptide prematurely 
by the invariant chain protein that blocks access to the peptide binding groove. When 
assembly is completed the MHC class II molecules are transported to the endosomal 
compartment and the invariant chain is cleaved by protease to form the CLIP that 
remains in the peptide binding grove. The MHC class II-like protein HLA-DM is 
found in the endocytic compartment and is able to stabilise the MHC class II 
molecules and mediate the release of CLIP, allowing peptides to bind.
MHC class II molecules are expressed by professional APC such as DCs, 
macrophages and B cells. APC are responsible for immune surveillance as they 
expressed in nearly all tissues in various guises. For example Langerhan cells are 
found in the epithelium and upon encountering antigen, migrate to the draining lymph 
nodes and mature into potent APC that are able to activate T cells. Several studies 
have suggested that the polarisation of an immune response (e.g. Thl or Th2 CD4 
polarisation), is largely dependent upon the status or type of APC. For example an 
APC that has been activated through TLR4 and LPS will produce high levels of IL-12
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that will promote CD4 T cells to become Thl. Furthermore, it has been suggested 
that DCs activated by CD40-CD40L interactions are able to then activate CD8 T cells 
to become more effective CTL (Bennett et al., 1998).
7.2.75 Cross presentation
Although it was originally considered that the MHC class and antigen source was a 
fixed rule, studies have also suggested that MHC class I molecules can present 
peptides that are derived from extracellular sources. It is thought that phagosomes 
can fuse with ER vesicles to form hybrid compartments that contain the components 
of class I assembly and newly synthesised class I MHC molecules. Then 
phagocytosed extracellular proteins are then degraded by the phagosomes and can be 
presented on class I molecules. Cross-priming may be functionally important to 
activate a CTL response when the virus would not normally infect the DC itself 
(Heath et al., 2004)
1.3 Mechanisms of immune regulation: success and failure
While the thymus is clearly the major organ for regulating tolerance against self­
antigens through the function of the AIRE transcription factor, this does not 
overcome the problems associated with the many commensal bacteria that reside in 
the GI tract. These antigens are not present in the thymus during negative selection 
and therefore potentially reactive T cells will escape deletion. Therefore, there are a
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number of peripheral mechanisms to control the activation of potentially autoreactive 
T cells.
1.3.1 Regulatory T cell subsets
Classically, Treg cells were identified by their ability to suppress the activation of 
naive T cells both in vitro and in vivo. So-called Th3 cells have been shown to 
secrete high level of TGFp and were originally thought to be induced by low-dose 
antigen feeding to establish oral tolerance, and also favoured by a Th2 cytokine 
milieu (Strober et al., 2002). In contrast, the Trl cell is thought to function by 
secreting large amounts of the anti-inflammatory cytokine IL-10 and can be induced 
by IL-10 itself and also IFNa. Lastly, the CD4 CD25+ Treg cell is thought be 
thymically derived and inhibits effector T cell by cell-cell contact mechanisms that 
are possibly mediated by surface bound TGFp (Nakamura et al., 2001). In situations 
of strong antigenic stimulation, these cells may also be able to secrete IL-10 and thus 
share properties of both Th3 and Trl regulatory cells. It is also possible that NK T 
cells have some suppressive function as the CD Id molecule that they recognise is 
found abundantly on epithelial cells and NK T cells have been shown to produce IL- 
10 (Godfrey and Kronenberg, 2004).
1.3.2 Anergy
In situation where a T cell encounters antigen without the delivery of the appropriate 
co-stimulatory signal, a state of subsequent non-responsiveness called anergy ensues
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(Schwartz, 2003). This may be an important mechanism of ensuring tolerance to 
tissue antigens as the cells presenting these peptide to T cells often do not express the 
necessary co-stimulatory molecules. Anergised T cells are thought to have undergone 
a number of phenotypic changes including the down-modulation of co-stimulatory 
receptors, and are subsequently unable to produce IL-2 even in response to full 
activation signals (Schwartz, 2003). It is unclear why these anergic autoreactive cells 
are often maintained in vivo, however they may serve to out- compete other 
potentially autoreactive naive cells that have not yet been activated. Interestingly, 
CD8 cells have been reported to undergo a form of anergy called AINR. This has 
been shown to differ from classical anergy as it can be induced after full T cell 
activation (Deeths et al., 1999). The purpose of such a mechanism may be to limit 
the duration of a CTL response (Tham et al.y 2002). It is also thought that T cells will 
become anergic if continually exposed to antigen in vivo during the course of chronic 
infections. This has been shown in a mouse engineered to express the peptide epitope 
of LCMV, in that transferred LCMV-specific CD8 cells rapidly became anergic (Ehl 
et al.y 1998).
1.3.3 AICD
Once a T cell becomes activated and the infection is neutralised, it is important to 
then curtail the immune response as prolonged effector function can prove harmful to 
self. One way in which this is achieved is through the elimination of activated T 
cells. It is thought that AICD involves the selective removal of pre-activated T cells 
by apoptosis-inducing mechanisms. This is thought to occur via the ligation of death
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receptors on the surface of activated T cells that include Fas and also TNFa 
(Lenardo et al., 1999). Furthermore, AICD may also link with anergy, as studies 
have shown that activation through the TCR alone may also induce T cell apoptosis 
(Shi et al., 1989). As well as active mechanisms to remove effector T cells, there are 
also death receptor independent methods (Lohman et al., 1996) that may act through 
the downregulation of the anti-apoptotic molecule Bcl-2 (Strasser et al., 1995). It is 
thought that Bcl-2 expression may be regulated by pro-survival cytokines, therefore 
the withdrawal of these cytokines may also result in T cell death. This mechanism is 
thought to regulate AINR mediated control of CTL responses as the CD8 cells die 
through a lack of IL-2 (Tham et al., 2002).
1.3.4 Autoimmunity
In situation where there is failures in the mechanism of tolerance, the attention of the 
immune system can turn toward self. This can lead to extensive tissue destruction at 
sites within the body by disregulated Thl mediated inflammation, CTL function, and 
by inappropriate B cell activation by T cells. For example, type I diabetes is caused 
by autoreactive cells specific for the pancreatic (3 cell antigen destroying these cells, 
leading to a loss of insulin production. Furthermore, arthritis is thought to arise from 
uncontrolled inflammation of the synovial membranes of the joint, driven by a 
disregulated Thl immune response. Interestingly, a number of immune disorders 
have been shown to also have strong association with specific HLA-subtypes. For 
example patients suffering from ankylosing spondylitis have been shown to express 
the potentially novel MHC-class I subtype, HLA-B27 (Reveille et al., 2001), which
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can be expressed as a homodimer without the (32 microglobulin. It is thought that the 
structure of HLA-B27 may contribute toward how the immune system recognises this 
MHC class I subtype (Allen and Trowsdale, 2004; Allen et al., 2001). Also HLA- 
DR4 has been shown to increase the susceptibility to rheumatoid arthritis.
Defects in AICD may also contribute to autoimmune disorders. The evidence for this 
comes from the gld/gld mice that lack functional FasL and the Ipr/lpr mice that do 
not express active Fas. Both mice suffer from systemic autoimmune disorders due to 
an inability to eliminate activated T cells (Suda et al., 1993; Watanabe-Fukunaga et 
al., 1992). Fas mutations have also been found in humans suffering from general 
lymphoproliferative autoimmune disorders (Fisher et al., 1995).
It is not only failures in peripheral tolerance mechanisms that can lead to 
autoimmunity. The AIRE protein was first identified as the mutated gene in humans 
suffering from a multi-organ autoimmune disorder (Anderson et al., 2002). 
Furthermore, AIRE'7' mice also suffer from autoimmune pathology, highlighting the 
importance of the thymus in regulating peripheral tolerance (Anderson et al., 2002).
1.4 Peripheral T  cell signalling: from  TCR to nucleus
One common question that arises is exactly how T cells are able to translate signals 
delivered through the TCR into several different functional outcomes. What is clear 
is that activation of Lck and Fyn is one of the earliest biochemical events detected
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upon TCR ligation. These are then responsible for transducing signals from the TCR 
to the nucleus through a number of signalling networks (see Figure 1.1)
1.4.1 Models for TCR engagement and activation
There are two models that have been proposed to explain how T cell activation is 
initiated via the TCR. The first is the serial engagement model and is based on the 
idea that when a T cell encounters an APC it requires that a certain number of TCR 
molecules are engaged by pMHC molecules in order to initiate signalling 
(Lanzavecchia and Sallusto, 2000). The problem with this model is that an APC will 
present both foreign and self-pMHC to a TCR. The second model is an advancement 
of the first in that the T cell does not simply activate after a certain number of pMHC 
engagements, but it is able to scan the APC and distinguish between self-pMHC and 
foreign pMHC molecules. This is termed the kinetic proofreading model 
(McKeithan, 1995). In the second model, although self-pMHC is expressed at 
~1000-fold higher density than foreign peptide fragments, it is thought that TCR will 
bind self-pMHC with ~ 10-fold lower affinity than foreign pMHC. Therefore only 
high affinity pMHC interaction will stimulate the T cell. However a TCR must strike 
a balance between binding avidity for foreign pMHC and the ability to disengage the 
limiting number of foreign pMHC, allowing them to trigger further TCR molecules. 
There are data that conflicts with the proofreading model in that a mutant high- 
affinity TCR showed no defect in triggering to limiting foreign pMHC (Holler et al., 
2001).
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1.4.2 IS formation and cytoskeletal arrangements
In a resting state, microscopic analysis of the T cell reveals that it is a small sphere 
with antigen and adhesion receptors distributed evenly on its surface. However T 
cells must be motile and be able to move toward agents such as chemoattractants that 
are produced by innate immune cells and signal potential sites of infection. They do 
this by forming actin polymer structures that push the T cell membrane forward, 
allowing the cell to move. Then upon encountering antigen the T cell alters its shape 
to reorientate itself to form a contact with the presenting APC. This involves the 
formation of flat sheet-like ruffles termed lamelipodia, spikes called filopodia and 
larger projections termed pseudopodia. In terms of signalling molecules, 30-40% of 
the TCR5 chain is physically linked to the cytoskeleton, as well as other molecules 
including MHC class I, CD2, CD4, CD8, LFA-1, CD28 and CD44. Therefore, upon 
activation these receptors are recruited to the actin cytoskeleton and form a cluster at 
the T cell-APC immunological synapse (IS) called a supra-molecular activation 
complex (SMAC). This is an important event in activation as it brings signalling 
molecules into proximity with one another and increases the potential density of 
signal. This can be visualised by staining with the mAb 4G10, revealing that the APC 
- T cell contact site is rich in pTyr moieties. Certainly, treatment of cells with agents 
that block cytoskeletal rearrangements such as cytochalasin D also prevent T cell 
activation. It has been described that the arrangement of these molecules is highly 
ordered in that the TCR, CD2, and CD28 form part of a central cluster called the 
cSMAC, whereas molecules such as LFA-1 are excluded into a peripheral ring, or 
pSMAC. Comparatively larger structures such as CD45 are completely excluded
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from the SMAC. These structures have been noted in Th cells, Tc cells and NK cells. 
Lck may be actively brought to the cSMAC by virtue of its association with CD4 and 
CD8, both of which are tethered to the cytoskeleton. Moreover, Lck may be 
important to the association of phosphorylated CD3£ with the cytoskeleton (Rozdzial 
eta l., 1998).
There are a number of molecules that have been shown to regulate cytoskeletal 
events, and deficiency in these molecules often abrogates T cell activation. For 
example VAV deficient T cells are defective in synapse formation and cytoskeletal 
rearrangement in response to APC stimulation. Interestingly Fyn has been implicated 
as the kinase responsible for VAV phosphorylation (Huang et al., 2000). Another 
important set of proteins that plays a role in cytoskeletal modelling is the 
ADAP/SLP-76 complex. This complex has been shown to contain Nek, VAV and 
WASp. The WASp protein activates the Arp2 complex that can act as the nucleating 
centre for actin, allowing the formation of F-acting polymers to occur. Interestingly 
humans deficient in the WASp protein have T cells that have defects in cytoskeletal 
organisation. Recent work has suggested that WASp phosphorylation is defective in 
the absence of Fyn. Furthermore, Fyn has also been shown to selectively 
phosphorylate the FAK family member Pyk2 (Qian et al., 1997), which is another 
family of proteins involved in cytoskeletal regulation. Moreover, ADAP binding to 
SLP-76 has been shown to be essential to the clustering of LFA-1 molecules on T 
cells (Wang et al., 2004), and Fyn has been implicated as the kinase responsible for 
phosphorylating ADAP, allowing SLP-76 to bind (Raab et al., 1999). However it
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should also be noted that the initiation of T cell signalling may occur before the 
formation of a mature IS, as it has been reported that although the TCR moves from 
the pSMAC to form part of the mature IS, Lck is only ever detectable in the pSMAC 
(Lee et al., 2002).
1.4.3 GEMs and TCR signalling
It has been hypothesised that the localisation and pardoning of signalling molecules 
are essential to their function. Proteins that are membrane localised are thought to be 
regulated in-part by the presence of specialised lipid domains called glycolipid- 
enriched microdomains (GEMs). These domains were first identified by their 
insoluble nature in cold, non-ionic detergents, as normal cell membrane components 
will dissolve in these conditions. It is possible to isolate GEMs using sucrose 
gradients due to their comparative buoyancy. It is thought that GEMs act as 
environments whereby signalling molecules can be brought together to perpetuate 
signals. Proteins can be recruited to GEMs by modifications such as GPI linkage and 
N/S-acetylation. Key signalling molecules such as LAT are present within these 
domains, acting as a scaffold for further molecules that are recruited to the GEM 
following activation. It is possible to isolate GEM from unstimulated and stimulated 
cells and detect gross differences in the proteins present. Interestingly, Lck and Fyn 
are both present in GEM by virtue of acetylation. However, in a resting cell the 
majority of Lck is located outside GEM due to co-receptor association, furthermore 
those molecules present in the GEM are in an inactive conformation possibly due to 
the presence of LAT (Kabouridis, 2003). In contrast, Fyn is thought to be ever
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present within the GEM (Yasuda et al., 2002) and upon activation, it is thought that 
co-receptor associated Lck translocates to lipid rafts, possibly to increase Fyn activity 
(Filipp et al., 2004; Filipp et al., 2003).
1.4.4 Co-stimulatory T cell receptors
Ligation of the TCR alone is often considered to be insufficient for full T cell 
activation and can lead to an anergic state (Schwartz, 2003). Expression of B7.1 and 
B7.2 on the presenting APC has been shown to activate the CD28 co-receptor 
expressed by T cells (Azuma et al., 1992) and deliver the so-called signal 2 to the T 
cell. CD28 has been shown to signal through PI3-K, ITK and Grb2, and 
interestingly, Fyn and Lck have been suggested as the kinases responsible for 
recruiting these molecules to the cytoplasmic tail of CD28 (Raab et al., 1995). CD28 
derived activation of PKB has been implicated in the regulation of cytokine 
production by NF-kB (Kane et al., 2002). CD28 signalling may also activate the Jnk 
family of MAPK, leading to the modulation of c-Jun expression and function. More 
classically, CD28 signalling has also been shown to upregulate IL-2 production by 
increasing the stability of IL-2 mRNA, but may also upregulate 112 transcription 
directly through the CD28RE within the 112 gene (Shapiro et al., 1997)
The SLAM receptor is a member of the CD2 superfamily and is upregulated on 
activated T cells (Cocks et al., 1995). It is thought that SLAM may modulate the 
immune response by regulating cytokine production and also possible CTL function 
(Henning et al., 2001). For signalling purposes the cytoplasmic tail associates with
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the SAP adapter molecule that has been shown to be mutated in human X-linked 
immunoproliferative disease (Davidson et al., 2004). SAP has been shown to bind to 
and recruit Fyn to the SLAM receptor, and Fyn is essential for phosphorylation of 
SLAM (Chan et al., 2003). Interestingly, SLAM signalling has been shown to couple 
with PKC0 mediated NF-kB regulation (Cannons et al., 2004; Davidson et al., 2004).
1.4.5 Signal regulation and termination mechanisms
Once a signal has been initiated, there is also a need for it to be terminated as and 
when the invading agent has been neutralised. Furthermore, naive peripheral T cells 
also require TCR engagement by self-pMHC molecules in order to survive (Seddon 
and Zamoyska, 2002). Without appropriate regulation of T cell signalling at the 
molecular level, a given response against a foreign or self-antigen may become 
perpetuated and harmful to the host, leading to autoimmune disorders.
1.4.6 Phosphatases
In general the addition of phosphate groups to amino acid residues in proteins is 
thought to promote signal transduction, therefore the removal of these moieties by 
phosphatase enzymes is thought to counteract this. PTEN is a phosphatase able to 
catalyse the conversion of the PKB activating lipid moieties PIP3 into PIP2 and then 
into PIP (Seminario and Wange, 2003), thus antagonising PI3-K function. This leads 
to a change in the membrane lipid constituents affecting PH domain containing 
proteins, and also may affect PLCyl activation due to breakdown of the PIP2 
substrate. Another phosphatase that metabolises PI3-K lipid products is SHIP,
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converting PIP3 to a PIP2 moiety that is distinct from the type generated by PTEN. 
Interestingly, SHIP7' mice develop severe multi-organ autoimmunity, underscoring 
the importance of this molecule in immune regulation. A further important T cell 
phosphatase is SHP-1. It has been shown to also antagonise PI3-K signalling by 
dephosphorylating Tyr688 within the SH2 domain of the p85 subunit (Seminario and 
Wange, 2003). Interestingly, it has also been suggested that SHP-1 may be able to 
dephosphorylate the IT AM residues in the CD3 complex (Raab and Rudd, 1996). 
The fact that so many phosphatases target PI3-k underscores the importance of this 
signalling molecule in the regulation of several pathways.
1.4.7 YTlM-containing receptors
Receptors that contain ITIMS have also been shown to regulate T cell activation. 
ITIMs are similar to an IT AM but tend to recruit phosphatases that serve to 
downmodulate signalling. An example of an ITIM containing receptor is PECAM-1. 
It has been shown to recruit SHP-2 and attenuate TCR signalling. Interestingly Lck 
has been implicated in the phosphorylation of the PECAM-1 ITIM, as it was 
undetectable in Lck deficient Jurkat cells (Newman et al., 2001). Another ITIM 
containing receptor is PD-1, and PD-17 mice suffer from an autoimmune disorder 
(Zha et al., 2004) underscoring the role of these receptors in controlling peripheral 
tolerance.
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1.4.8 CTLA-4
Co-stimulatory CD28 signals are antagonised by the B7 family member CTLA-4 
(Linsley and Ledbetter, 1993), which may also contain an ITIM motif. CTLA-4 
binds to CD28 with higher affinity than B7.1/2 and can associate with the 
phosphatase SHP-2. Mice lacking functional CTLA-4 suffer from an autoimmune 
syndrome (Tivol et al., 1995). Interestingly, a number of studies have implicated Lck 
and Fyn as the kinases responsible for phosphorylating the tyrosine residues 
important for SHP-2 binding and trafficking of CTLA-4 to the cell surface (Hu et al., 
2001; Chuang et al., 1999; Miyatake et al., 1998; Marengere et al., 1996).
1.5 TCR signalling molecules and pathways
The TCR is composed of a  and p polypeptide chains that confer antigen specificity. 
These are coupled to the three invariant chains of the CD3 complex, arranged as a 
heterodimers of e& and ye. The CD3 complex is further associated with the ££ 
homodimer. The CD3/£ complex contain motifs know as ITAMS (YxxfL/VJXg. 
9Yxx[L/V], where Y is tyrosine, L is leucine, V is valine and x can be any residue. 
When these ITAMS are phosphorylated they form docking sites for the ZAP-70 
tyrosine kinase, facilitating its activation also by phosphorylation. Studies have 
suggested that Lck may be essential to this step, as in the Lck deficient JCaMl cell 
line, phospho-^ induction, ZAP-70 recruitment and ZAP-70 phosphorylation were all 
defective in response to TCR signals (Williams et al., 1997b; al-Ramadi et al., 1996;
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Gupta et al., 1994; Straus and Weiss, 1992). The defective ZAP-70 activation could 
be restored by transfecting back Lck (Straus and Weiss, 1992). It has been suggested 
in Jurkat cell lines transfected with either Lck or Fyn, that Fyn is capable of 
mediating a distinctive pattern of ITAM phosphorylation (Denny et al., 2000). It is 
thought that ZAP-70 can bind to doubly phosphorylated ITAM motifs, but also it has 
been suggested other signalling molecules such as She (Osman et al., 1995), PI3-K 
(Exley et al., 1994) and Src kinases themselves (Johnson et al., 1995) can bind singly 
phosphorylated ITAMS. Once activated by phosphorylation of Tyr-493 in its 
activation loop by Lck (Chan et al., 1995), but possibly not Fyn (Denny et al., 2000), 
ZAP-70 is able to phosphoiylate LAT (Wardenburg et al., 1996) and SLP-76 (Zhang 
etal., 1998b).
1.5.1 LAT
LAT is a transmembrane adapter protein that contains two cysteine residues that 
when palmitoylated, target this protein to the plasma membrane (Lin et al., 1999; 
Zhang et al., 1998a). LAT contains a long cytosolic region containing 9 Tyr residues 
that can be phosphorylated to form a scaffold for binding several proteins. These 
include Grb2/SOS, GADS and PLCyl (Zhang et al., 2000). Interestingly, Lck has 
been shown to co-precipitate with LAT (Kabouridis, 2003). Moreover, these 
particular Lck molecules were shown to be in a closed inactive conformation and this 
was dependent on the co-localisation of LAT with Lck in lipid rafts. The second 
target of ZAP-70 phosphorylation, SLP-76 is also recruited to this complex by virtue 
of its association with GADS (Ishiai et al., 2000). SLP-76 also binds ITK, which
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may assist in the activation of LAT associated PLCyl (Su et al., 1999), and also 
molecules such as ADAP (Wang et al., 2004), VAV and Nek (Bubeck Wardenburg et 
al., 1998) that link into pathways regulating rearrangement of the actin cytoskeleton 
and cell adhesion. Interestingly, Fyn has been implicated in the phosphorylation of 
both ADAP (Raab et al., 1999) and VAV (Huang et al., 2000).
1.5.2 PLCyl
Activation of the PLCyl enzyme is another important step in T cell activation. Once 
activated, possibly by ITK-mediated phosphorylation, it catalyses the hydrolysis of 
the lipid moiety PIP2 into IP3 and DAG (Nishibe et al., 1990). However there are also 
reports that Lck and Fyn can associate with PLCyl directly (Weber et al., 1992), and 
have been shown to phosphorylate PLCyl in vitro (Liao et al., 1993). Furthermore, 
VAV may also be important to the activation of PLCyl as VAV'7' DP thymocytes 
show defects in calcium mobilisation and PLCyl phosphorylation (Reynolds et al., 
2002).
1.5.3 IP3f Cc?+ and NF-AT
Production of IP3 leads to the release of Ca2+ from the ER by binding to IP3 receptors 
located on the surface. Interestingly, it has been suggested that Fyn binds to theses 
IP3 receptors and may phosphorylate them (Jayaraman et al., 1996). The drop in 
intracellular Ca2+ includes the opening of the CRAC channels allowing entry of 
extracellular Ca2+ into the cell (Crabtree and Olson, 2002). The increase in 
intracellular calcium has been shown to lead to the activation of the Ca2+ /calmodulin-
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dependent phosphatase calcineurin (CN) (Aramburu et al., 2000). Once activated this 
has been shown to positively regulate the translocation of NF-AT family members to 
the nucleus to drive gene transcription. CN functions by dephosphorylating a number 
of serine residues in the N-termini of NF-AT members revealing the nuclear 
localisation signal sequence (Klemm et al., 1997). There are a total of 5 NF-AT 
members and NF-AT 1 (NF-ATp) and NF-AT2 (NF-ATC) are essential to the 
expression of immune regulator genes including IL-2, IL-4, CD40L and FasL (Peng 
et al., 2001). NF-AT nuclear translocation is antagonised by GSK3 as it can 
rephosphorylate the serine residues masking the nuclear translocation signals (Beals 
et al., 1997) and this has been shown to reduce IL-2 production (Ohteki et al., 2000).
1.5.4 Ras and Erk
DAG, the other product of PIP2 hydrolysis by PLCy, has been shown to activate 
RasGRP (Ebinu et al., 2000) and PKC0 (Isakov and Altman, 2002). RasGRP is a 
GEF, thought to be activated by DAG-mediated membrane translocation (Dower et 
al., 2000). It can mediate the activation of the small G protein Ras by catalysing the 
conversion of GDP to GTP. When Ras is bound to GDP it is inactive, however when 
GTP is bound it is in an active conformation. Alternatively, Ras can also be activated 
by the PLCy independent pathway involving another GEF called SOS. When SOS 
binds to the inducibly-phosphorylated adapter Grb2 and becomes membrane localised 
it becomes active and can also catalyse the conversion of GDP to GTP and activate 
Ras.
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Once activated, RasGTP has been shown to activate the Erk MAPK cascade through 
the activation of the MAPKKK Raf. Raf in turn phosphorylates a serine residue in 
the MAPKK Mekl. Mekl is then able to catalyse the dual phosphorylation of Tyr 
and threonine residues found in the activation segment of MAPK members. It is 
thought that in T cells the major MAPK activated by the Ras/Raf pathway is Erkl 
and Erk2. Erk has been shown to be able to translocate to the nucleus where it can 
activate members of the Ets family of transcription factors such as Elkl that has been 
shown to regulate the c-Fos gene, a component of the AP-1 transcription regulator. 
Also a recent paper has suggested that Erk and Lck can interact directly with one 
another (Stefanova et al., 2003).
Recently, another TCR regulated pathway has been described that influences Erk 
activity. The molecule She has been shown to bind to singly phosphorylated ITAM 
residues within the £ chain (Galandrini et al., 1997). It is thought that Lck may be 
able to phosphorylate at least one Tyr residue in She (Walk et al., 1998). Once 
phosphorylated, She can bind to Grb2/SOS and brings the whole complex to the 
membrane and activate the Ras/Raf/Erk cascade. It has been suggested that 
activation of Erk by She is important to the production of IL-2 by T cells by 
controlling the translocation of the NF-kB member c-Rel.
1.5.5 PKC6 and NF-kB
Another important target of the PIP2 cleavage product DAG is PKC0. In an inactive 
form PKC0 resides within the cytosol, however on binding DAG it translocates
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rapidly to the cSMAC of the IS. PKC0 has been shown to regulate the function of 
N F -kB  members by regulating IKK degradation through molecules such as 
CARMA1 and Bel 10 (Baier, 2003). When IKK is associated with NF-kB proteins it 
masks the nuclear translocation signal, therefore IKK degradation reveals this motif 
allowing NF-kB to enter the nucleus. Furthermore, PKC0 may also play a role in 
regulating NF-AT, possibly by regulating Gsk3 function via an association with PKB 
(Altman and Villalba, 2003). Finally PKC0 can also activate the Jnk pathway of 
MAPK (Ghaffari-Tabrizi et al., 1999). Interestingly, it has been suggested that Lck 
can phosphorylate PKC0 in Jurkat cells (Liu et al., 2000). Furthermore, it has 
recently been shown that Fyn deficiency may have a detrimental effect on PKC0 
regulated NF-kB activation. Fyn'7' CD4 T cells show impaired PKC0 membrane 
translocation and are unable to degrade IKBa, resulting in defects in cytokine 
production (Cannons et al., 2004).
1.5.6 Other MAPK pathways
Jnk activation is also an important event in T cell activation. Jnk is activated by 
MKK4/7 (Toumier et al., 2001; Yang et al., 1997), which in turn may be regulated by 
VAV and by PKC0 {Moller, 2001 #314}.. Once activated Jnk regulates the activity 
and expression of the c-Jun component of the AP-1 complex. Jnk exists as two 
different isoforms in T cells, and studies have suggested that Jnkl and Jnk2 may have 
distinct functions in CD8 T cell activation (Conze et al., 2002).
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Another signalling circuit important to T cell function is the p38 MAPK pathway. It 
is thought to be activated by MKK3 and MKK6, which may be downstream of 
molecules such as Cdc42 and Rac. The p38 MAPK can regulate the function of 
transcription factors such as ATF2 that plays a role in the production of c-Jun. 
Interestingly a very recent paper has suggested Lck may play a role in 
phosphorylating Tyr 323 of p38 MAPK via ZAP-70 activation, and that this residue 
is important for TCR mediated p38 activity (Salvador et al., 2005).
1.5.7 PI3-K and PKB
TCR activation can also induce the activity of PI3-K, possibly through the action of 
the adapter molecule Gab2 (Kane and Weiss, 2003). Interestingly, the SH3 domain 
of Lck has also been shown to bind a proline rich domain in the p85 subunit of PI3-K, 
possibly recruiting it to CD4 (Prasad et al., 1993b), furthermore the SH3 domain of 
Fyn may also bind PI3-K at the same region (Prasad et al., 1993a). PI3-K catalyses 
the formation of various phosphatidyl moieties including PIP2, the PLCy substrate, as 
well as PIP3. This changes the lipid constituents of the membrane facilitating the 
recruitment of PH-domain containing proteins to the plasma membrane (Kane and 
Weiss, 2003). One such PH-domain protein is the serine/threonine kinase PKB. 
Activation of PKB is mediated by another PH-domain protein PDK1, that can 
phosphorylation Thr308 located in the kinase activation loop (Cantrell, 2002). Once 
activated, PKB can regulate a number of cellular events by virtue of its downstream 
targets. For example, it can positively regulate NF-AT nuclear translocation by 
phosphorylating GSK3 and inactivating this kinase (Cantrell, 2002). Moreover
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expression of active PKB has been shown to increase production of NF-AT regulated 
cytokines including IL-2. PI3-K and PKB activation has also been shown to induce 
the E2F transcription factor that can regulate cell cycle progression and also c-myb, a 
regulator of cell survival (Cantrell, 2002). PKB may also regulate cell survival by 
phosphorylating and inactivating pro-apoptotic molecules such as BAD and caspase 9 
(Seminario and Wange, 2003).
1.6 Src kinases
Src was first identified as a viral gene product of the Rous sarcoma virus that had 
tyrosine kinase activity and cell transformation potential (Bernstein et al., 1976). 
Since then a total of 9 related Src family kinase, including Lck and Fyn, have been 
identified as signalling components in both non-transformed and transformed cells 
(Thomas and Brugge, 1997). Lck was first identified in the murine T cell lymphoma 
LSTRA, and was originally called the IskT gene (Marth et al., 1985). Fyn (originally 
called Syn) was identified by two groups from human cDNA libraries by virtue of its 
sequence similarity with Src (Kawakami et al., 1986; Semba et al., 1986). Work from 
several labs has identified Lck and Fyn as key mediators of cell signalling, including 
T cells that express Lck as well as the exon 7B splice variant of Fyn called FynT 
(Cooke and Perlmutter, 1989). Furthermore, they can both shown transforming 
potentials when expressed in mutant forms in various cell types (Adler and Sefton, 
1992; Semba et al., 1990).
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1.6.1 Src kinase structure
In terms of structure, each family member follows a strict molecular arrangement of 
protein domains (see Figure 1.2A). The SHI (kinase), SH2 and SH3 (both protein- 
protein interacting motifs) are highly conserved between Src members. SH2 domains 
bind to pTyr residues in target proteins facilitating protein-protein interactions by 
virtue of the secondary sequence structure. These motifs are composed of a 
phosphotyrosyl recognition pocket that contains a conserved arginine residue that 
mediates electrostatic interactions with the target pTyr (Waksman et al., 1992). 
However it is thought that substrate specificity of the SH2 domain is conferred by the 
divergent nature of the C-terminal recognition pocket (Kuriyan and Cowburn, 1997). 
SH3 domains of Src family kinases generally recognise and bind poly-projine motifs 
(RxxPxxP) in target molecules (Weng et al., 1995). Interestingly, the SH3 domain of 
Fyn is an exception in that it can interact with the proline independent motifs 
(RKxxYxxY) found in SKAP55 (Kang et al., 2000) and also to the SH2 domain of 
the adapter SAP (Latour et al., 2003).
Furthermore, Src kinases possess SH4 domains that contain a run of between 50-70 
residues known as the unique region that show no sequence similarities between 
family members. Within the SH4 region there are residues that can be mirystoylated, 
palmitoylated or s-acetylated to facilitate targeting to cellular membranes (Resh, 
1999; Koegl et al., 1994). The di-cysteine motif in the unique region of Lck has been 
shown to be essential for CD4/CD8 co-receptor binding (Shaw et al., 1989; Rudd et 
al., 1988; Veillette et al., 1988). The crystal structure of inactive Src has been solved
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(see Figure 1.2B) and shows the spatial arrangement of these domains (Williams et 
al., 1997a). The solved structure showed that kinase domain is composed of two 
lobes, with the C terminal lobe containing the regulatory activation loop, which in 
concert with the cleft formed between the two lobes, mediates the phosphotransfer 
reaction (Taylor et al., 1992).
7.6.2 Src kinase regulation
Src kinases, including Lck and Fyn can be regulated at several levels. For example, 
when phosphorylated on the Tyr residue located within the activation loop, the 
structure of the Lck catalytic domain has been shown to be held in an active 
conformation (Yamaguchi and Hendrickson, 1996). It is thought that 
phosphorylation of these residues in Lck and Fyn (see figure 1.2A) is mediated by 
transphosphorylation, however a recent study by Filipp and colleagues suggest that 
Lck may influence the phosphorylation of Tyr 417 in Fyn (Filipp et al., 2004; Filipp 
et al., 2003).
A second level of regulation is provided by the phosphorylation of the Tyr residue 
located in the C-termini of Src kinase molecules. This causes the SH2 and SH3 
domains to turn inward and make intramolecular association that close the catalytic 
domain into an inactive conformation (Williams et al., 1997a). These intramolecular 
interaction involve the inhibitory tyrosine binding to the SH2 domain, and this is then 
stabilised by the SH2-CD linker region associating with the SH3 domain (Gonfloni et 
al., 1997). Interestingly, studies have shown that the SH3 interaction with the SH2-
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CD linker is probably more important as the key regulator of the kinase domain 
because displacement of this interaction can lead to Src kinase activity regardless of 
the SH2 c-termini pTyr interaction (Moarefi et al., 1997). This suggests that a 
possible mechanism for regulating Src kinase function is SH3 domain interactions. 
Certainly, the recently described PxxP-containing Unci 19 protein has been shown to 
bind to Lck and Fyn via the SH3 domains leading to activation of these kinase, 
possibly by displacing the autoinhibitory interaction with the SH2-CD linker (Gorska 
et al., 2004). However, it is still considered that phosphorylation of the C-termini Tyr 
is first required in initiating the SH3 SH2-CD linker interaction as deletion of Tyr 505 
in Lck leads to a constitutively active kinase (Marth et al., 1988).
Finally, Lck and Fyn may be regulated, in part by their subcellular localisation. As 
mentioned previously, features within the SH4 and also the unique regions are 
responsible for targeting these kinase to distinct areas within the cell. For example, 
s-acetylation of Lck and subsequent membrane localisation has been shown to be 
important to phosphorylation events in cell lines, as has Lck association with the co­
receptors (Kabouridis et al., 1997). In terms of Fyn localisation mirystoylation of Fyn 
within the unique region has been shown to mediate its association with the CD3 
components (van't Hof and Resh, 1999), which may be essential to function. Fyn has 
also been suggested to interact with the mitotic spindle, but the significance of this 
interaction has not been established (Ley et al., 1994). Furthermore, it has been 
suggested that Lck exists primarily outside lipid raft fractions in resting T cells,
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whereas Fyn is found within these specialised domains, and that this may have 
functional significance (Filipp et al., 2003).
1.6.3 Role o f Src kinases in T cell development
Lck, and to a lesser extent Fyn, have both been shown to play important roles in the 
events regulating T cell development in the thymus. In the Lck'7' mouse, there is a 
profound reduction in thymus size due to a reduction in the number of DP cells. This 
is caused by a block at the DN3 to DN4 transition because of defective signalling for 
(J-selection in the absence of Lck (Molina et al., 1992). Those cells that are generated 
have lower CD5 levels and increased TCR expression due to the defective allelic 
exclusion of the TCR|3 gene locus (Anderson et al., 1993; Anderson et al., 1992). 
The cells that mature in the Lck 7' thymus presumably do so through Fyn signals, as 
Lck'7' Fyn'7' cells are completely arrested at the DN3 stage (Groves et al., 1996; van 
Oers et al., 1996). Expression of LckY505F mutant molecules in Rag-1'7' that would 
normally be completely blocked at the DN3 stage can drive cells across the |3 
selection checkpoint (Mombaerts et al., 1994). Although the thymic development in 
Fyn*7' mice was reported to be grossly normal (Appleby et al., 1992; Stein et al., 
1992). over expression of kinase-inactive Fyn was able to affect thymocyte signalling 
(Cooke et al., 1991). Interestingly, the preferential role of Lck in p selection is not 
mediated by the kinase domain, as the expression of a chimeric molecule composed 
of the kinase domain of Lck fused to the SH4,SH3 and SH2 domains of Fyn was not 
able to restore thymic development in Lck'7' mice (Lin et al., 2000).
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In terms of regulating the transition from DP to SP thymocytes, Fyn may not play any 
role at this stage as protein levels were shown to be undetectable in DP thymocytes 
(Olszowy et al., 1995). In contrast Lck has been heavily implicated in the signals that 
control lineage decision, partly because the impact of Lck deficiency on the SP 
population was even more profound than on the DP subset (Molina et al., 1992). It 
has been shown that CD4 binds Lck mores strongly than CD8 and chimeric 
molecules composed of the extracellular portion of CD8 fused to the intracellular 
domain of CD4 were able to divert class I restricted TCR transgenic cells from the 
CD8 lineage to the CD4 lineage (Seong et al., 1992). Moreover, decreasing Lck 
activity has been shown to promote CD8 differentiation (Legname et al., 2000) and 
increasing activity sends cells to the CD4 lineage (Hernandez-Hoyos et al., 2000). 
Furthermore, in our lab we have previously shown that co-ligation of DP thymocytes 
with bi-specific antibodies against either TCR/CD8 or TCR/CD4 always drove cells 
to the CD4 lineage, even when they expressed a class I-restricted TCR transgene 
(Bommhardt et al., 1997). In contrast cross-linking the TCR/CD3 alone instructed 
cells to proceed to the CD8 lineage even in class II transgenic systems (Basson et al., 
1998). Although unexpected, stimulation methods involving the co-receptors would 
presumably lead to the activation of Lck, again suggesting that the strength of Lck 
signal helps to determine lineage fate. Collectively, these data suggest that lineage 
commitment does involve an element of instructive signalling and is not merely a 
stochastic event, as has been proposed.
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1.6.4 Haematopoietic Src kinases in non- T cells
The BCR is composed of surface bound IgM molecules coupled to the invariant Iga 
and p chains, which each contain ITAM motifs. It is thought that the Src family 
kinase Lyn is responsible for phosphorylating these Tyr residues in order to initiate B 
cell signalling. Lyn is weakly associated with the non-phosphorylated ITAM in Iga, 
an interaction stabilised by its SH4 domain binding to the plasma membrane (Resh, 
1994) . Furthermore, Lyn has been shown to phosphorylate both Syk and Btk, 
essential downstream mediators of BCR signalling (Kurosaki, 1999). Interestingly 
Lyn"7' B cells are hyper-responsive, and maybe due to the fact that Lyn has also been 
shown to phosphorylate the B cell inhibitory receptors FcyRIIB (Nishizumi et al., 
1998) and CD22 (Smith et al., 1998). Thus Lyn may have a dual control over 
activation and signal termination (Xu et al., 2005).
In terms of B cells signalling, Lck has recently been shown to be expressed in a 
subset termed B la cells. The function of Lck in these cells seems to be suppressive 
as B la cells are generally hyporesponsive to activation compared to other B cell 
subsets. However in the absence of Lck, the responsiveness of these B la cells 
increase to resemble other B cell types (Dal Porto et al., 2004). While Fyn has been 
shown to be expressed in B cells and associate with components of the BCR, there 
has been no clear function assigned in terms of BCR signalling, however Fyn"7" B 
cells were slightly hyporesponsive to IgD/IgM regulated activation, interestingly this 
was exacerbated when Lyn'7' Fyn'7' B cells were used (Horikawa et al., 1999). Also 
Fyn has been implicated in the signalling of the CD38 expressed on B cells (Yasue et
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a/., 1997). Recently, Fyn expression has been reported in mast cells and has been 
shown to mediate a Lyn independent pathway of IgE mediated degranulation 
(Parravicini et al., 2002). Interestingly, the loss of Lyn expression was able to render 
this Fyn dependent pathway hyper-responsive suggesting that Lyn may also play a 
negative regulatory role in Fyn-mediated degranulation (Parravicini et al., 2002).
1.4.4 Molecules that modify Lck]Fyn activity
Having discussed the initiation of T cell signalling at the molecular level, and the 
importance of Lck and Fyn in these events, it is important to consider how the 
activity of these kinases are regulated in a T cell with respect to signal activation and 
termination. Over recent years a number of molecules have been described that 
interact with Lck/Fyn in such as way as to influence activity, either through changing 
the phosphorylation status of regulatory Tyr residues, or by altering the molecular 
conformation. These molecules are summarised in Figure 1.3.
1.6.6 Negative molecular regulators
Emerging evidence suggests that Lck and Fyn are regulated by a multiprotein 
complex containing a recently identified transmembrane adapter molecule termed 
PAG. PAG has been shown to reside in the GEM and is phosphorylated in resting T 
cells on Tyr317 facilitating an associate with Csk. Csk is a kinase that has been 
shown to phosphorylate the C-termini Tyr residue in Fyn and Lck promoting the 
closed conformation. Moreover, Csk has been shown to constitutively associate with
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two phosphatases PEP and PTP-PEST (Davidson and Veillette, 2001), both of which 
are capable of removing the phosphate from the Tyr residues within the kinase 
domains of Lck and Fyn. Interestingly, Fyn has been implicated as the preferential 
kinase able to phosphorylate Tyr317 in PAG and facilitate Csk/PEP binding (Yasuda 
et al., 2002). Furthermore, residual Fyn kinase activity can be detected in GEM from 
resting T cells suggesting that Fyn my function to keep T cells in a quiescent state. 
Interestingly the SH3 domain of Fyn has been shown to associate with a proline rich 
segment of PAG, and this may assist in keeping Fyn in a kinase active conformation, 
regardless of the phosphorylation status of the C-termini Tyr.
The function of Lck and Fyn may also be regulated by ubiquitin-mediated 
degradation. The E3 ubiquitin ligase c-Cbl has been shown to associate with Fyn and 
Lck (Feshchenko et al., 1998; Fukazawa et al., 1995). It may function to 
downregulate signalling in two ways. Firstly, it may tag them for lysosomal 
degradation, however c-Cbl may also serve to remove Lck and Fyn from the GEM 
(Hawash et al., 2002). T cells from c-Cbl'" mice are hyper-responsive to stimuli 
(Murphy et al., 1998). Finally, there is also some suggestion that SHP-1 phosphatase 
may be able to dephosphorylate the kinase-promoting residue in Lck, and this may 
downregulate function (Stefanova et al., 2003).
1.6.7 Positive molecular regulators
Recently a small molecule called Uncl99 has been shown to positively regulate 
Lck/Fyn activity in T cells by virtue of its association with the SH3 domains of these
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kinases (Gorska et al., 2004). It is considered that binding of Uncl99 to the SH3 
domain destabilises the closed molecular conformation, allowing the kinase domain 
to be accessible. However this would presumably not alter the SH2, C-termini Tyr 
association or the phosphorylation status of this residue. It has also been proposed 
that dephosphorylation of the C-termini inhibitory Tyr residue is important to 
Lck/Fyn activity and that this may be mediated by the CD45 phosphatase, however, 
no study has conclusively shown that the phosphorylation status of the C-termini Tyr 
residues alters upon T cell activation (Hasegawa et al., 2004). CD45 may simply 
function to dephosphoiylate Tyr317 in PAG (Davidson et al., 2003), however SHP-2 
has also been implicated in this process (Zhang et al., 2004). Loss of phospho-PAG 
Tyr 317 facilitates the loss of Csk/PEP from the GEM and eliminates the inhibition of 
Lck/Fyn function (Lindquist et al., 2003). Interestingly, a recently identified 
molecule G3BP has been shown to sequester Csk from the GEM and may function to 
counter the role of PAG (Rahmouni et al., 2005). Another recently identified adapter 
molecule termed LIME may also function as a positive regulator of Src kinase 
activation (Brdickova et al., 2003; Hur et al., 2003). Upon CD4 cross-linking, LIME 
is phosphorylated, presumably by Lck, and can then bind the SH2 domain of Lck and 
also Csk/PEP complexes. Due to the LIME-LckSH2 interaction, the fact that the C- 
termini Tyr is phosphorylated by Csk does not induce molecular closure, and thus 
LIME may be considered to positively regulate Lck activity. It has been proposed 
that the open Lck with Tyr505 phosphorylation may generate a binding site for other 
SH2 containing proteins (Brdickova et al., 2003). This may include Fyn, as recent 
work has suggested that Lck may positively act on Fyn kinase activity (Filipp et al.,
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2004; Filipp et al., 2003). Finally, it has also been suggested that Lck can be 
phosphorylated directly by Erk on serine residue 59. This is thought to antagonise 
the proposed negative function of the phosphatase SHP-1 (Stefanova et al., 2003).
1.7 Thesis aims
The overall aim of this thesis is to use transgenic mouse models to address what 
contribution Lck and Fyn make to T cell responses. Certainly, from the wealth of 
biochemical data being accumulated, it is possible that these kinases may not solely 
be responsible for driving T cell activation, but may also play a role in regulating the 
response.
In the first results chapter I will describe the basic characterisation of antigen- 
activated Fyn'7' CD8 T cells expressing a monoclonal class I-restricted TCR. The 
next two chapters detail the possible signalling mechanisms controlling the phenotype 
of the Fyn'7' CD8 T cells and the subsequent influence on effector function. The final 
results chapter describes the outcome of concomitantly eliminating Fyn expression 
and reducing Lck levels on the maintenance of peripheral T cell tolerance.
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Figure 1.1: T cell signalling pathways and Lck / Fyn
The major T cell signalling pathways influencing gene expression that are thought to 
be downstream of the TCR / CD3 / CD4/8 receptor complex are shown. Also the 
contribution of CD28 and SLAM to signalling is also included. Molecules that are 
denoted with a red asterix have been implicated as being directly able to interact with 
Fyn and/or Lck.
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Cytoskeleton  
Receptor clustering 
Chemotaxis
am
DAG IP3
ARP2/3
w Erk
CdC42 _
Rho Rac v WASp (>,
Figure 1.2: The structural feature of Src, Lck and Fyn
The arrangement of protein domains is shown for Lck and Fyn (A). Also the % of 
chemically similar amino acid residues is shown for each domain, as well as the % of 
identical residues. These were calculated using the pair-wise protein BLAST option 
on the NCBI website. The sequence accession numbers used were P39688 (Fyn) and 
P06239 (Lck). The crystal structure of inactive chicken Src (B) lacking the SH4 
domain is shown (Williams et al., 1997)
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Figure 1.3: Molecular regulation of Lck and Fyn
A summary of the major molecules that regulate the activity of Lck and Fyn. Upon 
activation (A), a number of molecules have been implicated in the activation of Lck 
and Fyn. Also it is thought that CD8/4 associated Lck is brought into the GEM, 
where it may actively phosphorylate Fyn and also LIME. At the same time, the 
PAG/Csk/PEP complex is thought disassociate due to the loss of pTyr 317 of PAG. 
It is thought that PAG Tyr 317 dephosphorylation may be mediated by CD45 or SHP- 
2. Furthermore, Csk may also be actively sequestered away from the GEM by virtue 
of the newly identified phospho-protein, G3BP. Then at comparatively later stages of 
activation, Fyn may be responsible for rephosphorylating PAG Tyr 317 and mediate 
the reassembly of the PAG/Csk/PEP complex to downmodulate signals through Src 
kinases.
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Chapter 2: Materials and Methods
2.1 Materials and solutions
Handling media
Air Buffered IMDM + 2% HI-FCS
R P M I164011MDM culture media 
RPMI or IMDM (Sigma, UK)
10% HI-FCS (Gibco BRL, UK)
100 U/ml Penicillin (Sigma)
100 pg/ml Streptomycin (Sigma)
2 xlO 3 M L-Glutamine (Sigma)
5 x10'5M p-mercaptoethanol (Sigma)
ACK
150 mM NH4CI 
10 mM KHC03 
0.1 mM Na2EDTA
FACS buffer
PBS + 0.5% Sodium Azide + 0.5% BSA
Dynal bead binding buffer 
PBS (Gibco) + 2% HI-FCS
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Bead wash buffer
PBS + 0.1% Tween-20 (Sigma)
Bead storage buffer
PBS + 40% Glycerol (BD chemicals, UK)
lOx Cytokine permeabilisation buffer 
1% NP40 (Sigma)
150 mM NaCl 
50 mM Tris pH 7
Confocal perm buffer
PBS + 3% HI-FCS + 0.25% Triton-X 100 (Sigma)
2jc Lysis buffer 
300 mM Nacl 
100 mM Tris pH.7 
20 mM NaF
20 mM Di-sodium phosphate 
2% n-Octyl-B-D-Glucopyranoside (Sigma)
0.2 mM Sodium Orthovanadate
10 ng / ml SPI (Antipain / Chymostatin / Leupeptin / Pepstatin all from Sigma) 
2 pM PEFA block (Sigma)
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3x reducing sample buffer 
4% SDS 
30% Glycerol 
0.1875 M Tris pH 6.8 
15% 2-Me
0.03% Bromophenol Blue
Lower gel buffer 
0.4% SDS
1.5 M Tris-HCL pH 8.8
Upper gel buffer 
0.4% SDS
0.5 M Tris-HCL pH 6.8 
Running buffer
IX Tris / Glycine / SDS buffer (Bio-rad)
Transfer buffer 
IX CAPS
Blocking buffer
PBS + 0.5% Tween-20 + 5% dry marvel milk
Wash buffer
PBS + 1% Tween-20
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Stripping buffer
100 mM 2-Me 
2% SDS
62.5 mM Tris pH 6.7 
dH20
2.2 Mice
Mice with a homozygous disruption of the Fyn gene were a gift from Dr P 
Soriano (University of Pensilvania) and have been described elsewhere (Stein et 
al., 1992). Rag-1' mice (Mombaerts et al., 1992) and F5 Rag-1' (Mamalaki et 
a l., 1992) have all been described previously. Rag-1' F5 F y n ' mice were 
generated by back-crossing F5 Rag-l"' mice with Fyn"' animals. The resulting Fl 
generation was inter-bred to homozygosity. Lck"' mice harbouring the Lck-i 
transgene controlled by the tetO/CMV promoter and Lck '" mice containing the 
rtTA under the control of the huCD2 LCR have been described previously 
(Legname et al., 2000) and Lck,Dd mice were generated by intercrossing these two 
lines. LckInd Fyn'" mice have also been described elsewhere (Seddon and 
Zamoyska, 2002a; Seddon and Zamoyska, 2002b). Lck expression was 
maintained by administering either 1 or 3 mg/g Dox food. The genotype of all 
mice was determined by a combination of PCR and FACS analysis of PBL. All 
mice were bred and housed under SPF conditions in concordance with home 
office regulations at the N1MR animal facility.
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2.3 Cell isolation, purification and culture
2.3.1 Cell isolation protocols
2.3.2 Isolation o f thymocytes and peripheral T cells
The cervical, axillary, inguinal and mesenteric lymph nodes were obtained from 
age matched groups of mice. In some cases the thymus and / or spleen were also 
removed (mice used for thymic analysis were always <6 weeks of age). Single 
cell suspensions were prepared by gently teasing the organs through a sterile 
gauze, allowing the cells to disperse into handling media. Cell were washed once, 
resuspended in handling media and counted using a Casy-1 automated cell 
counter (Scharfe system, Germany).
2.3.3 Generation o f bone marrow-derived dendritic cells
The back legs (Tibia and Fibia) of C57BL/6 mice were obtained and the bone 
marrow was extracted using a fine gauge needle and 1 ml syringe to flush 
handling media into the bone. Bone marrow cells were washed once by 
centrifugation at 20°C and 10,000 rpm. Cell were then counted and resuspended 
in RPMI culture media. Then 5 x 106 bone marrow cells were cultured in 10ml of 
RPMI culture media containing 10% neat supernatant from the Ag8653 myeloma 
cell line that has been transfected with murine GM-CSF (20 U/ml). The cell were 
cultured at 37°C / 5% C 0 2 in 9 cm petri-dishes (Nunc, Denmark) for an initial 
period of 4 days after which media was replaced to remove non-adherent 
granulocyte cells. At day 6-8 BMDC were harvested from the plates and were
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either pulsed with antigen for 4 hrs at a density of 5 x 106 cells/ml in 50ml Falcon 
tubes at 37°C / 5% C 0 2 or left unpulsed for control purposes. Antigen pulsed 
BMDC were washed three times before use.
2.3.4 Isolation o f PBL
Briefly, ~100pl of blood was collected via the tail vein into 1.5ml eppendorf 
tubes containing lOOpl of heparin (Sigma). Blood samples were then transferred 
to 6ml FACS tubes and 2ml of ACK was added and mixed briefly with vortexing. 
Samples were left for 10 minutes at room temperature, after which tubes were 
filled to the top with ice cold FACS buffer and spun at 1200rpm for 5 minutes at 
4°C. The liquid was aspirated away to leave the pellet of RBC-depleted PBL.
2.3.5 Purification strategies
2.3.6 Dynal bead depletion
For some experiments it was necessary to negatively deplete to enrich for or 
purify the T cells. Briefly, cells were labelled on ice for 30 minutes with various 
biotinylated antibody cocktails (see table 2.1) at saturating concentrations in 
handling media (100 pi / 107 cells). Samples were then washed and resuspended 
in 4ml of Dynal bead binding buffer as it was essential that there was no biotin so 
as not to compete with the reaction. Dynal beads (M280, Dynal, Norway) were 
added at a ratio of 2:1, beads to cells for a further 30 minutes with constant 
rotation at 4°C. Cells bound to dynal beads (negative fraction) were then 
removed using a magnetic particle concentrator (Dynal). After a wash step cells
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were resuspended in the appropriate media and counted. The success of the 
depletion was determined using flow cytometry.
Specificity Clone Conjugate Supplier Dilution
yb receptor GL-3 Biotin BD 1/400
CD1 lb/Mac-1 M l/70 Biotin BD 1/400
I-Ab 25-2-17 Biotin BD 1/400
CD49d DX-5 Biotin BD 1/400
CD45R/B220 RA3-6B2 Biotin BD 1/400
Table 2.1: Antibodies used for dynal bead depletion.
2.3.7 MACS and MOFLO sorting
An auto-MACS machine was used to obtain specific pure cell populations by 
positive selection when sterility was not important to the subsequent assay. 
Briefly, the desired cell population was first enriched for by removing unwanted 
cells using the Dynal bead strategy described previously (2.3.6). Then the 
remaining target population was labelled with a specific PE conjugated antibody 
for 30 minutes on ice at a density of 100 pi per 106 cells. After washing, cells 
were then incubated with lOpl per 106 cells of a 1:10 dilution of anti-PE MACS 
beads (Miltenyi biotech, UK) for 30 minutes on ice. Cells were then washed and 
passed through a 70 pM filter (BD Falcon, USA) to remove any cell clumps. 
Positive selection was achieved using the POSL programme for MACS selection 
based on the fact that the target population was often ^10% of the total cell 
population. After separation, cells were counted for use in downstream 
applications.
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For downstream application where sterility was essential, MOFLO separation was 
used. In this case unwanted cell types were also removed by Dynal beads (section 
2.3.6). Cells were then labelled with fluorescently tagged antibodies against 
various cell markers such as CD4, CD8 and CD45RB for 30 minutes on ice. 
After washing cells were passed through a 70 pM filter and separation of cell 
populations was achieved using a MOFLO cell sorter (DAKO Cytomation, USA).
2.3.8 Pre-culture cell modifications
2.3.9 Cell labelling with intracellular fluorescent dyes
For experiments designed to measure proliferation, conjugate formation or in 
circumstances requiring the ability to distinguish two cell populations, cells were 
labelled with the CFSE or SNARF-1 (both Molecular probes, USA). Briefly, 
prior to labelling cells were washed once in serum free media to remove excess 
protein that could compete with CFSE/SNARF-1 binding to cellular proteins. 
Cells were then resuspended in Dulbeccos PBS (Gibco, UK) containing 0.1 pM 
CFSE or 1 pM SNARF-1 (prewarmed to 37°C) at a minimum density of 3 x 107 
cells / ml for 10 minutes at room temperature. After labelling, cells were washed 
twice in handling media, counted and resuspended in the appropriate media for 
downstream applications.
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2.4 In vitro T cell activation
2.4.1 Preparation of stimuli
2.4.2 Peptide
The F5 TCR transgenic line recognises the influenza virus nuclear protein NP68 
(Ala, Ser, Asn, Glu, Asn, Met, Asp, Ala, Met) in the context of H-2Db. This 
peptide was synthesised and purified in the N1MR division of Protein Structure.
2.4.3 Generation o f microbeads
For some experiments, cells were stimulated using bead-immobilised antibodies. 
CELLection biotin binder beads (Dynal, Norway) were washed three times by 
adding 1 ml of bead wash buffer, placing the eppendorf into a MPC, and 
aspirating the liquid away. Beads were then resuspended in 500 pi of bead wash 
buffer containing 20 pi (10 pg) of each biotinylated antibody was added (see table 
2.2). To ensure that the final concentration of antibodies on beads with anti- 
CD3/CD28 was comparable to beads with three different antibodies, an irrelevant 
IgG biotinylated antibody was also included on the CD3/28 beads to offer 
competition for biotin binding sites. Tubes were placed on a rotator for 30 
minutes at RT after which the beads were washed 3 times in bead wash buffer as 
mentioned previously. Finally, beads were resuspended at an appropriate 
concentration in sterile bead storage buffer, and stored at -20°C till use. Before 
using beads in an assay they were washed once in culture media.
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Specificity Clone Conjugate Supplier
CD3e 145-2C11 Biotin BD
CD4 RM4-5 Biotin BD
CD8P 53-5.8 Biotin BD
CD28 37.51 Biotin BD
IgGl A85-1 Biotin BD
Table 2.2: Antibodies used for microbead coating
2.4.4 pMHC dimer preparation
Peptide loaded recombinant soluble dimeric mouse MHC class I : Ig fusion 
proteins (BD Biosciences, UK, Cat no: 551323) were prepared as outlined in 
manufacturers instructions (hereon referred to as pMHC dimers). Briefly, the 
correct ratio of MHC dimer to peptide was calculated using the following 
equation:
M p= MDb x R x Dp 
DDb
Dp = Molecular weight of peptide (eg 8mer = 130 x 8 = 1,040 Daltons).
DDb = Molecular weight of H2Db : Ig = 250,000 Daltons.
R = desired excess molar ratio of 160
Mp = micrograms of peptide of interest
MD = micrograms of H2Db : Ig in the reaction
The volume of the solution was adjusted to the desired concentration using PBS. 
Loading and assembly of the MHC dimer and peptide was achieved by an
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overnight incubation at 37°C. In all experiments correct assembly was assessed 
by incubating loaded dimer with 1 x 106 F5 lymph node cells for one hour, then 
incubating with a PE labelled anti mouse IgGl (BD) to visualise pMHC dimer 
molecules bound to F5 CD8 T cells.
2.4.5 Stimulation conditions
2.4.6 Soluble NP68
For antigen specific stimulation of F5 CD8+ T cells using soluble NP68 peptide 
and APC, preparations of total LN cells were seeded in a 96 well round bottom 
tissue culture plate (Nunc, Denmark) at a density of 1 -  2 x 105 cells per well in 
IMDM culture media. Samples were then incubated with a titration or a fixed 
dose of NP68 peptide at 37°C / 5% C 0 2. Cultures were terminated at specific 
time points for analysis. In some experiments, cells were pre-incubated with 10 
pg / ml CTLA4-Ig (gift from Peter Lane, University of Birmingham, UK) or 
control Ig for 45 minutes at 37°C / 5% C 0 2. Then NP68 was added to begin the 
stimulation. Furthermore, in other specific experiments, cells were co-incubated 
with NP68 and either the anti-IL-2 antibody S4B6 (1:50 of dilution of the cell line 
supernatant), or 10 units of recombinant IL-2 (R&D systems, UK) or a 1/50 
dilution of supernatant from the cell line X63-IL-2 for the full period of the 
culture.
2.4.7 Activation with beads
For stimulations using synthetic beads, F5 lymph node cell suspensions were 
prepared as outlined and were depleted of APC using dynal beads and labelled 
with CFSE (as described). Cell were plated out at a density of 2 x 105 cells per
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well and the specified beads (see 2.4.3) were added at a final ratio of 1:1 cells to 
beads. Cells were then placed at 37°C / 5% C 0 2 for the indicated time points.
2.4.8 pMHC dimer activation
A 96 well flat-bottomed plate (Nunc, Denmark) was coated overnight with a 5 
pg/ml solution of NP68 loaded pMHC dimer solution prepared as outlined in 
section 2.4.4. LN cells from F5 mice were harvested and depleted for APC with 
anti-CDl 1 b/I-Ab biotinylated antibodies using the strategy outlined in section 
2.3.6. Cells were then spun down at 400rpm for 30 seconds onto the layer of 
pMHC dimers at a density of 2 x 105 cells per well and incubated for specific 
times. Negative control stimulations were carried out using pMHC-dimers loaded 
with the non-stimulatory GAG peptide.
2.4.9 Assaying cell function
2.4.10 4 -  colour FACS staining and analysis
The expression of cell surface markers by ex vivo and in vitro activated cells was 
assessed using 4-colour flow cytometry. Briefly 1 x 106 cells were incubated with 
100 pi of FACS buffer containing a 1/50 dilution of the anti-Fc receptor antibody 
2.4G2 to reduce non-specific binding and specified dilutions of directly 
conjugated fluorescent antibodies or biotinylated antibodies against surface 
receptors (see table 2.3). Samples were incubated for 30 minutes on ice, followed 
by a wash step. If required, cells were incubated for 10 minutes on ice with a 
second layer streptavidin PerCP conjugated fluorophore (BD) to reveal the 
presence of biotinylated antibodies. Samples were again washed once and
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resuspended in 100 pi of ice cold before acquisition on a FACScalibur machine 
(BD). Data analysis was carried out using the FloJo software analysis platform 
(Tree star, USA).
Specificity Clone Conjugate Supplier Dilution
Fc receptors 2.4.62 Un-conjugated From cell line 1/50
CD45RB 16A FITC BD 1/400
CD25 7D4 FTTC/APC BD 1/200
TCRP H57-597 FITC/PE/APC BD 1/400
CD8P 53-5.8 FITC BD 1/400
CD5 53-7.3 FTTC/PE BD 1/400
Isotype cont. XMG1.2 FITC BD 1/200
CD4 GK1.5 PE BD 1/400
CD8a 53-6.7 PE/APC/PerCP BD 1/400 1/200
CD25 PC61 PE BD 1/400
CD69 H1.2F3 PE/Biotin BD 1/400 1/200
CD44 IM7 PE/APC BD / Leinco 1/400 1/200
CD45RB 23G2 PE BD 1/400
Isotype R3-34 PE BD 1/200
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CD4 RM4-5 APC/PerCP BD 1/400 1/200
V(J4 KT4 Biotin BD 1/50
VP5 MR9-4 Biotin BD 1/50
VP6 RR4-7 Biotin BD 1/50
VP7 TR310 Biotin Caltag 1/50
Vp8.1/2 MR5-2 Biotin Caltag 1/50
Vp8.3 1B3.3 Biotin BD 1/50
vpio B21.5 Biotin Caltag 1/50
vpn RR3-15 PE Caltag 1/50
V pi2 MR11-1 Biotin Caltag 1/50
V pl4 14-2 Biotin BD 1/50
V pi7 KJ23 Biotin BD 1/50
Table 2.3: FACS antibodies used in this study
2.4.11 CFSE proliferation and calculations
For the measurement of cell proliferation, F5 cells were labelled with CFSE as 
described. After activation using any of the described protocols, samples were 
stained with the required antibodies combinations for the discrimination of cell
populations and activation marker expression. These were labelled with 
fluorophores that did not fluoresce in the FL-1 channel. Samples were then 
acquired on the FACScalibur and a minimum of 40,000 events was collected per 
sample in order to achieve good CFSE peak discrimination. Data files were 
analysed using CellQuest software and gates were set manually to determine cell 
frequencies within each round of division. The calculations used to analyse the 
proliferation were as follows. Data of the frequency of CFSE labelled cells (F) 
that had undergone division rounds (d) were used to calculate the adjusted 
frequencies (AdF), this was achieved by dividing F by 2d. The burst size was 
obtained from the calculation Z(AdF x d) / 2 F  (for d > 0) The percentage of cells 
triggered to divide was calculated by using the equation (1 -  [AdF0 / ZAdFJ) x 
100.
2.4.12 Intracellular cytokine / granzyme staining
For the detection of cytokines by intra-cellular cytokine staining, antigen activated 
cells or ex vivo cells were treated with final concentrations of 0.5 pg/ml PdbU, 
Ionomycin (Sigma) and 1 pg/ml Brefeldin A (Sigma) for 4 hours at 37°C 5% C 0 2. 
Cells were then washed and stained for the expression of surface markers (as 
outlined). After a wash step, cells were resuspended in 100 pi of PBS and 100 pi 
of 6% paraformaldehyde was added to give a final concentration of 3% fixative. 
After 20 minutes on ice, cells were washed and resuspended in 100 pi of lx 
cytokine permeabilisation buffer for exactly 3 minutes after which 100 pi of 
FACS buffer was added per well. Cells were washed once and resuspended in 
100 pi of FACS buffer containing fluorescently labelled anti-cytokine antibodies 
or irrelevant isotype controls (see table 2.4). After a minimum 30 minute
incubation on ice, cell were washed once and acquired on a FACScalibur (BD). 
For granzyme staining, no PdbU, ionomycin or Brefeldin was used prior to intra­
cellular staining.
Specificity Clone Conjugate Supplier Dilution
IFNy XMG1.2 FITC/PE BD 1/200
IL-2 S4B6 PE BD 1/200
IL-2 JES6-5H4 APC BD 1/100
Granzyme B GB12 PE Caltag 1/100
Isotype MOPC-21 PE Caltag 1/100
Table 2.4: FACS antibodies for intracellular staining
2.4.13 CTLL-2 assay
In certain circumstances, media was harvested from activated cells and the IL-2 
content was measured using the CTLL-2 bioassay. Briefly, 50 pi of supernatant 
from stimulated F5 cells were harvested at the defined time points. And incubated 
with a total of 5 xlO3 CTLL-2 cells (ATCC cat no. TIB 214) for 24 hours at 37°C 
/ 5% C 0 2. At the same time CTLL-2 were incubated with a titration of 
recombinant IL-2 to generate a standard curve. After 24 hours, 10 pi of Almar 
blue solution (Biosource, UK) was added to each well and incubated over night. 
The plate was then read using a Luminescence Spectrometer LS50B (Perkin 
Elmer, UK) at 590 nm and data analysed using FL WinLab software (Perkin 
Elmer). The standard curve was used to calculate the IL-2 content in U/ml.
2.4.14 IL-2 capture assay
Detection of IL-2 production using the commercially available IL-2 capture assay 
(Miltenyi Biotech, UK) was carried out as outlined in the manufactures protocol. 
Briefly, a minimum of 1 x 106 activated cells were washed once, placed in a 1.5 
ml sterile eppendorf tube and labelled with 100 pi of a 1/10 dilution of IL-2 
capture antibody in ice cold IMDM for 10 minutes on ice. Volumes were then 
made up to 1 ml with pre-warmed culture media and placed at 37°C / 5% C 0 2 for 
1 hour with constant agitation. After this cells were washed once and labelled 
with 100 pi of ice-cold media containing a 1/10 dilution of the anti-IL-2 PE 
detection antibody and any other surface marker antibodies required. A 1/100 
dilution of the anti-Fc receptor antibody 2.4G2 was also added at this stage. Cells 
were incubated for 15 minutes on ice, washed once and acquired immediately on a 
FACScalibur.
2.4.15 Conjugate assay
For the detection of T cell-APC conjugate formation by FACS, BMDC were 
grown 7 days prior to the assay as described. The F5 T cells were labelled with 
CFSE and the BMDC with SNARF-1, also as outlined previously. To induce 
conjugates, cells suspended in IMDM culture media were placed in 1.5ml 
eppendorf tubes, mixed at a 1:1 ratio (5 x 105 per cell type) and spun down at 
1200rpm for 10 seconds at room temperature. The pellets were quickly and 
vigorously resuspended and tubes were placed at 37°C 15%  C 0 2 for 10 minutes, 
after which they were acquired on the FACScalibur. For controls, gates were set
using T cells or BMDC alone or with T cells conjugated with non-peptide-pulsed 
APC. Analysis was carried out using CellQuest software.
2.4.16 CTL assay
Prior to the assay, the target EL-4 thymoma line was maintained in IMDM culture 
media and split at ~80% confluence so cells were in the log phase of growth the 
day before the assay. Three days prior to the assay, suspensions of LN and spleen 
were prepared from F5 mice and activated with 1 pM NP68 at a cell density of 5 x 
105 cell/ml in culture IMDM. Cultures were grown in upright culture flasks and 
with a minimum of 10 ml cell suspension for 3 days at 37°C / 5% C02. On the 
day of the assay F5 cells and EL-4 cells were washed once and counted. The EL- 
4 cells were then resuspended at 6 x 106 per ml in serum free AB IMDM and split 
into two equal groups, one aliquot was pulsed with 10 pM of NP68 and the other 
was left un-pulsed. EL-4 cells were then incubated for 3 hours at 37°C / 5% C02. 
After a wash step, EL-4 cells were labelled with 1.85 Mbq of 51Cr and incubated 
for 1.5hrs at 37°C / 5% C02. Effector cells were added at a concentration 
representing the top effector to target ration and serially diluted 1/3 across the 96 
well round bottom plate. Then a total of 1 xlO4 pulsed, 51Cr labelled EL-4 cells 
was added to respective wells to give the correct effector to target ratios in the 
well. The maximum 51Cr release was measured by lysing pulsed targets with 1% 
Triton-X. The plate was spun down at 1000 rpm for 1 minute then incubated at 
37°C / 5% C02 for 4 hours. After this time 25 pi of supernatant was harvested 
using a micro-96 harvester (Skatron instruments, USA) and transferred to a 
printed filter mat A (Wallac, Finland). These mats were dried in the microwave
for 1 minute, and immersed in liquid scintillant (Wallac). The degree of 51Cr 
release was measured using a 1205 automated P-plate counter (Wallac). The 
NP68 specific 51Cr release was calculated using the following equation.
(Experimental - Spontaneous release) xlOO = % specific 5,Cr release 
(Maximal release -  Spontaneous release)
2.4.17 Intracellular Ca2* fluxing
For antigenic stimulation BMDC were grown for 1 week prior to the experiment 
as outlined. On the day of the experiment these were either pulsed for 4 hrs with 
10 pM NP68 or with media alone at 37°C / 5% C 0 2. Suspensions of F5 CD8 T 
cells were prepared as described and loaded with 4 pg/ml of Indo-1 AM 
(Molecular probes) in RPMI 1640 media +1%  BSA at a density of 2 x 106 cells 
per ml by incubating in a 37°C water bath for 40 minutes followed by a wash step. 
For antibody induced calcium fluxing samples were incubated with saturating 
concentrations of either biotinylated 2C11 (BD), biotinylated CD8|3 (BD) or both 
for 15 minutes on ice, followed by a wash step. Calcium flux measurements were 
carried out by monitoring the change in FL-4 / FL-5 fluorescence ratio using a 
LSR flow cytometer (BD). In the case of antibody induced calcium flux, samples 
were acquired for 30 seconds to establish a baseline, then 20 pg avidin was added 
in order to cross link the pre-bound biotinylated antibodies. Samples were then 
returned to the LSR and acquired for a further 370 seconds. To measure antigen- 
specific calcium fluxes T cells were acquired for 30 seconds to establish a 
baseline. Cells were mixed 1:1 with either NP68 pulsed DC’s or with DC’s alone 
and centrifuged at 12,000 rpm for 10 seconds to induce conjugate formation.
After resuspension, samples were then returned to the LSR and acquired for a 
further 370 seconds.
2.4.18 Real-time PCR analysis
Purified F5 cells were obtained from the LN of mice and 1 x 106 cells were 
activated on a layer of NP68 pMHC dimers. At specific time points, cells were 
harvested and spun down at 1200rpm at 4°C for 1 minute. Media was aspirated 
away from the pellet and this was resuspended in 1 ml of Trizol (Invitrogen, UK). 
RNA was extracted using RNeasy Kit (Qiagen, Germany) and reverse-transcribed 
with oligo (dT) 16 (Applied Biosystems, USA) according to the manufacturer's 
protocol. cDNA served as template for the amplification of specific genes and the 
housekeeping gene Hprt transcripts by real-time PCR using Assays-on-Demand 
gene expression probes (Applied Biosystems, USA), Universal PCR Master Mix 
(Applied Biosystems, UK) and the ABI-PRISM 7000 Sequence detection system 
(Applied Biosystems, USA). Target gene expression was calculated using the 
comparative Ct method for relative quantitation upon normalization to Hprt gene 
expression.
Gene Cat no. Supplier
Hprt Mm00446968 Applied Biosystems
1L-2 Mm00434256 Applied Biosystems
IFNy Mm00801778 Applied Biosystems
c-Rel Mm00485657 Applied Biosystems
c-Jun Mm00495062 Applied Biosystems
JunB Mm00492781 Applied Biosystems
c-Fos Mm00487425 Applied Biosystems
FosB Mm00500401 Applied Biosystems
NF-ATcl Mm00479445 Applied Biosystems
Table 2.5: Real time PCF primers used
2.4.19 Confocal analysis
A day prior to the experiment, 12 mm diameter round cover-slips were placed into 
a 24 well plate (Nunc). Coating of the coverslips was achieved by the addition of 
500 pi of 0.01% poly-l-lysine solution (Sigma) for 3 hours at room temperature. 
The solution was aspirated away and the slips were left to air-dry overnight. Cell 
suspensions from F5 mice were prepared and activated with soluble NP68 as 
described. After 1-4 hours, cells were washed in PBS and resuspended at a 
density of 3 x 106 cells per ml. A total of 100 pi of cell suspension was then 
added slowly to the centre of the poly-l-lysine coated cover-slips. These were 
incubated for 10 minutes at room temperature after which the 100 pi was carefully 
removed from each slip. Next 100 pi of 2% paraformaldehyde was added 
carefully to each slide and incubated for 15 minutes at room temperature. After 
this the paraformaldehyde was removed and slides were washed 3 times using 500 
pi of PBS containing 3% FCS. Next, 500 pi of confocal perm buffer was added 
for 10 minutes to permeabilise cells for intra-cellular staining. Cells were then 
incubated with a 1/20 dilution of rabbit-anti mouse c-Rel antibody (Santa cruz, 
USA) or an irrelevant rabbit Ig isotype control, made up in the confocal perm 
buffer, or solution alone, for 45 minutes at room temperature. After this samples 
were washed 3 times in confocal perm buffer and incubated with a 1/50 dilution 
of anti-rabbit Ig F(ab*)2 fragments conjugated to Alexa 440 (Molecular probes) or
buffer alone for 30 minutes at room temperature. Cells were washed 3 times in 
500 pi of confocal perm buffer and 100 pi of 2% paraformaldehyde was added for 
15 minutes. Finally slips were washed 3 times with 500 pi of PBS alone and 
mounted on slides with one drop of I mounting media containing PI (Vecta-shield, 
USA). Samples were then acquired using a Leica delta vision confocal 
microscope (Leica, USA).
2.4.20 Duration o f stimulation experiment
Prior to the assay, 96 well flat-bottom plates (Nunc) were coated with 5 pg/ml of 
NP68 pMHC dimers overnight and washed 10 times in PBS on the day of the 
assay to remove residual peptide. Suspensions of F5 cells were prepared and 
depleted of all APC using dynal beads as described, and a total of 5 xlO5 T cells 
were spun down onto the activating layer then incubated at 37°C / 5% C 0 2. At 
specified time points, cells were taken off the dimer layer, washed 5 times and 
transferred to a fresh 96 well flat bottomed plates. To control for any carrier over 
of antigen, 1 x 105 CFSE labelled naive F5 cells were spiked into the wells. Also 
to minimise further activation 10 pg/ml of the anti-MHC class I blocking antibody 
(28-14-8 anti- mouse H-2Db, BD) was also added to the wells. The plate was 
cultured at 37°C / 5% C02 and was analysed after 24 hours for the expression of 
activation markers and the detection of intra-cellular cytokines as described 
previously.
2.4.21 Inhibition ofErk or Src activity
For the measurement of IL-2 after treatment with the Mek inhibitor PD90859 
(Calbiochem, USA), F5 cells were purified as described from the LN of mice and 
activated on a NP68 pMHC dimer layer. Cells were treated with 100 pi of 20 pM 
PD90859 in culture media per 1 x 106 cells, either for 30 minutes prior to 
activation on the layer or for the specified time points after which the inhibitor 
was removed by washing cells 3 times at 1000 rpm and resuspending in fresh 
IMDM culture medium and returning to the stimulus. IL-2 production was 
measured after a total of 24 hours in culture by intra-cellular cytokine staining as 
described. For the inhibition of Src kinases, either 20 pM PP2 or PP3 (Both 
Calbiochem) was added to cells, either 30 minutes before adding stimulus, or after 
3 hours of activation. IL-2 analysis was conducted as described for PD90859 
experiments.
2.5 Measurement of in vivo T cell function
2.5.1 In vivo F5 activation with AJNT/60-68flu virus
Cells from F5 mice were isolated as described and 3 x 106 cells suspended in 150 
pi of handling media with no serum were injected via the tail vein into Rag-1'7' 
mice along with an optimal dose (PfU) of the A/NT/60-68 influenza virus. After 
7 days, recipient mice were sacrificed and LN and spleen were collected and 
analysed for cell number, cell phenotype and intra-cellular cytokine production by
FACS. As controls, F5 cells were transferred without virus. Recipients were 
routinely housed in SPF conditions at the NIMR animal facility.
2.5.2 Transfer o f cells into Rag-1' hosts
Specified cell populations were isolated using both negative and positive selection 
strategies outlined previously. When the desired purity was achieved and checked 
by FACS, defined numbers of cells were injected into Rag-17 hosts via the tail 
vein. The success of transfer was assessed by bleeding mice after 24 hours and 
looking for the frequency of PBL by FACS. Recipients were then housed in SPF 
conditions at the NIMR animal facility. Mouse weights were monitored on a 
weekly basis.
2.5.3 Analysis o fG I  tract pathology
The entire GI tract was removed from mice and flushed with 20 ml of PBS. Then 
the GI tract was flushed with Bouins fixative and stored in the dark at room 
temperature, submerged in Bouins solution. For histology, portions were cut with 
a scalpol and embedded in wax and sections and stained with H & E at the NIMR 
division of histology. Slides were then analysed on a standard light microscope 
with digital camera attached (Fuji). Photos were taken using 100X magnification 
and 2X digital zoom.
2.6 Biochemical analysis
2.6.1 Stimulation conditions
For stimulation of F5 cells for biochemistry, a minimum of 5 x 106 cells in culture 
IMDM were activated on NP68 pMHC dimer layers for defined time points at 
37°C / 5% COz. After these periods cells were removed from the layer and 10 pi 
were kept for FACS analysis of activation markers and the rest were transferred to 
pre-chilled 1.5 ml eppendorf tubes and spun down at 1000 rpm, 4°C for 30 
seconds to pellet cells. After the supernatant was aspirated away, pellets were 
snap frozen in liquid nitrogen and stored at -70°C till use.
2.6.2 Sample preparations
2.6.3 Cell lysis
Cell pellets were lysed in a minimum of 500 pi of ice-cold lx lysis buffer by 
repeat pipetting. Tubes were then left on ice for 20 minutes after which samples 
were spun down at 2000 rpm for 10 minutes at 4°C. The lysate was then 
transferred to clean pre-chilled 1.5 ml Eppendorf tubes.
2.6.4 Acetone precipitation
To concentrate the protein content of the lysates, 1.5 volumes of ice-cold acetone 
was added to each tube containing the lysate. Tubes were mixed and left
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overnight at 4°C. Subsequently, acetone precipitates were washed 3 times in 70% 
ethanol always at 4°C, after which pellets were resuspended in the desired volume 
of 3x reducing sample buffer and placed on a mechanical tube shaker at 4°C for 2- 
3 hours. Samples were then either boiled for 5 minutes and loaded directly onto 
the SDS-PAGE gel or snap frozen and stored at -70°C.
2.6.5 Gel preparation, running and transfer
2.6.6 Preparation o f lower gel and upper gel sections
Briefly, the plates were washed in water and 100% ethanol and dried thoroughly. 
After assembling the plates with 1mm spacers (Bio-rad), typically a 10% PAGE 
gel was used and made as follows:
7.5 ml Lower gel buffer
10 ml of 30% w/v Acrylamide stock (Protogel, National Diagnostics, UK)
100 pi of 10% APS (Bio-rad)
10 pi of TEMED (Bio-rad) 
dH20 to 50 ml
The gel was poured and a layer of H20  saturated Butanol was placed onto the top. 
The gel was left for 1-2 hours to polymerise. The top of the lower gel section was 
washed with an excess of DI H20  and the upper gel was made up as outlined:
2.5 ml Upper gel buffer
1.5 ml of 30% w/v Acrylamide stock
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6 ml dH20
50 til of 10% APS
10 pi of TEMED
After pouring the upper gel, the 1mm well former was added and the gel was left 
to polymerise for ~lhr. After this time, all wells were washed with lx running 
buffer.
2.6.7 Loading and running o f  gels
Prior to loading on the gel, samples were boiled for 5 minutes in a heat block at 
100°C. After a brief period of centrifugation (for ~5 seconds), samples were 
loaded onto the gel with the molecular weight markers (Rainbow markers, Bio- 
rad, USA). Gels were typically run at 25 mA for 4-5 hours, or at 5 mA overnight 
using the Hoefer SE400 gel system (Amersham Biosciences, USA) with running 
buffer in the upper and lower chambers and a p5500XT DC power pack (Hoefer 
Scientific Instruments, USA).
2.6.8 Transfer conditions
For transfer of protein from the SDS-PAGE gel to a nitrocellulose membrane the 
following protocol was used. The membrane (Immobilon P, Millipore, USA) was 
activated by a brief submersion in methanol. The transfer was set up with the 
cassettes, sponges, gel and membrane all submerged in transfer buffer. The order
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of assembly from the cathode to anode was, sponge, 2x filter paper, gel, 
membrane, 2x filter paper, sponge. Transfers were conducted using the Trans- 
Blot Cell system (Bio-rad). For 4 hour transfers the condition were 100 v 400 mA 
and for overnight transfers the condition were 30 v 100mA.
2.6.9 Western blotting analysis
2.6.10 Antibody incubations
Membranes were blocked in blocking buffer for a minimum of 2 hours at room 
temperature with constant agitation. Membranes were then incubated with 
blocking buffer containing the appropriate dilution of antibody for the optimal 
time period (see table).
Specificity Residues Supplier Dilution Incubation
pErkl/2 Tyr Biosource Int 1/1000 4 hours
Total Erk 2 N/A Cell signalling 1/2000 Overnight
pJnkl/2 Thr/Tyr
165
Cell signalling 1/2000 Overnight
Total Jnkl/2 N/A Cell signalling 1/2000 Overnight
anti-Rabbit
HRP
N/A Cell signalling 1/3000 1 hour
Table 2.6: Antibodies used for western blotting
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After this point, the membrane was submerged in wash buffer for a minimum of 1 
hr with at least 4 changes of buffer. Membranes were then incubated with the 
appropriate HRP conjugated secondary antibody in blocking buffer (see table 5.2) 
for 1 hr after which washing was carried out as before. For chemiluminescent 
visualisation of bands, the membrane was covered with ECL solution (Amersham, 
UK) for 1 minute with agitation and placed in a screened cassette. Membranes 
were then exposed to blue film (Kodak MXB Film, France) for the desired period 
in darkness and developed using a FPM 2100 X-ray film processor (Fuji). For the 
detection of total protein for loading controls, membranes were stripped using 
stripping buffer for 20 minutes at 60°C then the process was repeated again using 
antibodies against total protein.
2.6.11 Quantification
The measurement of band intensities relative to loading controls was carried out 
using a Calibrated imaging densitometer (GS-710, Bio-rad). Briefly, films were 
scanned and the density of band signal was measured. The densitometry values 
generated for the phospho-bands were divided by the values then obtained for the 
loading controls and the ratio of phospho to total protein was calculated. For 
replicate experiments, the corrected ratios obtained for WT cells were set at 100% 
for each time point analysed. The mutant was then expressed as a percentage of 
these values at each respective time point.
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Chapter 3: The role of Fyn in peripheral CD8 T cell activation
3.1 Introduction
Fyn deficient mice have been previously generated by two independent groups 
and the characterisation of the thymocytes and peripheral T cells have been 
described (Appleby et al., 1992; Stein et al., 1992). Soriano and colleagues used 
a knockout strategy that eliminated expression of both Fyn splice variants (FynT 
and FynB) by disrupting exon 2 that contains the initiator methionine (Stein et al., 
1992). In contrast Perlmutter and co-workers used a strategy that only disrupted 
exon 7B, which is incorporated into FynT transcripts and therefore did not affect 
FynB expression (Appleby et al., 1992). When analysing thymic development, 
both groups found that it was unaffected. Appleby et al showed that the thymic 
profiles of Fyn'7' mice were comparable to WT mice and did not exhibit the 
profound block at the DN3 to DN4 transition evident in thymi from Lck'7' animals 
(Molina et al., 1992). The numbers of peripheral T cells and the ratio of CD4: 
CD8 cells were also comparable between Fyn'7' and WT mice in both studies. 
Collectively these data showed that Fyn, unlike Lck, was not essential to thymic 
development and peripheral repertoire generation.
When Fyn'7' thymocytes were activated with anti-CD3 antibodies plus PMA to 
provide signal 2, both groups reported reduced proliferation, intra-cellular calcium 
mobilisation and IL-2 production were reduced (Appleby et al., 1992; Stein et al., 
1992). These defects could be overcome by stimulating with PMA and 
ionomycin that bypassed the requirement for TCR signalling. Work by Soriano
110
and colleagues also suggest that Fyn'7' mice showed defects in the deletion of 
thymocytes specific for the M ls-la self-super antigen (Stein et al., 1992).
When the peripheral T cells were analysed both groups found that Fyn"7' splenic T 
cells recovered some degree of proliferative capacity compared to Fyn7 SP 
thymocytes. However both studies showed that there was still a reduction in the 
response of splenic T cells from Fyn'7' mice compared to WT, albeit not as 
profound as that seen within the thymocyte populations. Intracellular calcium 
mobilisation and IL-2 production were still defective in peripheral Fyn'7' T cells. 
These data were obtained by activating the cells using antibodies against the CD3 
complex with PMA. When other stimuli were used such as allogenic stimulator 
cells or SEA the proliferative defect of the Fyn'7' cells compared to WT was not as 
profound (Appleby et al., 1992; Stein et al., 1992). Together these data supported 
a role for Fyn as a positive regulator of T cell responses, with particular emphasis 
on calcium mobilisation and IL-2 production.
Work pre-dating the publication of the Fyn'7' mice using cell lines and transgenic 
over-expression strategies also supported the conclusion that Fyn played a 
positive role in T cell activation. For example over-expression of Fyn in T cell 
hybridomas resulted in attenuated IL-2 production (Davidson et al., 1992). Later 
studies also in T cell lines suggested that Fyn may positively regulate IL-2 
production (Fusaki et al., 1994; Karnitz et al., 1994). Furthermore transgenic 
mice expressing 20-fold more Fyn compared to control animals generated 
thymocytes that were hyper-responsive to anti-CD3 stimulation, whereas
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expression of catalytically inactive Fyn lead to hypo-responsiveness in response 
to anti-CD3 stimulation (Cooke et al., 1991).
In the initial Fyn'7' publications, both groups also conducted basic biochemical 
analysis of TCR induced phospho-tyrosine levels by stimulating cells with anti- 
CD3. Stein et al showed there was no change in the timing of phosphorylation or 
the identity of the proteins phosphorylated, however they did show a global 
reduction in the absolute phospho-tyrosine levels (Stein et al., 1992). Appleby et 
al showed that Fyn deficiency led to the reduced phosphorylation of specific 
substrates while the tyrosine phosphorylation of other proteins remained 
comparable to those induced in cells from WT mice (Appleby et al., 1992). These 
data provided biochemical evidence that Fyn was contributing to the induction of 
TCR mediated phosphorylation events.
Further biochemical analysis using Jurkat cell lines transfected with either Lck or 
Fyn suggested that Fyn was able to regulate a distinct pattern of protein 
phosphorylation with respect to Lck. The phospho-protein pattern observed in 
Fyn transfected cells resembled that induced by altered peptide ligands (Denny et 
al., 2000). In concordance with this theory, Fyn7' cells have been shown to be 
defective in their response to weak TCR agonists (Utting et al., 1998). 
Furthermore, stimulation of T cells with TCR antagonists has been shown to 
preferentially lead to the activation of Fyn ((Huang et al., 2000b; Huang et al., 
2000a). The conclusions drawn from these data was that Fyn was able to mediate 
positive signals downstream of the TCR via pathways that may be qualitatively 
and/or quantitativly different from Lck.
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The role of Fyn in T cell responses to pMHC has not been extensively addressed. 
As discussed, the initial description of T cell activation events in the absence of 
Fyn involved activating polyclonal cells with anti-CD3 plus PMA. Anti-CD3 
and PMA primarily activate through the TCR with no involvement of co-receptor 
molecules such as CD4 and CD8, which are known to associate with Lck (Barber 
et al., 1989; Veillette et al., 1988). Furthermore stimulation with MHC-peptide in 
the context of an APC will also involve a number of other co-stimulatory 
pathways. Fyn has been implicated in the signalling pathways downstream of a 
number of these co-stimulatory receptors, these include SLAM (Chan et al., 
2003), CD2 (Fukai et al., 2000) and CD28 (Raab et al., 1995). Physiological 
stimulation conditions would presumably involve ligation of not just the TCR, but 
also the panoply of receptors and ligands found on the T cell and APC, and may 
therefore utilise Fyn differently from antibody stimulation solely through the 
TCR.
The aim of this study was to determine the role of Fyn in peripheral T cell 
activation using pMHC and APCs, in contrast to anti-CD3 stimulation. To this 
end the Fyn'7' mice described by Stein et al were crossed onto the class I restricted 
F5 TCR transgenic line. T cells expressing the F5 TCR can be identified by using 
the VP 11-specific antibody OKT-1. The F5 TCR recognises the NP peptide 
(amino acids 366 -  374) of the influenza A virus A/NT/60-68 (H3N2) in the 
context of H2-Db (Mamalaki et al., 1993b; Mamalaki et al., 1992). Fyn 7 F5 mice 
crossed onto a Rag-17 background have a monoclonal CD8 T cell repertoire that 
can be activated using the NP68 peptide. For clarity, I will refer to the Rag-1'7' F5
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Fyn sufficient mice as F5 WT mice and the Rag-1'7' F5 Fyn 7' mice as F5 Fyn'7 
mice.
3.2 Fyn deficiency does not alter CD8 T cell development in F5 mice
The development of F5 T cells and the response to cognate antigen has been well 
characterised (Smyth et al., 2002; Mamalaki et al., 1992). Introduction of the F5 
TCR transgene into Rag-1'7' mice exclusively leads to positive selection of the 
CD8SP lineage (Mamalaki et al., 1993b). As expected from the previous Fyn'7' 
reports selection into the CD8SP lineage proceeded normally in the absence of 
Fyn with no CD4SP evident (Figure 3.1), furthermore the frequency of DP cells 
was also comparable to WT F5 mice. Within the CD8SP population there are 
immature CD8ISP and mature CD8SP, which can be distinguished by TCR 
expression levels whereby cells that have up-regulated their TCR levels are 
mature CD8SP cells (Schrum et al., 2003). Figure 3.1 A shows that maturation of 
CD8SP cells, as judged by TCR levels expressed on CD8SP, proceeded normally 
in the absence of Fyn. Figure IB shows that the absolute numbers of DN, DP and 
mature CD8SP was also comparable between WT F5 and Fyn'7' F5 thymi. More 
detailed analysis of the DN population on the basis of CD25 and CD44 expression 
revealed that there was a small but significant increase in the frequency (Figure 
3.1C) and absolute number (Figure 3.ID) of DN3 cells in the thymi from Fyn'7' F5 
mice, whereas other DN populations were comparable. Therefore, while the 
maturation of CD8SP was normal, Fyn did seem to play a role at the DN3 to DN4 
transition, even in the presence of Lck.
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Analysis of the peripheral lymphoid organs of these mice revealed that in both 
groups the frequency of CD8+ V p il+ in the PLN was ~90% (Figure 3 .IE). 
However, the absolute numbers of CD8+V p il+ cells were elevated in the PLN of 
F5 Fyn*7' mice compared to F5 WT mice (Figure IF). Expression of CD62L, 
which is cleaved and shed by activated T cells (Chen et al., 1995; Tedder et al., 
1995), was comparable between both groups and CD5 levels were also identical 
(Figure IE), as were the expression levels of CD25 and CD69 (data not shown).. 
Despite the increase in the number of peripheral T cells from F5 Fyn'7* looked 
phenotypically normal compared to F5 WT cells and typically naive, as judged by 
the expression of activation markers.
3.3 Fyn deficiency increases cell division and CD25 expression but not 
triggering or cell cycle entry
Upon stimulation with cognate antigen, a naive CD8 T cell will become activated 
and upregulate a number of cell markers, before entering into a programme of cell 
division and differentiation. In order to address the role of Fyn in the initiation of 
an antigen specific CD8 T cell response in vitro, proliferation and expression of 
activation markers was examined by flow cytometry. Upon T cell activation, one 
of the earliest markers to be expressed is the type II membrane glycoprotein CD69 
(Castellanos et al., 1997; Hamann et al., 1993). Although there has been no 
function assigned to this molecule, it is considered to reflect the activation status 
of a cell as a result of TCR triggering (Zola, 2000). At 24 hrs after primary 
stimulation, T cells have not yet entered division, therefore CD69 expression was 
assessed as a measure of early cell activation in the absence of Fyn. Figure 3.2A
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shows bi-variant FACS plots for three concentrations of NP68 for each group in 
order to highlight how gating and analysis was performed. These FACS data 
were then used to generate Figure 3.2B by plotting the percentage of CD69+ cells 
versus NP68 concentration. From the data in Figure 3.2B it is clear that F5 Fyn/_ 
T cells behave the same as F5 WT cells over a range of peptide concentrations, as 
judged by the induction of CD69 expression.
Activation of CD8 T cells also induces the expression of the surface receptor 
CD25. CD25 is the a  subunit of the IL-2 receptor, and in concert with the p 
(CD122) and y (CD132) subunits forms the high affinity complex (Leonard et al., 
1990). CD25 expression has a functional consequence for the T cell enabling it to 
respond to IL-2 (Leonard and Lin, 2000). Figure 3.2C shows that the MFI of 
CD25 expression was comparable in both groups of cells at 24 hrs. Also the 
percentage of Fyn deficient F5 CD8 T cells that had upregulated CD25 at 24 hrs 
in response to a titration of NP68 was identical to controls (Figure 3.2D).
In order to assess the proliferative capacity, cells were labelled with CFSE and 
activated for various times with a titration of NP68 peptide. Two informative 
parameters were determined from the analysis of the CFSE division profiles. First 
we determined the proportion of cells that were triggered to divide at a particular 
antigen concentration (% divided). Second we calculated the average number of 
divisions a cell underwent once it had been triggered (burst size). In both cases 
the parameters are adjusted to relate back to the starting cell population by 
correcting for cellular divisions (Gett and Hodgkin, 2000). By 48 hrs both F5 WT 
and Fyn';' cells had divided as shown by the dilution of CFSE (Figure 3.3A).
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Analysing the data in Figure 3.3A revealed that the proportion of cells entering 
division (Figure 3.3B) and the number of divisions they carried out (Figure 3.3C) 
were comparable. In contrast to the CFSE data, analysis of CD25 expression at 
48 hrs revealed that in the absence of Fyn, the MFI of this marker was elevated ~ 
2-fold compared to F5 WT cells (Figure 3.3D). Furthermore, the percentage of 
F5 Fyn'7' cells expressing CD25 was increased by ~3-fold at a dose of 10'2 pM 
NP68 (Figure 3.2D and E).
When division was assessed at 72 hrs, as shown in Figure 3.4B, it was clear that 
F5 Fyn'7' cells had undergone an extra round of division compared to F5 WT over 
a range of peptide concentrations. The increase in the burst size is illustrated in 
the CFSE histograms, as they show a greater frequency of cells in the later 
division peaks in the absence of Fyn (Figure 3.4A). Analysis of CD25 expression 
at 72 hrs showed that the increased expression in the absence of Fyn was 
sustained both in terms of the MFI (Figure 3.4C) and the percentage of cells 
expressing CD25 (Figure 3.4D) compared to F5 WT cells.
3.4 Fyn*7' and WT F5 cells have similar activation kinetics
One possibility to explain the elevated expression of CD25 observed at 48 hrs in 
the absence of Fyn could be due to altered kinetics of the response. For example, 
if CD25 expression peaked earlier in F5 WT cells than the F5 Fyn'7', at later time 
points the expression by F5 WT cells would already be in decline and the F5 Fyn'7' 
response would appear elevated. Therefore the expression levels of CD25 and 
CD69 before 24 hrs was analysed to address this issue. To this end Fyn deficient
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and WT F5 T cells were activated using a single dose of NP68 peptide and 
analysed for CD69 expression (Figure 3.5A) and CD25 expression (Figure 3.5B) 
at the indicated time points. In both groups CD69 expression was comparable and 
was first detected at 1 hr, peaked between 3 and 24 hrs and then declined at 48 
hrs. As with CD69, prior to 24 hrs, CD25 expression was equivalent in the 
absence of Fyn, however from the data in Figure 3.5B it is clear that CD25 
expression remained elevated at 48 hrs. In contrast to this, CD25 expression in 
the Fyn sufficient group dropped by 50% at 48 hrs. By 72 hrs CD25 expression in 
both groups was comparable. Therefore, the observed elevation of CD25 
expression in the F5 Fyn'7' T cells was not due to delayed kinetics of the response.
3.5 Fyn*7* F5 T cells produce more IL-2 in response to NP68 stimulation
In order to determine why F5 Fyn'7' CD8 T cells show prolonged CD25 expression 
and an increased burst size, the production of IL-2 by these cells was measured. 
TCR derived signals drive the initial expression of CD25 and IL-2 by the T cell 
(Kim and Leonard, 2002). However, the level of CD25 is then maintained on the 
surface of the cell by a classical feedback mechanism whereby IL-2 binds the high 
affinity receptor activating STAT5 leading to further CD25 expression (Kim et 
al., 2001; Smith and Cantrell, 1985). It seemed plausible that prolonged 
expression of CD25 observed in the absence of Fyn was a direct result of the 
capacity of these cells to make IL-2. Therefore IL-2 production by Fyn deficient 
F5 CD8 T cells compared to F5 WT cells was determined using a number of 
different techniques. Figure 3.6A shows IL-2 production by antigen activated 
CD69+ F5 CD8 cells as measured by a FACS based assay detecting secreted IL-2
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protein at the single cell level. When these data were plotted in graphical form, it 
was clear that the initiation of IL-2 production in both groups was comparable 
(Figure 3.6B). However the percentage of CD69+ F5 Fyn7 CD8 T cells able to 
make IL-2 was elevated by ~ 2-fold at 6 hrs and at every time point measured 
thereafter compared to  F5 WT cells. The increased production of IL-2 was also 
confirmed by measuring the amount of cytokine in the supernatants after 48 hrs of 
culture using the CTLL-2 bioassay, this is shown in the insert panel of Figure 
3.6B. There was a 10-fold increase in IL-2 production in supernatants from F5 
Fyn7' cell cultures compared to F5 WT samples. Therefore, increased production 
of IL-2 by F5 Fyn'7' correlated with increased accumulation in the media. To 
confirm these observations, real time PCR for steady-state IL-2 mRNA was 
performed. IL-2 mRNA levels were elevated ~2 fold in the Fyn deficient F5 T 
cells activated with NP68 (Figure 6C). These data show that mRNA production 
peaked in both groups at 4  hrs, which was one hr before peak production 
measured using the IL-2 capture assay (Figure 3.6B), therefore mRNA and 
protein production correlated well. Furthermore, from the profile of IL-2 mRNA 
transcription it was unlikely that an increase in IL-2 message stability was 
responsible for the elevated IL-2 in the absence of Fyn, as levels began to 
decrease with similar kinetics in both groups (Figure 3.6C). The capture assay 
and real time PCR data suggested that IL-2 production by activated CD8 T cells 
occurred between 3 - 1 0  hrs after activation, which is prior to entry into cell 
division. Upon recall stimulation with PdbU, ionomycin and with Brefeldin A 
present to block protein export, Fyn deficient cells again produced more IL-2 than 
F5 WT cells (Figures 3.6D and 3.6E). Intracellular staining was maximal at 24 
hrs in both groups with a gradual decline over 48 and 72 hrs. At 48 and 72 hrs the
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MFI values for IL-2 staining in the absence of Fyn were ~2.5 times those of 
control values (Figure 3.6E). Additionally, F5 Fyn'7' cells retained the ability to 
produce more IL-2 than F5 WT cells throughout each division peak (Figure 
3.6D). In all experiments, prior activation with NP68 peptide was required in 
conjunction with restimulation to detect IL-2 by intracellular staining as PdbU, 
ionomycin and Brefeldin A alone for 4 hrs gave no signal (data not shown).
3.6 Prolonged CD25 expression by F5 Fyn7' cells is a direct result of 
increased IL-2 production
It was possible that the increase in IL-2 production seen in the absence of Fyn was 
not the direct or only cause of the prolonged CD25 expression, but rather that 
there were defects in the processes to down modulate this receptor. The next set 
of experiments was designed to answer this question. The strategy employed was 
two fold. Firstly, the availability of IL-2 in the culture well was blocked using the 
anti-IL-2 antibody S4B6 to determine whether the expression of CD25 on the F5 
Fyn deficient cells could be reduced to that of F5 WT cells. Secondly, cultures 
were spiked with an excess of IL-2 to determine if CD25 expression on F5 WT 
cells could be increased to the levels seen in the absence of Fyn. The expression 
of CD69 is not influenced by IL-2 (Nakajima et al., 1997) unlike CD25, and 
served as a control in these experiments. From the graphs in Figures 3.7B and 
3.7D it was clear that blocking IL-2 or spiking with IL-2 respectively had no 
influence on the expression of CD69 in either group. In contrast IL-2 
manipulation had a profound influence on CD25 expression. Blocking IL-2 
(Figure 3.7A) reduced the expression of CD25 in the F5 Fyn'7' group to a level
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similar to that of untreated F5 WT cells at 48 hrs, and completely at 72 hrs. At 24 
hrs blocking IL-2 had no effect on CD25 expression, this was expected as initial 
CD25 expression is driven by TCR signals and is independent of IL-2 (Nakajima 
et al., 1997). Therefore prolonged CD25 expression seen in the absence of Fyn 
was a direct result of IL-2 availability in the culture wells. Interestingly, blocking 
IL-2 in the culture was unable to reduce expression of CD25 on the surface of F5 
WT cells further. This implies that the small quantity these cells were making 
was probably immediately utilised and not secreted into the media. This 
conclusion is supported by the CTLL-2 assay data (Figure 3.6B, insert panel) 
showing that IL-2 content in the media of control cells at 48 hrs was very low. 
The converse experiment of spiking cultures with IL-2 revealed that CD25 
expression by the F5 Fyn'7' cells could not be elevated further (Figure 3.7B). This 
suggested that production and response to this cytokine was already maximal. 
Addition of IL-2 to F5 WT cells was able to prolong CD25 expression but was 
unable to achieve levels seen in the Fyn deficient group. This result may reflect a 
functional advantage that autocrine IL-2 consumption may have over paracrine or 
it may suggest that F5 Fyn 7' cells can respond better to the presence of IL-2 than 
F5 WT cells.
3.7 Increased IL-2 levels improve cell survival of F5 Fyn 7’ cells increasing the 
burst size at 72 hrs.
IL-2 has pleotropic effects on a T cell and it is thought to play a role in sustaining 
cell division either by increasing cell cycling or by improving cell survival (Van 
Parijs et al., 1999). We wanted to address if the increased IL-2 production by F5
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Fyn7 was also responsible for the increased burst size at 72 hrs. The mechanism 
by which faster cell cycling could affect the bursts size values is clear, in that 
increased cycling would lead to more cells undergoing more rounds of division. 
However cell survival could also affect the burst size value independently of a 
cells ability to cycle. If more cells within a division peak survive long enough to 
undergo the next round of division, this would lead to an exponential increase in 
cell numbers significantly increasing the burst size. Conversely, if a cell 
population showed decreased survival potential then this would lower the 
probability of cells undergoing further rounds of division, decreasing burst size 
values. To answer these questions the frequency of apoptotic cells within each 
round of cell division was measured at 72 hrs in cell populations with or without 
Fyn that had been CFSE labelled and activated with NP68. Additionally, to 
further elucidate the role of IL-2 in this process the IL-2 blocking antibody S4B6 
was included in some samples. Firstly, from the data in Figure 3.8A, it is clear 
that without any IL-2 manipulation (hatched bars) there were more live cells in 
the division peaks of CFSE labelled NP68 activated F5 Fyn'7' cells (red hash) 
compared to the controls (blue hash). The survival advantage was particularly 
evident in the second and third rounds of division. The inclusion of S4B6 was 
able to eliminate the survival advantage of Fyn deficient cells, reducing the 
frequency of Annexin V negative cells to a comparable level with F5 WT cells 
without S4B6. The correlation of these data with the burst size values is striking. 
Blocking IL-2 in the cultures containing F5 Fyn'7' cells also reduced the burst size 
values to exactly that of F5 WT cells without any IL-2 manipulation (Figure 
3.8B).
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These data show that IL-2 was responsible for the elevated burst size at 72 hrs, 
however from the data in Figure 3.5B it is clear that maximal IL-2 levels would 
be present in the supernatants at earlier time points. It is therefore unclear why 
burst size values at 48 hrs were comparable between F5 WT and Fyn'7' (Figure 
3.3C) if more IL-2 is clearly available to the F5 Fyn'7' cells. Classically IL-2 is 
thought of as a T cell mitogen (Morgan et al., 1976) and has been shown to drive 
cell cycle entry and progression via STAT5 signalling (Moriggl et a/., 1999). It 
was interesting, therefore, that F5 Fyn'7' cells did not show increased propensity to 
enter division even though IL-2 levels were elevated at 48 hrs. To confirm that 
IL-2 could not influence the burst size values at 48 hrs the same strategy of 
blocking IL-2 with the S4B6 antibody was employed. From Figure 8C it is clear 
that blocking IL-2 has no effect on the burst size in either group. The addition of 
a large excess of recombinant IL-2 also had no effect (data not shown). 
Furthermore the addition of a large excess IL-2 could not influence the percent 
divided parameter at 48 hrs in either group (Figure 3.8D). The reciprocal 
experiment using blocking antibody also had no effect on cell entry into division 
(data not shown). Collectively, these data suggest that initial entry into and the 
initial progression of the CD8 division programme is independent of IL-2, but 
becomes dependent thereafter.
3.8 The activation phenotype of Fyn*7' cells depends upon the method of 
stimulation
It has been previously reported that Fyn deficient T cells were hypo-responsive to 
stimuli and failed to produce IL-2 (Appleby et al., 1992; Stein et al., 1992). In
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contrast the data presented here shows that F5 Fyn deficient cells were instead 
hyper-responsive producing elevated amounts of IL-2 compared to F5 WT cells. 
There are a number of possible explanations for this result. Firstly the original 
studies investigated the response of a polyclonal repertoire of splenic CD4 and 
CD8 cells, whereas the F5 system has monoclonal population of CD8 T cells. 
Secondly, the F5 system allowed activation with pMHC and APCs whereas 
polyclonal cells were activated using anti-CD3 antibodies plus PMA with no co- 
receptor involvement. Therefore, the next set of experiments was designed to 
establish whether these discrepancies arose from the different stimuli employed or 
from the use of a monoclonal versus polyclonal T cell repertoire. In the original 
publications, stimulations were carried out using the mAb 2C11. The clone 2C11 
is specific for the epsilon chain of the CD3 complex and has been shown to 
induce T cell activation in a dose dependent manner (Leo et al., 1987). In order to 
provide signal 2 to the T cell, PMA was also included in the stimulation 
conditions (Weiss et al., 1986). We wanted to determine if stimulation in this 
manner with 2C11 would lead to hypo-responsiveness or hyper-resposiveness of 
F5 Fyn ; cells.
To address this question, stimulations were carried out using antibodies 
immobilised on micro-beads to act as artificial APC. The advantage of this 
system over soluble antibodies and APC is that stimulating antibodies become 
fixed on a surface thus preventing internalisation and signal termination, and it is 
possible to control which receptors are engaged. In these sets of experiments anti- 
CD28 antibody was used to provide signal 2, however PMA also gave the same 
result (data not shown). The data in Figure 3.9A shows that stimulation of Fyn
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deficient F5 CD8 T cells with 2C11 and anti-CD28 antibodies (broken lines) 
immobilised on the surface of a micro-bead led to a reduction in the % divided at 
48 and 72 hrs compared to F5 WT cells. Figure 3.9B shows that the burst size of 
F5 Fyn'7' cells was also reduced compared to F5 WT cells, as was the percentage 
of CD25 expressing cells (Figure 3.9C) and IL-2 expressing cells (Figure 3.9D). 
Therefore F5 Fyn'7" cells showed a similar hypo-responsive phenotype reported for 
the polyclonal cells when stimulated through the TCR and CD28.
One significant difference between an anti-CD3 stimulation versus pMHC 
stimulation is the involvement CD8 co-receptor in the latter. Moreover a single 
pMHC molecule will not only bind to the TCR on the surface of the responding T 
cell, it will also engage the CD8 co-receptor (Gao et al., 1997; Salter et al., 1990). 
Lck has been shown to be associated with the cytoplasmic tail of CD8 (Veillette 
et al., 1988) and engagement of MHC-peptide will bring Lck into the proximity of 
the TCR /CD3 complex. In order to determine whether the hyper-responsiveness 
of F5 Fyn'7' cells to pMHC stimulations was influenced by co-engagement of the 
TCR and CD8, micro-beads with immobilised anti-CD3, CD28 and CD8 
antibodies were used. Figure 3.9A shows that inclusion of the anti-CD8 antibody 
(solid lines) in the stimulus restored the ability of F5 Fyn'7' to enter division 
compared to F5 WT cells. Furthermore, inclusion of anti-CD8 antibody also 
elevated the burst size of F5 Fyn'7' cells (Figure 9B), it was also able to increase 
CD25 expression (Figure 3.9C) and, most significantly, induce elevated IL-2 
production (Figure 3.9D) compared to F5 WT cells activated in the same manner. 
Therefore, inclusion of anti-CD8 antibody into the stimulus, along with anti-CD3
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was able to fully mimic the hyper-responsive phenotype seen with antigen in the 
absence of Fyn.
3.9 Increased production of IL-2 by F5 Fyn'7' cells is regulated by TCR and 
CD8 engagement alone
As well as CD8 co-ligation with the TCR, soluble NP68 peptide activation of 
whole F5 lymph node preparations will involve the subsequent engagement of 
multiple co-receptors on the T cell and APC. This is an important consideration 
as Fyn has been implicated in the signalling processes of a number of different 
receptors on the T cell such as CD2 (Fukai et al., 2000), CD45 (Shiroo et al., 
1992) and SLAM (Chan et al., 2003) the ligands of which are expressed on the 
APC. Although activation through the TCR and CD8 was able to induce F5 Fyn'7' 
to produce elevated IL-2 levels it could not be excluded that other receptors 
contributed during antigen recognition. To confirm that the only requisite for 
inducing elevated IL-2 levels in the absence of Fyn during antigenic stimulation 
was co-ligation of CD8 and TCR complexes by pMHC complexes, stimulations 
were carried out using highly purified F5 CD8 T cells from both groups (~99.6% 
TCR+ CD8+ cells). These cells were placed onto an immobilised layer of NP68 
loaded MHC-dimer molecules for defined time points. The pMHC dimer 
molecules will only signal through the TCR and CD8 molecules on the T cell 
surface and have been shown to drive activation without a need for signal 2 
(Goldstein et al., 1998). Stimulation of purified F5 Fyn'7' cells on the MHC- 
peptide layer led to identical % divided values but, as after APC-Peptide 
stimulations, elevated IL-2 production (Figure 3.10A and 3.10B). Collectively
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these data showed that activation using MHC-dimer molecules in the absence of 
co-stimulatory APC interactions were able to mimic the response of F5 Fyn'7' cells 
activated by peptide in the presence of APC.
The contribution of APC derived co-stimulation to the hyper-responsive 
phenotype of the F5 Fyn 7' cells was further addressed using soluble 2C11 as a 
stimulus. Activation in this manner requires APCs to bind the Fc portion of the 
antibody via Fc receptors (Leo et al., 1987). This will lead to stimulation via the 
TCR and other co-stimulatory molecules, however CD8 will not be brought into 
close proximity with the TCR as the self-MHC class I molecules will not be 
stimulatory without loaded peptide. Stimulations using 2C11-loaded APCs lead 
to a reduction in CD69 expression and IL-2 production respectively by F5 Fyn7 T 
cells (Figures 3. IOC and 3.10D). This showed that stimulation via the TCR and 
other co-stimulatory molecules expressed on the APC were not able to induce 
hyper-responsiveness of F5 Fyn'7' cells, and instead resembled stimulation through 
the TCR alone.
CD28 has been shown to play a role in increasing IL-2 production by activated T 
cells (Fraser et al., 1991; Jenkins et al., 1991). CD28 is expressed on T cells and 
binds to CD80 (B7-1) and CD86 (B7-2) located on the surface of the APC 
(Collins et al., 2002; Green et al., 1994). Ligation of CD28 leads to increase IL-2 
mRNA by elevating the transcriptional activity of the 112 promoter through the 
CD28RE (Diehn et al., 2002; Shapiro et al., 1997) and also by regulating signals 
that improve stability of the transcripts (Umlauf et al., 1995). Stimulations using 
micro-beads also included the use of an anti-CD28 antibody, furthermore
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activated CD8 T cells have been shown to express the CD28 ligands B7-1 and 
B7-2 (Hathcock et al., 1994). Therefore, even after APC depletion it could not be 
fully excluded that the CD28 pathway was not playing a role in the increased IL-2 
levels produced by F5 Fyn7 cells. It should also be noted that Lck and Fyn have 
been implicated in CD28-mediated signalling (Holdorf et al., 1999; Raab et al., 
1995). To address the role of CD28 pathways in inducing elevated IL-2 
production in the absence of Fyn we exploited the fact that B7-1/2 - CD28 
interaction is antagonised by the molecule CTLA-4. This molecule can bind to 
B7-1/2 with a higher affinity than CD28 (Tivol et al., 1995). To this end, cells 
were pre-incubated with 10 pg /ml of a CTLA-4 Ig molecule previously shown to 
inhibit CD28 signalling at the level of CD28RE activity of the 11-2 promoter 
(Shapiro et al., 1998). If the increased IL-2 in the absence of Fyn was due to 
CD28 signals then blocking with CTLA-4Ig should reduce production to WT 
levels. The data in Figure 6.11A shows that inhibition of CD28 co-stimulation 
was able to reduce IL-2 production in both groups by ~28%, however F5 Fyn'7' 
cells were still able to produce more IL-2 than F5 WT cells (data not shown).
To further confirm that co-stimulation through CD28 was not responsible for the 
F5 Fyn'7' phenotype, the ability of peptide pulsed APC or pMHC dimers and no 
APC to induce IL-2 mRNA was compared. Figure 3.1 IB shows that 112 gene 
transcription was up-regulated in F5 Fyn'7' cells compared to F5 WT cells, 
regardless of the stimulation method employed. Stimulation with APC served to 
upregulate IL-2 mRNA in both groups. Therefore, it was concluded that CD28 
signals were able to increase IL-2 production in both stes of cells, but did not
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contribute to the ability of F5 Fyn 7 cells to make elevated IL-2 levels compared to 
F5 WT cells.
3.10 Polyclonal Fyn'7' CD8+ cells produce more IL-2 after TCR and CD8 
crosslinking
If F5 Fyn7" cells were activated using MHC-peptide they were hyper-responsive 
whereas published data using polyclonal Fyn'7' cells showed that these cell were 
hypo-responsive to an anti-CD3 antibody stimulus. The data in figures 3.9 and
3.10 indicate that these discrepancies were due to the method of stimulation and 
not due to differences in the cell type and specificity. Therefore, if this conclusion 
was correct, stimulating polyclonal Fyn'7' cells using a method that cross-linked 
the TCR and CD8 should induce hyper-responsiveness and mimic the pMHC 
response. Naive CD8 cells (CD62L high) were obtained from polyclonal Fyn'7' 
mice and WT controls (C57BL/6 mice) using a cell sorter. In all experiments 
purity in both groups was greater than 97% (TCR+, CD8+ CD62LW, CD4410). 
Stimulations were carried out using beads coated with different combinations of 
immobilised stimulatory antibodies as described for Figures 3.10A and 3.10B.
When naive polyclonal CD8 cells were activated using beads coated with anti- 
CD3 and anti-CD28 antibodies only, analysis of cell division and IL-2 production 
at 72 hrs revealed that Fyn deficient cells were hypo-responsive to this stimulus 
compared to WT cells in terms of the burst size (Figure 3.12A, left panels). This 
was in concordance with the published data on polyclonal Fyn'7' cells, showing 
reduced proliferation. However, stimulation with beads that included an anti-CD8
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antibody in conjunction with anti-CD3 and anti-CD28 antibodies increased the 
ability of Fyn'7' CD8 cells to divide compared to WT cells, specifically elevating 
the burst size values (Figure 3.12A, right panels). Stimulation using beads coated 
with anti-CD3, CD28 and CD8 antibodies also led to an increase in the production 
of IL-2 by the Fyn'7' CD8 cells (Figure 3.12B). Therefore, when Fyn'7 polyclonal 
CD8 were stimulated via the TCR and CD8 the response mimicked the hyper­
responsiveness induced by antigen.
3.11 Discussion
The aim of the work presented in this chapter was to establish the role of Fyn in 
the activation of peripheral CD8 T cells by MHC-peptide and APC. To this end, 
Fyn'7* mice were back-crossed with mice expressing the class-I restricted F5 TCR 
transgene on a Rag-1'7' background, generating a monoclonal CD8 T cell 
repertoire that would respond to cognate antigen.
Thymic development in the F5 Fyn'7' mice proceeded normally and generated a 
peripheral repertoire of CD8 T cells comparable to F5 WT controls. When LN 
cells were activated using the NP68 peptide the threshold of activation was the 
same in both groups, however F5 Fyn'7' cells produced elevated levels of IL-2 at 
early time points. The increase in IL-2 production led to elevated expression of 
CD25 on the cell surface and improved cell survival, which in turn increased the 
proliferative capacity of the F5 Fyn 7' compared to F5 WT cells at later time 
points. The hyper-responsiveness of the monoclonal Fyn'7' cells was different 
from the activation phenotype of polyclonal Fyn'7' cells reported by Stein et al and
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Appleby et al. In those studies, Fyn7 cells were hypo-responsive to stimuli that 
primarily engaged the TCR alone. When we stimulated the F5 Fyn 7 cells with 
anti-CD3 alone we obtained similar results. However, the use of stimuli that 
were able to engage both the TCR and CD8 molecules induced the hyper- 
responsive phenotype in both F5 Fyn'7' and the polyclonal CD8+ Fyn*7' cells 
compared to WT controls. Moreover, we could exclude that this hyper-responsive 
phenotype resulted from stimulation of any receptors other than the TCR and CD8 
either by removing APC and engaging the TCR and CD8 directly with antibodies 
or MHC-dimers, or by directly antagonising engagement of other receptors. 
Collectively these data suggest that Fyn can act as a negative regulator of T cell 
activation, by regulating IL-2 production by antigen activated CD8 T cells.
The reason for the different outcomes induced after anti- CD3 versus anti-CD3/8 
or antigen stimulation of Fyn'7' cells may be explained by the nature in which the 
different stimuli engage Src kinases. Our data, in concordance with Stein et al 
and Appleby et al, indicate that Fyn plays a positive role in transducing signals via 
the TCR. Moreover three recent reports have also shown that stimulation of Fyn'7" 
cells with ant-CD3 led to general defects in T cell activation (Cannons et al., 
2004; Davidson et al., 2004; Sugie et al., 2004). Furthermore, it has been 
proposed that Fyn is important for T cell responses to stimuli such as weak TCR 
agonists (Utting et al., 1998) and antagonists (Huang et al., 2000b; Huang et al., 
2000a). These altered peptide ligands do not activate T cells as efficiently as a 
full agonist ligands, potentially due to reduced activation of the Lck substrate 
ZAP-70 compared to levels induced by full agonistic ligands (Reis e Sousa et al., 
1996; Madrenas et al., 1995; Sloan-Lancaster et al., 1994). Within a T cell the
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CD8-associated Lck kinase activity has been shown to be important to T cell 
responses (Irie et al., 1998; Irie et al., 1995) and therefore anti-CD3 cross-linking 
in the absence of CD8 may not utilise this Lck activity efficiently, resulting in 
signals similar to those induced by the low affinity peptides. With CD3 
stimulation, weak TCR ligands may preferentially signal through the TCR and 
Fyn. Furthermore, the observations that Fyn can associate with components of 
the CD3 complex (Timson Gauen et al., 1992; Samelson et al., 1990), and that 
TCR stimulation in the absencse of Fyn leads to a reduction in phosphorylation of 
downstream proteins (Fusaki et a/., 1994) provides some biochemical evidence 
that the TCR may have a dependency on Fyn for signal transduction.
In contrast to anti-CD3 alone, activation with MHC-peptide molecules or cross- 
linking antibodies that were able to bring the TCR and CD8 into close proximity 
with one another overcame the triggering defect in both the monoclonal and 
polyclonal Fyn ; cells. Several other groups showed little or no defect in Fyn ; 
cells in response to stimuli able to engage both CD8 and TCR molecules into 
close proximity (Utting et al., 1998; Liao et al., 1997). Furthermore, both Stein et 
al and Appleby et al showed that stimulation with allogeneic stimulator cells 
(MLR) was capable of inducing improved activation of Fyn'7' cells compared to 
anti-CD3 alone. Interestingly, MLR induced proliferation by Fyn' cells may 
even have surpassed that of WT control cells in one study (Stein et al., 1992) 
indicating that Fyn '" polyclonal cells may also be hyper-responsive to antigen.
The cytoplasmic domain of CD8 has been shown to associate with LAT (Bosselut 
et al., 1999), LIME (Brdickova et al., 2003; Hur et al.y 2003) and Lck (Veillette et
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al., 1988) all of which could in theory circumvent the need for Fyn-mediated 
activation signals. We favour the idea that CD8 associated Lck is responsible for 
overcoming the hypo-responsive T cell activation in Fyn7 cells after TCR 
stimulation alone. It has long been established that co-ligating CD8 with the TCR 
enhances T cell activation (Jonsson et al., 1989; Boyce et al., 1988). Moreover, 
Lck can phosphorylate the ITAM residues in the CD3 complex (van Oers et al., 
1996a; Wange et al., 1995; Iwashima et al., 1994) and activate ZAP-70 (Kong et 
al., 1996; Chan et al., 1995) thus mediating a number of the proximal signalling 
events in a T cell that after TCR stimulation alone may be defective in the absence 
of Fyn.
These data raise the question of how bringing CD8 to the TCR could lead to 
elevated IL-2 levels in the absence of Fyn. Certainly, several previous reports 
state that stimulation of Fyn'7' primary cells or cell lines expressing mutant Fyn 
molecules led to reduced IL-2 production (Fusaki et al., 1994; Appleby et al., 
1992; Stein et al., 1992). Reciprocally, over expression of Fyn then greatly 
attenuated IL-2 production (Fusaki et al., 1994; Davidson et al., 1992). However, 
these studies were either conducted in cell lines, which may be co-receptor 
independent or if primary cells were used, then the method of stimulation may not 
have effectively activated Lck. Furthermore, the activity of Lck and Fyn are 
regulated by the phosphorylation status of the positively regulating tyrosine 
residues within the kinase domains (Tyr394 in Lck, and Tyr417 in Fyn) as well as 
the inhibitory tyrosine residues located in the C-termi (Tyr505 Lck and Tyr529 in 
Fyn) (Yamaguchi and Hendrickson, 1996). Dephosphorylation of the Tyr 
residues that promote kinase activity is mediated by phoshpatases such as PEP
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(Cloutier and Veillette, 1999; Gjorloff-Wingren et al., 1999), PtP-PEST (Mustelin 
and Tasken, 2003) and possibly CD45 (Burns et al., 1994; Sieh et al., 1993). 
Furthermore, phosphorylation of the inhibitory C-terminus Tyr residues is 
mediated by the PEP associated kinase Csk (Chow et al., 1993; Bergman et al., 
1992; Okada et al., 1991). These two molecules are brought into cellular 
proximity with Lck and Fyn through the actions of the transmembrane adapter 
molecule PAG. When PAG is phosphoryalted on Tyr317, Csk and associated 
PEP are able to form a protein complex that acts to down-regulate Lck and Fyn 
activity (see Figure 1.3). Fyn has been shown to associate constitutively with 
PAG via its SH3 domain (Brdicka et al., 2000; Marie-Cardine et al., 1999) and 
may be responsible for phosphorylating Tyr317 as in Fyn'7' thymocytes 
phosphorylation of this residue is defective (Yasuda et al., 2002). Therefore, in 
the absence of Fyn, the inability to efficiently form the inhibitory PAG/CSK/PEP 
complex could disregulate Lck kinase activity. This could, in theory, lead to 
increased duration of Lck signalling and increase IL-2 production. Certainly, 
disregulated Lck mutants that lack the negative regulatory Tyr 505 when 
expressed in cell lines show attenuated IL-2 production after stimulation (Luo and 
Sefton, 1992).
Another molecule that has been shown to influence IL-2 production in T cells is 
the co-stimulatory molecule CD28 (Fraser et al., 1991; Jenkins et al., 1991). To 
address whether CD28 co-stimulation contributed to the elevated IL-2 production 
in the absence of Fyn, we antagonised the B7-1/2 interaction with anti-CTLA-4 
Ig. The results suggested that CD28 signalling was responsible for ~30% of total 
IL-2 production in both groups, but not responsible for the increase in the absence
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of Fyn. The effect of CD28 stimulation may have been mediated by changes in 
the transcriptional activity of the 112 gene, or by differences in stability of the IL-2 
message as CD28 signals potentially control both (Sanchez-Lockhart et al., 2004). 
Furthermore, previous studies have shown that CD28 stimulation combined with 
TCR activation led to a 30% increase in IL-2 production (Umlauf et al., 1995), a 
figure consistent with our findings. Also, gene chip analysis of global expression 
patterns suggested that CD28 co-ligation with the TCR serves to induce 
quantitative changes rather than qualitative in gene transcription (Diehn et al., 
2002). However, both Lck and Fyn have been shown to be important to the 
phosphorylation of Tyr 191 withinin the cytoplasmic tail of CD28, mediating the 
binding of factors such as PI 3-kinase, Grb2 and Itk (Raab et al., 1995). 
Therefore, the loss of Fyn, and the potential disregulation of Lck could in theory 
have altered CD28 signalling, however using the critera of IL-2 production to 
judge CD28 co-stimulation we observed no effect in the absence of Fyn in our 
system.
After in vitro activation, proliferation of CD8 T cells has been shown to peak after 
~3 days and then decline. This was thought to be due in part to the elimination of 
antigen-pusled APC as CD8 cells became CTL after 3 days (Sprent and Schaefer, 
1989). However, stimulation of CD8 cells using artificial stimuli that could not 
be eliminated by CTL activity were also shown to lead to a loss of proliferative 
capacity after 3 days (Deeths and Mescher, 1997). Studies have shown that the 
decline in CD8 proliferation corresponds with the loss of the ability of these cells 
to produce IL-2, even after re-stimulation. This phenomenon has been termed 
Activation Induced Non-Responsiveness (AINR) (Deeths et al., 1999). Our data
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supports this concept, as after primary stimulation, IL-2 production measured by 
the capture assay became undetectable by ~10 hrs. Although IL-2 production 
could still be detected at 24 hrs after re-stimulation with PdbU and ionomycin, by 
72 hrs even such recall stimulations became ineffective in both groups suggesting 
that they had become refactory to restimulation and possibly undergone AINR. 
Furthermore, as PdbU and ionomycin bypass the need for TCR signalling, this 
supported the idea that whatever the mechanism responsible for down-regultaing 
IL-2 production after restimulation, it had been established by the initial pMHC 
driven signals.
In the absence of Fyn the initiation of IL-2 protein secretion measured by capture 
assay occurred with similar kinetics to F5 WT controls, however the magnitude 
and duration of production was increased. This correlated with improved survival 
and proliferation of F5 Fyn'7' cells after 3 days in culture. As IL-2 is important for 
CD8 cell survival, it has been proposed that the induction of AINR acts as a 
mechanism to limit expansion because CD8 cells will die by passive mechanisms 
when IL-2 is unavailable (Tham et al., 2002). Therefore AINR will regulate the 
proliferative response of CD8 cells by setting the production and availability of 
IL-2. It is plausible therefore that Fyn influences the duration of a CD8 T cell 
response by regulating the period of IL-2 production and possibly controlling the 
manifestation of AINR.
Although AINR can be induced after optimal stimulation of CD8 cells it is 
thought to be related to classical anergy (Deeths et al., 1999). Moreover, anergy 
is often defined as the inability of a T cell to produce IL-2 upon restimulation
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(Jenkins and Schwartz, 1987). Interestingly, anergic CD8 cells have been shown 
to possess elevated Fyn kinase activity (Welke and Zavazava, 2002; Utting et al., 
2000; Gajewski et al., 1994). Also, anergised T cells lacking Fyn regain the 
potential to proliferate in response to antigen (Utting et al., 2001). These data 
again support the idea that Fyn could play a role in negatively regulating the 
activation status of a T cell, possibly though controlling IL-2 production with 
relevance to the induction of anergy.
In our hands, increased IL-2 production in the absence of Fyn specifically led to 
improved T cell survival correlating with elevated proliferation at 72 hrs of 
culture, but had no measurable influence before this point. The role of IL-2 in T 
cell function is complex, initial studies suggested that it functioned as a mitogen 
driving and sustaining T cell proliferation (Morgan et al., 1976). Indeed IL-2 has 
been shown to regulate cyclins and cell cycle progression through the induction of 
genes such as c-myc, cyclin D2 and cyclin E  (Lord et al., 2000; Lord et al., 1998; 
Liu et al., 1995; Minami et al., 1995). However this may not be its primary role 
as CD8 cells can proliferate in the absence of IL-2 (Kramer et al., 1994). IL-2 has 
also been shown to act as a T cell survival factor by up-regulating anti-apoptotic 
molecules such as Bcl-2 (Lord et al., 1998; Akbar et al., 1996). In concordance 
with our data, a role for IL-2 in supporting the late stage of CD8 T cell expansion 
has also been shown in vivo by Lefrancois and colleagues. They showed that IL-2 
was dispensable for initiating the response of OT-1 7/2'A CD8 cells to antigen, but 
greatly improved the proliferative response at later periods, possibly through 
increasing cell survival (D'Souza and Lefrancois, 2003) This may reflect that 
there is a time in the expansion phase of CD8 cells where IL-2 is in limiting
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quantities, so differences in production may have profound and amplified effects 
on T cell survival.
The increase in IL-2 levels in the absence of Fyn was also interesting as there was 
no evidence of increased cell death after exposure to this cytokine. While IL-2 
was initially considered to be a positive regulator of T cell function, analysis of 
112 '' mice and IL-2 receptor a  or p deficient mice revealed that it also plays a role 
in maintaining peripheral tolerance. These animals did not suffer from 
immunodeficiency, as may have been expected, but instead displayed severe 
lymphoproliferation and auto-immunity (Suzuki et al., 1995; Willerford et al., 
1995; Sadlack et al., 1993). A possible explanation for this phenotype is that IL-2 
has also been shown to promote AICD by up-regulating expression of FasL 
(Kneitz et al., 1995). However work by Cheng et al that showed enhanced IL-2 
receptor signalling in CD8 cells promoted survival and proliferation but not death 
(Cheng et al., 2002), supporting our observation that IL-2 exposure may favour 
survival over death in CD8 cells.
A further explanation for the lack of AICD is that Fyn has been shown to 
associate with the intra-cellular domain of Fas (Atkinson et al., 1996), and a 
previous report has shown that Fyn"7' cells are resistant to Fas-mediated AICD 
(Ricci et al., 2001). Although expression of FasL was not addressed in our study, 
the ability of F5 Fyn'7' to undergo Fas mediated AICD in response to anti-Fas 
antibody was measured (data not shown). Consistent with previous reports, F5 
Fyn'7' cells were resistant to AICD induced by cross-linking the Fas receptor with 
the Jo-2 mAb.
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A consequence of elevated IL-2 levels was to prolong CD25 expression on the 
surface of Fyn7 cells. Initial CD25 expression is driven by TCR derived signals 
(Kim and Leonard, 2002). However expression of CD25 is then maintained by a 
classical feedback loop where by IL-2 receptor signals activate STAT5, which 
binds to the promoter of CD25 (Kim et al., 2001). IL-2-driven CD25 expression 
is antagonised by molecules such as SOCS-1 and SOCS-3 (Sporri et al., 2001; 
Alexander et al., 1999; Cohney et al., 1999; Starr et al., 1997). Expression of 
these molecules are also regulated by IL-2 receptor signals (Sporri et al., 2001). 
We did not see any influence of Fyn deficiency on the TCR driven CD25 
expression that occured before 24 hrs. However the prolonged expression of 
CD25 by F5 Fyn'7' cells after this time could be solely attributed to increased IL-2 
content in the culture well as down-modulation could be forced by the inclusion 
of the blocking antibody S4B6. The experiments manipulating IL-2 levels did not 
exclude that a loss of SOCS/CIS function contributed to prolonged CD25 
expression on F5 Fyn'7' cells. Evidence for a possible defect in SOCS function 
comes from the fact that addition of excess recombinant IL-2 to F5 WT cells did 
not induce CD25 expression levels equivalent to those on untreated F5 Fyn7' 
control cells. Therefore, although IL-2 levels available to the F5 WT cells would 
surpass even that available to untreated F5 Fyn'7' cells, yet expression levels of 
CD25 were still reduced. These observations suggest that there may be a 
mechanism present in WT cells that limits CD25 expression regardless of IL-2 
levels, which is not functioning as efficiently in Fyn'7" cells. It is a possibility that 
IL-2 receptor signals are altered in the absence of Fyn, as studies have shown that 
Src kinases can associate with the IL-2 receptor p chain, and may play a role in 
signalling (Kamitz et al., 1994). Furthermore, the region of the IL-2R p chain
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containing Tyr 338, that may bind Lck, (Hatakeyama et al., 1991) has been 
shown to link the IL-2 receptor to several pathways including MAPK (Friedmann 
et a l , 1996), PI 3-kinase (Remillard et a l, 1991) and STAT5 (Gaffen et a l,  
1995).
Analysis of the periphery of the F5 Fyn'7' mice revealed that they were comparable 
to F5 WT mice in terms of cells frequency and expression of the T cell markers 
examined. Work by Yasuda et al showed that Fyn'7' cells from polyclonal mice 
had an a pre-activated phenotype with lower levels of CD62L expression than WT 
mice (Yasuda et a l,  2002). We did not find this to be the case in our F5 or 
polyclonal Fyn'7' mouse lines. There was however a statistically significant 
increase in the overall peripheral cellularity of the F5 Fyn'7 mice. The reason for 
this is unclear, but may be due to the fact that the levels of IL-7 receptor on the 
surface of peripheral F5 Fyn'7' cells were higher than F5 WT levels (data not 
shown). As IL-7 has been shown to regulate survival of T cells (Schluns and 
Lefrancois, 2003), and mice expressing IL-7 as a transgene also have increased 
peripheral cell numbers (Kieper et a l,  2002), it is possible that increased IL-7R 
expression may have led to prolonged naive cell survival and, therefore, increased 
peripheral numbers. It is also a possibility that the increase in peripheral CD8 
numbers is an in vivo manifestation of the hyper-responsive phenotype of the F5 
Fyn'7' cells. This may be driven by responses to self-peptide MHC that are 
responsible for driving homeostatic proliferation and providing survival signals to 
a T cell without causing activation. Indeed, there was no evidence of an increase 
in CD44+ cells in the absence of Fyn (data not shown).
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The F5 TCR is restricted to recognise MHC class I molecules (Townsend et al., 
1985; Townsend and McMichael, 1985) and has been used to study positive 
selection to the CD8SP lineage (Mamalaki et al., 1993b; Mamalaki et al., 1993a; 
Mamalaki et al., 1992). It is clear that in the absence of Fyn, there was no overt 
phenotypic changes in the F5 system as the numbers and frequency of DP and 
CD8SP cells were comparable to F5 WT thymi, with no CD4SP evident in either 
group. However, when the DN populations were examined, the loss of Fyn did 
increase the frequency and absolute number of DN3 cells. There was also a 
concomittent decrease in the frequency and numbers of DN4 cells. This was not 
reported by Stein et al or Appleby et al, also a number of other studies have 
shown that Fyn is not essential to thymocyte development of a (3 T cells (Lin et 
al., 2000; Liao et al., 1997). In the F5 system the mature TCR is expressed earlier 
than normal from the CD2 expression cassette and may override any requirement 
for the pre-TCR. Instead of associating with the pre-Ta, the F5 p chain will 
presumably associate with the transgenic alpha-chain. As there is no co-receptor 
expressed at the DN stage, the block in signalling may be reminiscent of the 
situation observed when peripheral T cells are activated through the TCR alone in 
the absence of Fyn. It is unclear therefore, if the partial block at the DN3 stage is 
a due to pre-TCR signalling or signals through the transgenic receptor itself. It is 
generally considered that Lck is the important kinase for pre-TCR signalling. 
However, it should be noted that a proportion of cells from Lck'7' thymi are able to 
undergo beta-selection and progress from the DN3 to DN4 stage (Molina et al., 
1992). These cells utilise Fyn because in the thymi of Lck'7' Fyn'7' mice 
development is completely arrested at the DN3 stage (Groves et al., 1996; van 
Oers et al., 1996b). The pre-TCR is composed of the p chain, the pre-Ta and the
141
CD3 complex (Groettrup et al., 1993). Fyn has been shown to associate 
preferentially with components of the CD3 (Timson Gauen et al., 1992; Samelson 
et al., 1990); therefore it is possible that it could be involved in pre-TCR 
signalling in some capacity. Catalytically active Fyn expressed as a transgene 
does rescue some aspects of thymic development in an Lck'7' mouse (Groves et 
al., 1996; Anderson et al., 1992). Furthermore NK-T cell development is arrested 
in Fyn 7' mice (Eberl et al., 1999; Gadue et al., 1999), highlighting the fact that 
Fyn can influence the development of other a|3 TCR expressing cell lineages. 
This putative role for Fyn in driving progression for DN3 to DN4 may only be 
evident when looking at a monoclonal TCR repertoire; therefore it may be of 
interest to look at the DN population in thymi from other Fyn 7' TCR transgenic 
mouse lines.
Recently, a group reported that the defects in triggering Fyn*7' CD4 cells could be 
overcome by cross-linking the CD4 co-receptor and the TCR, however they did 
not report whether these cells were now hyper-responsive (Sugie et al., 2004). 
We have also addressed the role of CD4 in rescuing the proliferative response of 
highly purified polyclonal CD4 Fyn'7' cells. In our hands, activation of CD4 cells 
lacking Fyn was defective in response to anti-CD3 and anti- CD28 antibodies 
(data not shown). This was consistent with other studies that have specifically 
looked at Fyn'7' CD4 cells (Cannons et al., 2004; Davidson et al., 2004). 
However, we did not see an improvement in the response when anti-CD4 
antibody was included in the stimulus (data not shown). The difference between 
these data and the work by Sugie et al could be explained by the fact that they 
looked at a monoclonal class II restricted transgenic TCR, whereas we looked at
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purified naive polyclonal CD4. Alternatively, it is possible that CD4 and CD8 
cells have different dependencies for Fyn in terms of driving activation and 
terminating the response. We are currently back-crossing Fyn7 mice onto a class 
II restricted transgenic TCR background to address these questions.
From the observation made in this chapter, there are a number of questions that 
still need to be addressed. Firstly, although these data presented here support the 
idea that the inclusion of co-receptor associated Lck in the stimulation of Fyn'7' 
cells is essential to generating the hyper-responsive phenotype, a role for other 
CD8 associated molecules cannot be excluded. One way to address this and to 
determine if molecules other than Lck improve the activation response of a T cell 
after CD8 and TCR cross-linking, the activation of F5 Lck'7' cells in response to 
anti-CD3 and anti-CD3 plus anti-CD8 could be measured. If CD8 associated Lck 
is the only molecule responsible for improving T cell activation by cross-linking 
CD8 there should be no improvement in the response by involving this receptor 
versus CD3 alone.
Another interesting point raised by the work presented in this chapter is the 
observation that F5 WT cells failed to maintain CD25 expression at the same 
levels compared to Fyn'7' cells even in the presence of excess IL-2. This 
suggested that there may be changes in IL-2 receptor signalling in the absence of 
Fyn. Firstly, it would be of interest to look at the expression of SOCS proteins in 
the absence of Fyn after pMHC stimulation. Furthermore it would be interesting 
to compare IL-2 receptor signalling in F5 WT and Fyn'7' cells. T o  control for 
higher levels of endogenous IL-2 in the absence of Fyn, the F5 W T and Fyn7
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mice could be crossed to an IL-2'7' background. This would allow the exposure 
levels of IL-2 to be controlled by addition of known quantities of exogenous 
cytokine and CD25 expression, proliferation and SOCS expression assayed as the 
readout of IL-2 signalling.
Although we did measure the contribution of CD28 co-stimulation to the Fyn 
phenomenon and found no influence, it was possible that other aspects of CD28 
signalling not addressed by us were affecetd in Fyn'7'cells. For example, CD28 
signalling has also been shown to induce the expression of CTLA-4 (Linsley and 
Ledbetter, 1993). Furthermore, Lck and Fyn have been implicated in the function 
of CTLA-4 by mediating phosphorylation of this molecule in intra-cellular 
compartments (Hu et al., 2001). Therefore it is possible that the expression 
and/or function of endogenous CTLA-4 was reduced in the absence of Fyn and 
this could indirectly influence IL-2 production. By adding a recombinant CTLA- 
4 molecule in excess we were only asking how the cells could respond to 
inhibition of CD28 signalling, but were not addressing how endogenous CTLA-4 
production and function occurred in the absence of Fyn. To this end, we plan to 
look at CTLA-4 expression by activated F5 WT and Fyn'7' cells.
Collectively, these data presented in this chapter suggest that Fyn may act as a 
negative regulator of CD8 T cell activation in response to stimuli transmitted via 
the TCR and CD8 co-receptor. TCR stimulation alone requires Fyn for optimal 
signal transduction, but inclusion of CD8 and presumably associated Lck to the 
TCR complex circumvents requirement for Fyn in transducing activation signals. 
In this situation the cells become hyper-responsive due to elevated IL-2
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production, possibly due to the disregulation of Lck activity caused by a failure to 
efficiently form the PAG/CSK/PEP complex in these cells. The subject of the next 
chapter of this thesis will be how we have addressed the biochemical basis for the 
increased IL-2 production in the absence of Fyn.
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Figure 3.1: Thymic development in F5 Fyn'7' mice is normal and generates a 
periphery phenotypically comparable to F5 WT mice.
F5 WT and F5 Fyn'7' thymocyte development (Figures A-D) and the peripheral 
phenotype were examined in 5 week-old mice (as indicated). Thymocyte 
development was addressed by measuring the frequency (A) and absolute number (B) 
of DN, DP and mature SP cells compared to age matched WT controls. TCR 
expression is shown for CD8SP gated thymocytes. The frequency (C) of DN cells, 
gated as shown after staining with anti-CD4 and anti-CD8 antibodies, were analysed 
for expression of CD44 and CD25 to enumerate the different populations (D). 
Frequencies are shown on the FACS plots for relevant cell populations, these were 
used to calculate absolute cell numbers. A minimum of 100,000 events were 
collected per thymic sample (A -  B). For DN analysis (C -  D) a minimum of 10,000 
events were collected in the DN gate. For peripheral analysis, the frequency (E) and 
absolute number (F) of CD8+ TCR+ cells was determined. The expression of CD62L 
and CD5 on TCR+ CD8+ cells is also shown (Figure E), and the frequency of cells or 
the mean MFI values are shown where appropriate. For peripheral analysis, a 
minimum of 20,000 events was collected per sample. On each graph of cell number, 
the mean (n = 5) is plotted and error bars are shown as ±SD. Statistical significance 
was calculated using the t-test (* = p>0.05 ** = p>0.01).
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Figure 3.2: Antigen activated F5 Fyn A cells show no defect in activation marker 
expression at 24 hours.
F5 WT and Fyn ; cells (as indicated) were activated using a titration of NP68 peptide 
presented by endogenous APCs and the expression of activation markers at 24 hours 
were assessed by FACS. As an example of how gating and analysis was performed, 
bi-variant dot plots of CFSE versus CD69 (Figure A and CD25 (C) are shown for 3 
peptide concentrations. Gates were set using unstimulated and isotype matched 
controls. The MFI values for the respective marker are shown in the top left of the 
FACS plot. These data were used to generate plots of the percentage of cells 
expressing CD69 (B) and CD25 (D). These data are representative of 5 independent 
experiments.
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Figure 3.3: Fyn deficiency does not alter F5 cell division at 48 hrs, but does 
affect CD25 expression
F5 WT and Fyn'7' cells (as indicated) were activated as described for Figure 3.2. At 
48 hours post activation, cell division (A - C) and the expression of CD25 (D and E) 
was assessed by FACS. Histograms of CFSE expression are shown for 3 peptide 
doses per group (Figure A), and these data were used to plot the % divided (B) and 
the burst size (Figure C). D shows FACS data of CFSE versus CD25 expression for 3 
peptide doses showing the gates that were applied. Gates were set using unstimulated 
cells and isotype controls. The MFI values of CD25 expression are shown in the top 
left of the quadrant. These data were used to generate plots of the percentage of cells 
expressing CD25 (D). These data are representative of 5 independent experiments.
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3.4: F5 Fyn'7' cells have elevated burst size and CD25 expression after 72 hours 
of activation
F5 WT and Fyn'7' cells (as indicated) were activated as described in Figures 3.1 -  3.2. 
At 72 hours, proliferation and CD25 expression was assessed by FACS. Figure A 
shows CFSE histograms for 3 peptide doses per group, these data were then used to 
plot burst size values (B). C shows bi-variant FACS plots of CD25 versus CFSE for 
three peptide doses per group. MFI values of CD25 expression and gates are 
indicated on the plots. Gates were set using unstimulated controls and isotype 
matched antibodies. These data were used to generate a plot of the % CD25 
expressing cells versus NP68 concentration. These data are representative of 5 
independent experiments.
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Figure 3.5: Fyn deficiency alters the duration of CD25 expression
F5 WT and Fyn'/_ cells (as indicated) were activated with 1 pM NP68, using 
endogenous APCs, for the indicated time points and CD69 (A) and CD25 (B) 
expression was assessed by FACS, and plotted as the MFI of expression levels. 
Gates were set using unstimulated controls and isotype matched antibodies. MFI 
values were not plotted if the % of positive cells was ^10%. The data shown are 
representative of 3 independent experiments.
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3.6: F5 Fyn'" cells activated with antigen make more IL-2 than F5 WT cells
The ability of WT and Fyn '" F5 cells (as indicated) to produce IL-2 after 1 pM NP68 
activation was measured using the IL-2 capture assay (A and B), CTLL-2 bioassay 
(B, insert panel), real time PCR (C) and intra-cellular cytokine staining (D). For the 
IL-2 capture assay, A shows FACS plots of IL-2 versus CD69 expression for each 
indicated time point. Gates were set using un-stimulated control samples. These 
data were used to plot the % of CD69+ IL-2+ cells as a function of time. The insert 
panel of B shows the accumulation of IL-2 protein in the media at 48 hours measured 
by the CTLL-2 bioassay. For real time PCR analysis, RNA was extracted from 1 x 
106 cells at the indicated time points. After cDNA was prepared, real time PCR for 
IL-2 mRNA was carried out . The values plotted in C show IL-2 mRNA levels 
relative to the housekeeping gene HPRT. For intracellular detection of IL-2 D shows 
FACS plots of CFSE versus IL-2 at the indicated time points for each group. Gates 
were set using PdbU and ionomycin treated cells lacking prior pMHC exposure, and 
isotype matched antibodies. These data were used to generate a plot of IL-2 MFI 
versus time of antigen exposure. These data are representative of 2 (Capture assay 
and real time PCR) and 3 (intra-cellular cytokine staining) independent experiments.
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Figure 3.7: Prolonged CD25 expression by F5 Fyn*7' cells is dependent on IL-2
The IL-2 availability for antigen activated WT and Fyn'7' cells was manipulated as 
indicated in the graph legends. The effect that blocking IL-2 with S4B6 had on the 
MFI of CD25 expression (A) and CD69 expression (B) is shown. Figures C and D 
show the effect that spiking with 50 U of recombinant IL-2 had on the MFI of CD25 
(B) and CD69 (D) expression respectively. Gates were set using unstimulated cells 
and isotype controls. MFI values were only plotted when the % of cells expressing 
an activation marker was ^10%. These data are representative of 2 independent 
experiments.
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Figure 3.8: The increase in the burst size of F5 Fyn'7' cells at 72 hours is 
influenced by IL-2 and correlates with cell survival.
The effect of blocking IL-2 at 72 hours on survival (A) and burst size (B) was 
measured using cells stimulated as described for figure 3.7. Also, at 48 hours, the 
effect of blocking IL-2 with the monoclonal antibody S4B6 on the burst size (C) and 
the influence of spiking with IL-2 on the % divided (D) is shown. Cell viability was 
assessed using Annexin V staining, and a minimum of 50,000 events was collected 
per-sample. Burst size and % divided values were obtained using the calculations 
outlined in the material and methods section. These data are representative of 2 
independent experiments.
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Figure 3.9: Stimulation through the TCR and CD8 leads to increased IL-2 
production by F5 Fyn '" cells.
The ability of WT and Fyn"7' F5 cells to proliferate in response to beads coated with 
anti-CD3 with or without anti-CD8 (as indicated) was determined by measuring the 
% divided (A), the burst size (B), CD25 expression (C) and IL-2 production by 
intracellular staining (D). In all groups, cell preparations were depleted of APCs 
using negative selection prior to activation. Gates were set using unstimulated 
controls and isotype matched antibodies. These data are representative of 2 
independent experiments.
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Figure 3.10: Elevated IL-2 production by F5 Fyn'7' cells is regulated by the TCR 
and CD8, not other co-receptors.
The proliferative response of highly purified WT and Fyn'7' F5 cells (as indicated) in 
response to immobilised MHC-peptide complexes was measured in terms of % 
divided (A) and the MFI of IL-2 production (B). C and D show the response of F5 
cells with or without Fyn to anti-CD3 loaded APCs as measured by CD69 expression 
and IL-2 production respectively. These data are representative of 2 independent 
experiments.
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Figure 3.11: CD28 co-stimulation does not control the ability of F5 Fyn'7' cells to 
produce more IL-2
The contribution of CD28 co-stimulation to IL-2 production in the absence of Fyn 
was determined by blocking CD28 engagement with CTLA-4 Ig molecules and 
measuring intracellular cytokine production at 24 hours (A). Values were calculated 
as the % inhibition of IL-2 MFI relative to MFI values obtained without adding 
CTLA-4Ig. This was done by taking the MFI of untreated cell to be 100%, and 
working out the % IL-2 MFI reduction that the CTLA-4 Ig was able to induce. These 
data are the mean of 3 independent experiments and the ± SD is plotted as error bars. 
The influence of APC co-stimulation on IL-2 mRNA levels versus the use of purified 
T cells stimulated with MHC-peptide dimers as measured by real time PCR (B).
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Figure 3.12: Crosslinking TCR and CD8 molecules on polyclonal CD8 Fyn'7' 
induces elevated burst size and IL-2 production at 24 hrs
Naive polyclonal CD8 cells were isolated by FACS from the LN of WT or Fyn 7‘ 
mice. Figure A shows CFSE profiles for polyclonal WT and Fyn'7' cells stimulated 
as indicated. The burst size values are shown in the top left of the histogram. B 
shows FACS plots of IL-2 production detected by intra-cellular staining and the % of 
IL-2 positive cells is shown in the top left of the quadrant. Gates were set using 
unstimulated controls and isotype antibodies. These data are representative of 2 
independent experiments.
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Chapter 4: Determining the basis of the elevated IL-2 production by 
F5 Fyn'7’ cells
4.1 Introduction
From the data presented in chapter 3 it was clear that Fyn7 CD8 T cells produced 
more IL-2 upon TCR and CD8 ligation than F5 WT cells. The aim of work presented 
in this chapter was to determine how Fyn deficiency could affect T cell signalling in 
manner that led to increased IL-2 production without affecting activation marker 
expression or cell cycle entry.
Regulation of the 112 gene is complex involving many transcription factors, the 
activity of which, are regulated in T cells via shared and distinct signalling pathways. 
Studies have identified a ~300bp segment upstream of the 112 gene capable of 
conferring T cell specific, inducible transcription of linked reporter genes (Riegel et 
al., 1992; Durand et al., 1988; Durand et al., 1987; Fujita et al., 1986). This 
sequence is referred to as the 112 minimal enhancer region and it contains a number of 
binding sites for transcription factors (Figure 4.1 A). The most well studied groups of 
factors that bind to sequences in this regulatory region are members of the Oct, 
NFAT, NF-kB, and AP-1 families. While the interaction of Oct-1 with its target 
sequence is activation independent, the binding of NFAT, NF-kB and AP-1 is 
induced only after T cell stimulation (Rooney et al., 1995; Serfling et al., 1989; 
Brunvand et al., 1988). It is interesting that none of these factors are specific to the
//2 gene or to T cells, and yet production of IL-2 is thought to be highly cell-type 
restricted and dependent upon activation. To date no single transcription factor has 
been identified as a unique regulator of the 7/2 gene. Instead, transcription of IL-2 
seems to be achieved by the co-operative actions of all these ubiquitous factors 
binding to their target sequences within the minimal enhancer. Loss of binding 
mutations in any site has profound effects on the transcription of linked reporter 
constructs (Zhang and Nabel, 1994; Jain et al., 1992; Thompson et al., 1992; Kamps 
et al., 1990). Interestingly, the binding sites for all these factors are non-consensus 
sites, possessing a ~ 10-fold lower affinity than corresponding consensus sites located 
in other genes also regulated by these common factors. This relatively weak affinity 
of the target sites is thought to be what controls the T cell specific production of IL-2, 
as conversion of these sequences from non-consensus to consensus sites is able to 
then drive IL2 reporter gene transcription in non-T cells (Hentsch et al., 1992). 
Therefore, production of IL-2 by an activated T cell is a tightly regulated process 
because only the correct stimulus, able to induce the co-ordinate activation and 
binding of all factors to their relatively weak recognition sites, will induce 
transcription of this cytokine. In contrast partial or sub-optimal stimuli may lead 
only to the activation of one or two factors and will not be sufficient to drive IL-2 
production. Certainly, DNA foot-print analysis has revealed that all sites in the 112 
minimal enhancer are occupied when the factors are present and active, or all empty 
if only a few are functional (Chen and Rothenberg, 1994; Garrity et al., 1994).
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The factors that bind to the 112 minimal enhancer region can be sub-divided into two 
categories depending on when they can be detected in the nucleus (Jain et al., 1995) 
(Figure 4 .IB). The earliest factors present within 1 hour following activation include 
NFATc2, AP-1, and Rel-A. AP-1 and Rel-A, in concert with other transcription 
factors activated within this time frame (^1 hour) have been shown to induce the 
expression of CD69 (Castellanos et al., 1997) and CD25 (John et al., 1995) 
respectively. However IL-2 transcription also requires the action of late factors such 
as c-Rel, Oct-2 and NFATcl that are detectable in the nucleus ~4 hrs post activation 
(Venkataraman et al., 1995; Northrop et al., 1994; Kang et al., 1992). The need for 
these distal factors correlates with the observation that IL-2 production requires a 
more prolonged period of stimulation than the expression of activation markers. For 
example stimulation with soluble antibodies is capable of inducing expression of 
CD69 but not IL-2 (Wacholtz and Lipsky, 1993). With such a stimulus, the signals 
will be rapidly terminated because the antibodies will be internalised. In contrast, 
antibodies immobilised on a fixed surface will not be internalised inducing more 
sustained signals resulting in IL-2 production. Also treatment of Con A activated T 
cells with the competitive inhibitor alpha-methyl mannoside showed that 2-4 hrs of 
sustained activation was required for IL-2 mRNA production (Weiss et al., 1987). 
This requirement for sustained antigen exposure has also been demonstrated by 
several other groups by controlling the period a T cell was in contact with the 
stimulus and looking at the ability to express activation markers and IL-2 
(Lanzavecchia et al., 1999; Iezzi et al., 1998; Waldrop et al., 1998; Itoh and Germain, 
1997; Viola and Lanzavecchia, 1996; Shaw et al., 1988) or by addressing the period
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of APC contact required to induce IL-2 production at the single cell level (Hurez et 
aU 2003).
In this model (Figure 4 .IB), activation marker expression is controlled by the first 
threshold of signal that is sufficient to activate the early factors NFATc2, Rel-A and 
AP-1. However IL-2 production is then regulated by a second threshold of signal, 
achieved only when the duration and / or intensity of signal is sufficient to activate 
the later factors such as c-Rel and Oct. There is one excellent piece of evidence for 
this theory that has been described by several groups. Within a population of 
activated T cells, optimal stimulations in vitro using immobilised antibodies or 
pMHC, is capable of inducing ~90% of cells to express CD69/25, however IL-2 
production within this same population rarely exceeds 50% (La Gruta et al., 2004; 
Kristensen et al., 2002; Panus et al., 2000; Veiga-Femandes et al., 2000; Khoruts et 
al., 1998; Weaver et al., 1998; Itoh and Germain, 1997; Rogers et al., 1997; Bucy et 
al., 1995). These data suggest that, within a population of polyclonal, and even 
monoclonal T cells, there is heterogeneity based on the ability of a cell to make IL-2. 
Therefore ~90% of cells receive sufficient signal duration/intensity to cross the 
threshold for activation marker expression, however only a fraction of these cells then 
receive the additional period of stimulation to cross the second threshold and produce 
IL-2 (see Figure 4 .IB).
From chapter 3 it was clear that the loss of Fyn was able to increase the percentage of 
IL-2 producers within a population of activated cells, without altering the expression
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of activation markers. These data suggested that the loss of Fyn was somehow 
specifically affecting the ability of cells to cross the second signalling threshold and 
commit to IL-2 production. Fyn deficiency could affect the threshold controlling IL-2 
production in several ways. Firstly, the loss of Fyn may be affecting the function of 
the early factors in someway so that when the late factors became activated they 
would collectively result in improved efficiency of IL-2 production. Secondly, the 
early transcription factors may be unaffected, and instead the efficiency of the 
activation of the late factors may be elevated, resulting again in improved ability to 
produce IL-2. Thirdly, Fyn deficiency may be affecting both the early and late 
factors, resulting in a synergistic effect on IL-2 transcription. A further degree of 
complexity is introduced by considering how Fyn could be affecting these factors. 
For example, the effect on IL-2 production may be directly due to the loss of 
activation of Fyn specific substrates. Certainly, studies in human T cells revealed 
that Fyn may be part of a multi-protein complex consisting of basely phosphorylated 
proteins that include ADAP, SKAP55 and Pyk2 (Marie-Cardine et al., 1999). 
Furthermore, upon T cell stimulation and in transformed cell lines, the composition of 
this complex alters, suggesting that it may play a role in regulating the activation 
status of the T cell (Marie-Cardine et al., 1999). However, the influence on the 
magnitude of IL-2 production in the absence of Fyn may be more indirect, and could 
be mediated through the putative disregulation of Lck activity caused by a reduction 
of PAG phosphorylation discussed in chapter 3. Again, it cannot be discounted that a 
combination of these effects are contributing to the increase in IL-2 production 
without Fyn.
174
4.2 Fyn deficiency increases the frequency of activated cells able to make IL-2
To address whether we could define these putative signalling thresholds for the 
regulation of activation marker expression versus IL-2 production in F5 T cells, we 
set up experiments to measure the kinetics of CD25 and CD69 expression and IL-2 
production within the same population of cells. If there were indeed a requirement 
for more sustained periods of activation to induce IL-2 expression compared to 
activation markers, we would expect observe the following. Firstly, CD69 and CD25 
expression should precede IL-2 production, and secondly that not all activated cells 
would be able to produce IL-2. To this end F5 WT and Fyn'7' cells were activated 
using peptide loaded dimer molecules and the kinetics of CD69 and CD25 expression 
and IL-2 secretion were measured within the same population on a single cell basis. 
Figure 4.2 shows that CD69 was the earliest marker to be expressed by activated F5 
cells appearing after 1 hour of activation. The timing and level of CD69 expression 
was comparable between the WT and Fyn'7' cells, reaching a plateau by 3 hrs. CD25 
expression appeared at ~3 hrs in both groups, plateau at ~96% after 12 hrs. In 
contrast to activation marker expression, IL-2 production within these cell 
populations was first detected by capture assay at 4 hrs. Furthermore, this was 
restricted to only a sub-population of activated cells in both groups. By 5 hrs the 
percentage of activated F5 Fyn'7' cells producing IL-2 exceeded that of activated F5 
WT cells, but CD69/25 expression was unaltered. Collectively these data confirmed 
that IL-2 production occurs after activation markers expression, and is restricted to 
only a sub-set of responding cells. Moreover, Fyn deficiency did not affect whether a
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given cell reached the first threshold controlling activation marker expression, but it 
did increase the frequency of cells within a population able to reach the second 
threshold for IL-2 production.
4.3 The period of stimulation required to commit a cell to IL-2 production is 
reduced in the absence of Fyn
Having established that IL-2 production by antigen activated F5 cells occurred after 
the detection of activation markers, and was restricted to a subset of cells, we wanted 
to ask about the duration of antigen exposure that was required to induce IL-2 
production versus CD69 expression. More specifically, the question was how Fyn 
deficiency could have affected these thresholds so that F5 Fyn'7' cells produced more 
IL-2 while not affecting up-regulation of CD69. To this end we exposed purified F5 
WT and Fyn'7' T cells to a layer of NP68 pMHC dimers for defined periods, then 
removed them from the stimulus and put them into culture away from antigen and 
assayed these cells at 24 hrs for the expression of CD69 and intracellular IL-2 
staining.
Previous studies have also addressed how long a stimulus was required for T cell 
activation and IL-2 production, using plate bound antibodies and pMHC-complexes 
(Iezzi et al., 1998). However these studies did not control for the possibility of 
antigenic carry-over after cells were removed from the stimulus. This was a concern, 
as any residual antigen carried over would have compromised the interpretation of the
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data. Therefore to control for this we removed the F5 cells from the stimulus, washed 
them extensively and placed them in wells that contained CFSE labelled naive F5 
cells that would act as indicators, becoming activated if antigen were present. 
Figures 4.3A and B show that there was no significant antigenic carry over in all 
wells, as CFSE labelled cells showed only background staining levels (CD69 <5% 
Figure 4.3A and IL-2 ^8% Figure 4.3B). Expression of CD69 and IL-2 was then 
assessed after a total of 24 hrs of culture to address the level of activation and 
commitment to IL-2 production induced after the defined periods of antigenic 
contact.
From Figure 4.3C it is evident that ~3 hrs of exposure to stimulus was required to 
upregulate CD69 expression in 50% of cells in both groups. In contrast commitment 
to express IL-2 in a similar proportion of cells required a longer period of stimulation. 
These data supported published observations that short periods of antigen exposure 
were enough to induce CD69 expression but that increased periods were required for 
IL-2 production (Wacholtz and Lipsky, 1993; Weiss et al., 1987). Remarkably, F5 
Fyn"7 cells required a period of ~10 hrs of antigenic exposure for 50% of cells to 
produce IL-2, whereas F5 WT cells required ~24 hrs of antigen exposure to reach a 
comparable percentage of IL-2 + cells. These data indicate that Fyn deficiency 
reduced the period of antigenic exposure required for IL-2 production by ~2-fold 
compared to WT cells without affecting CD69 expression.
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It is also of note that regardless of how long the cells were exposed to antigen, 
production of IL-2 by F5 Fyn 7' cells was consistently elevated compared to F5 WT 
cells. As increased IL-2 production by F5 Fyn 7' cells was seen regardless of the 
length of exposure to antigen, it suggested that this phenomenon did not require a 
particular length of time on the dimer layer. However, as the increased IL-2 
production was observed after all periods of stimulation capable of inducing IL-2 in 
either group, it suggested that it was not the duration of signal that controlled the 
elevated IL-2 production but altered sensitivity of the F5 Fyn'7' cells.
Another interesting observation from these data is that 1 hour of stimulation was 
enough to induce detectable IL-2 production in the F5 Fyn'7' cells 24 hrs later. This 
was unexpected as transcription of the late factors, such as c-Rel or Oct2, should not 
have occurred in this 1 hour time frame of stimulation (Venkataraman et al., 1995; 
Kang et al., 1992). Indeed, WT F5 cells required at least 4 hrs of antigenic exposure 
to commit to IL-2 production 24 hrs later, supporting the idea that more prolonged 
signals are required compared to activation marker expression.
4.4 The relationship between Src kinase activity and antigen exposure is 
uncoupled with respect to IL-2 production in F5 Fyn'7' cells
From the data in Figure 4.3. There were two possible explanations for why IL-2 
production could be observed after just 1 hour of antigen exposure. Firstly, in the 
absence of Fyn the duration of signal continued even after removal of the antigen, or
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secondly that the strength of signal induced in 1 hour was elevated compared to WT 
leading to the premature activation of the late factors required for IL-2 transcription.
To try and resolve the reason why F5 Fyn'7' cells were able to make IL-2 24 hrs later 
after just 1 hour of antigen exposure, we decided to ask if signalling was terminated 
by addition of inhibitors at this time, would the signals already generated still be 
sufficient to drive IL-2 production 24 hrs later. We used the Src specific inhibitor 
PP2, adding it to F5 cells 3 hrs after triggering with peptide, and at 24 hrs we 
measured the ability to produce IL-2 by intracellular staining. If the signals 
established during the 1 hour of antigen exposure in the absence of Fyn were 
sufficient to induce IL-2 production, the termination of Src kinase activity at 3 hrs 
should not have any effect on the ability to observe IL-2 24 hrs later. The decision to 
add PP2 at 3 hrs and not earlier was based on the observation that CD69 expression 
could be achieved prior to this point, but CD25 expression could not (Figure 4.2). 
Therefore measuring CD69 expression before 3 hrs would indicate that cells had been 
successfully activated, while lack of CD25 expression after PP2 was added, would 
indicate that inhibition had occurred.
From Figure 4.4A it is clear that treatment of both groups with PP2 from the start of 
activation inhibited CD69 expression. This was specific for PP2 as the non- 
inhibitory, related compound, PP3, gave identical CD69 expression profile as 
untreated cells. Treatment of the cells with PP2 3 hrs after activation had no effect on 
CD69 expression in either group. When CD25 expression was measured (Figure
179
4.4B), again the addition of PP2 from the start of activation inhibited both groups, as 
did addition of PP2 after 3 hrs. These data indicate that Src kinase activity for longer 
than 3 hrs of antigen exposure was required to drive CD25 expression in activated 
CD8 T cells.
As a further measure of cell activation, we determined the level of antigen-induced 
TCR down-modulation. From Figure 4.4C it is clear that in both F5 WT and Fyn7 
treatment with PP2 from the start of activation completely blocked TCR down- 
modulation. TCR down-modulation occurred with the uninhibited cells and PP3 
treated cells. When PP2 was added after 3 hrs of stimulation, any further TCR 
downmodulation was prevented and levels even increased in both groups of cells. 
Interestingly F5 Fyn'7' cells down-modulated their TCR levels more rapidly compared 
to WT cells in the absence of inhibitor. This may reflect a heightened degree of 
activation in the absence of Fyn as it is thought that TCR downmodulation occurs in 
response to T cell activation (Alcover and Alarcon, 2000).
When IL-2 production was measured in these cells at 24 hrs, treatment with PP2 from 
the start of antigen treatment eliminated IL-2 production in both groups (Figure 
4.4D). This was expected, as these cells did not activate as judged by CD69 and 
CD25 expression. However, when PP2 was added at 3 hrs, although CD69 
expression was unaffected, IL-2 production was inhibited in both groups. This was 
surprising, as the data in Figure 4.3 indicated that 1 hour of antigen exposure was 
enough to commit Fyn7 cells to IL-2 production 24 hrs later, therefore one may have
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expected that inhibiting Src kinase signals at 3 hrs would have had no effect in the 
absence of Fyn. Collectively these data, and the data in Figure 4.3, show that IL-2 
production by Fyn' cells may require only 1 hour of antigen exposure, but did 
require Src kinase activity beyond 3 hrs.
4.5 The efficiency of conjugate formation is normal in the absence of Fyn
A possible explanation for the elevated IL-2 production in the absence of Fyn was 
that the formation of stable T cell APC conjugates was altered, leading to increased 
signal duration, which was able to push more cells over the second activation 
threshold (Fig 4 .IB). A recent study by Weaver and colleagues has shown that T 
cells that form stable conjugates with an APC may be more likely to produce IL-2 
(Hurez et al., 2003). Conjugate formation is regulated, in part, by the re-arrangement 
of cytoskeletal components (Fuller et al., 2003). A number of Fyn substrates such as 
ADAP (Wang et a l ,  2004; Wang et a l., 2003; Liu et al., 1998), Vav (Huang et a l , 
2000; Michel et a l., 1998) Pyk2 (Qian et a l , 1997) and WASp (Badour et a l , 2004) 
have been shown to be involved in cytoskeletal rearrangement. Therefore it seemed 
plausible that Fyn deficiency could influence IL-2 production by increasing the 
efficiency of stable conjugate formation, and thus the duration of signal delivered to 
the T cell.
To this end conjugate formation by F5 CD8 T cells was measured by a FACS based 
method. This involved labelling peptide pulsed APC with an intracellular fluorescent
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dye and T cells with a dye, fluorescing in a distinct channel. These populations were 
then mixed at a 1:1 ratio and centrifuged to form conjugates. The stability of the 
conjugates was assessed by vigorously resuspending the cell pellet and incubating 
cells for 10 min at 37°C / 5% C 0 2. Conjugation of F5 T cells with APC but no 
peptide did not lead to any double positive cell conjugates (Figure 4.5A, left panel). 
When F5 cells were centrifuged with peptide pulsed APC, we were able to detect 
doublet cells in the top right quadrant (Figure 4.5A, right panel). From Figure 4.5B it 
is evident that the frequency of F5 T cells forming conjugates with peptide pulsed 
APC increased with rising antigen concentration, however the dose response was not 
altered in the absence of Fyn. These data suggested that any elevation in IL-2 
production by F5 F y n c e l ls  was unlikely to be a result of increased signal duration 
due to improved formation of T cell - APC stable conjugates.
4.6 Ca2* signals are normal in response to antigen in the absence of Fyn
Having established that the increase in IL-2 production in the absence of Fyn was 
most likely due to changes in how a given signal was interpreted rather than gross 
changes in the interaction with antigen, we wanted to look at the pathways regulating 
IL-2 production. In terms of the early factors, the IL-2 promoter contains two NF-AT 
binding sites (Nolan, 1994) and mutations in both, leading to loss of binding is 
needed to abrogate promoter function (Zhang and Nabel, 1994; Thompson et al., 
1992). Also use of a dominant negative NF-AT molecules is able to reduce IL-2 
production (Chow et a l., 1997). NF-AT activity is controlled via the TCR by the
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cleavage of PIP2 by the enzyme PLC-yl generating DAG and IP3 (Nishibe et al., 
1990). IP3 induces the mobilisation of intra-cellular Ca2+ that activates calcineurin, 
which in turn dephosphorylates NF-AT allowing it to enter the nucleus and bind to 
the promoter of the 112 gene (Aramburu et al., 2000; Whitney and Sutherland, 1972). 
IL-2 production by T cells is also reliant on sustained Ca2+ mobilisation (Wacholtz 
and Lipsky, 1993; Goldsmith and Weiss, 1988), presumably to regulate NF-AT 
activity (Timmerman et al., 1996). Both Lck and Fyn have been implicated as 
activators of PLC-y 1 (Fusaki et al., 1994; Liao et al., 1993; Weber et al., 1992) and 
thus disregulation of these molecules could affect NFAT activation through Ca2+ 
dependent pathways.
It was possible that the strength and/or duration of antigen induced Ca2+ mobilisation 
was increased in F5 Fyn'7' T cells. This could explain why they were able to produce 
more IL-2 compared to F5 WT cells after identical periods of antigenic contact 
(Figure 4.3C). The release of intracellular Ca2+ can be readily measured at the single 
cell level using flow cytometric techniques. To this end F5 WT and Fyn'7' CD8 cells 
were loaded with the Ca2+ indicator dye Indo-1 and a flux was induced by conjugating 
T cells with NP68 pulsed APC. From Figure 4.6A and 4.6B it is evident that 
conjugation with pulsed APC was able to induce a comparable Ca2+ flux in both 
groups in terms of intensity and duration. This was peptide specific, as conjugation 
with unpulsed APC induced no flux in either group.
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To further confirm that Ca2+ signalling was not altered in the absence of Fyn, we 
measured the transcription of NF-ATcl. NF-ATc2 is expressed in resting T cells, 
however NF-ATcl expression is induced after stimulation (Wang et al., 1995; 
Northrop et al.y 1994). The transcription of NF-ATcl is regulated by activation of 
NF-ATc2 (Zhou et al., 2002), itself a direct downstream target of Ca2+ signalling, 
therefore expression of NF-ATcl was assessed using real-time PCR. From Figure 
4.6C it is evident that the detection of steady state NF-ATcl mRNA reached maximal 
levels by 180 min in both groups, then dropped by 240 min. From the experiment 
shown in Figure 4.6C, there was a slight increase in NF-ATcl mRNA levels in the 
absence of Fyn at 1 hour compare to WT, however this was not a reproducible 
difference. In concordance with the Ca2+ flux data in response to pMHC, Fyn 
deficiency did not seem to exert an effect on the proximal or distal aspects of Ca2+ 
signalling.
The ability of Fyn"7' cells to flux calcium in response to anti-CD3 was reported to be 
reduced in the absence of Fyn (Appleby et al., 1992; Stein et al., 1992). As shown in 
chapter 3, the use of anti-CD3 antibodies as a stimulus led to a hypo-responsive 
phenotype, however if CD8 was co-ligated with the TCR then cell triggering was 
restored and IL-2 production was elevated in the absence of Fyn. Therefore we asked 
whether co-ligating CD8 with CD3 would overcome the defect in Ca2+ mobilisation 
reported in Fyn'7" cells stimulated with anti-CD3 alone. To this end F5 WT and Fyn"7 
were loaded with Indo-1 and pre-labelled with biotinylated antibodies against anti- 
CD3, anti-CD8 or anti-CD3 and anti-CD8 together. A Ca2+ flux was induced using
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avidin to cross-link the bound antibody. From Figure 4.6D it is clear that anti-CD3 
alone was able to induce a small Ca2+ flux in F5 WT cells, however cross-linking 
CD3 and CD8 was able to improve the speed of initiating the flux and also the level. 
Figure 4.6E shows that, as reported previously for polyclonal cells, F5 Fyn7' cells 
mounted a slower and reduced flux in response to anti-CD3 alone compared to F5 
WT cells with the same stimulus. However, cross-linking CD8 and CD3 was able to 
improve the response of F5 Fyn'7' cells generating a comparable flux to F5 WT cells 
with the same stimuli. These data again underscore the importance of CD8 in 
restoring any signalling defects observed in Fyn'7' cells after TCR stimulation.
4.7 Erk phosphorylation is sustained in antigen activated F5 Fyn*7' cells
Due to the fact that elevated IL-2 production in the absence of Fyn could not be 
attributed to changes in Ca2+ mobilisation we wanted to look at other pathways 
controlling factors responsible for regulating IL-2 production downstream of the TCR 
and CD8. It has been proposed that sustained Erk activation is important for T cell 
activation and effector differentiation (Berg et al., 1998). Downstream of Erk are 
members of the Ets family of transcription factors that regulate transcription of the 
AP-1 family members (Rincon and Flavell, 1994). Specifically, the Erk target Elk-1 
has been shown to be important to the transcription of the c-Fos gene (Marshall, 
1995; Marais et al., 1993; Gille et al., 1992), thus Erk may influence the ability to 
produce more IL-2. Activation of Erk is controlled by Mek, which is in turn 
downstream of Grb2 / SOS and RasGRP activation (Aronheim et al., 1994). As Lck
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and Fyn are upstream of these molecules it was possible that Erk activity could be 
altered in the absence of Fyn.
To determine the influence of Fyn deficiency on Erk activation, cells were stimulated 
on a layer of peptide-loaded dimers for defined time points. At each point, prior to 
cell lysis, a sample of cells was stained for the expression of the activation markers 
CD69 and CD25 to check the level of stimulation between samples and groups. 
From Figure 4.7A it is clear that the cells activated comparably and, from Figure 
4.7B, that the induction of phospho-Erkl and 2 could be detected in the lysates of 
these samples. However, when the degree of pErkl (Figure 4.7C) and pErk2 (Figure 
4.7E) was quantified using densitometry it appeared that in the absence of Fyn, Erk 
activation was prolonged compared to WT controls. This late period of Erk activation 
between 2 and 8 hrs correlated with the period of IL-2 production by activated F5 
cells (Figure 4.2).
To compare the differences in phospho-Erk induction in three independent 
experiments, values obtained for WT cells were set at 100% for every time point and 
the values for the Fyn'7' signal was expressed as a percentage of WT values. This 
corrected for variation in the WT values over the three independent experiments. 
Figures 4.7D and 4.7F show that less phospho-Erkl and 2 signal was detected after 
activation in the absence of Fyn at 5 and 15 min over 3 independent experiments, 
however by 1 hour Fyn'7' values were similar to WT. At later time points, the pErkl/2 
signal was greater than WT in the absence of Fyn. Collectively, these data show that
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Fyn deficiency resulted in decreased phosphorylation of Erk 1/2 before 1 hour of 
activation, but elevated phosphorylation between 2 and 9 hrs.
4.8 The kinetics of c-Rel nuclear translocation is normal in the absence of Fyn.
Although proximal Erk phosphorylation was reduced in the absence of Fyn it was 
interesting that distal Erk signal seemed prolonged. Work by Iwashima and 
colleagues has proposed that the activity of Erk ~4 hrs after TCR activation is 
essential to IL-2 production whereas proximal Erk activity may be dispensable. They 
based these conclusions on the observation that the use of an inhibitor of the upstream 
kinase Mek was able to abrogate IL-2 production when given to the cells after 4 hrs 
of stimulation, but had little or no effect if given from 0 to 4 hrs (Koike et al., 2003). 
Treatment with the Mek inhibitor also blocked the nuclear translocation of the NF-kB 
transcription factor c-Rel. This molecule is important for IL-2 production because T 
cells from c-Rel'7' mice produce 50% less IL-2 upon stimulation, but show no defect 
in the upregulation of CD25 and CD69 (Kontgen et al., 1995). It was interesting, 
therefore, that Fyn deficiency also specifically affected IL-2 production without 
altering activation marker expression.
To ask if the increase in distal Erk activation in the absence of Fyn correlated with an 
increased ability for c-Rel to translocate to the nucleus we decided to measure this 
event in F5 T cells using fluorescent confocal microscopy. Figure 4.8A shows the 
pattern of staining obtained using control rabbit sera incubated with the secondary
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Alexa-440 conjugated Fab2 anti-rabbit antibody (upper panels). In resting T cells and 
also 1 hour after stimulation c-Rel:Alexa 440 staining was excluded from the nucleus 
in both groups as judged by overlaying the Alexa-440 and PI signals from the images 
of the same cells. However, after 4 hrs of antigen activation, c-Rel was now present 
in the nucleus. Moreover the pattern of c-Rel signal followed the typical pattern 
observed for a nuclear localised transcription factor as, although clearly in the 
nucleus, it remained excluded from regions of heterochromatin (dark red areas). We 
also enumerated the cells positive for nuclear c-Rel in each group at 4 hrs and found 
there to be no overt difference (data not shown). However, these data did not rule out 
that subtle changes in the translocation of c-Rel had occurred, possibly in a 
quantitative rather than qualitative manner.
Although c-Rel is present in a resting T cell, it has been suggested that only de novo 
synthesised molecules can translocate to the nucleus and thus are important for IL-2 
production (Kane et al., 2002; Venkataraman et al., 1995). To this end we used real 
time PCR to measure the steady state levels of c-Rel mRNA in response to antigen 
activation, as this may represent the most relevant pool of c-Rel within the cell. 
Figure 4.8B shows that the levels of c-Rel transcripts peaked in both groups at 180 
min (3 hrs) after stimulation, preceding the detection of nuclear c-Rel protein at 4 hrs 
(Figure 4.7A). These data suggested that in the absence of Fyn c-Rel mRNA levels 
were normal, there was a suggestion that Fyn'7' cells contained more c-Rel mRNA at 
~300 min, however the differences were comparatively small. Furthermore, the
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transcription of c-Rel is likely to be regulated by calcium signals through NFAT 
(Venkataraman et al., 1995), and we observed no gross defect in this pathway either.
4.9 Inhibition of distal Erk activity does not eliminate elevated IL-2 production 
by F5 Fyn'7' cells.
Analysis of c-Rel nuclear translocation did not reveal any gross differences in the 
level of nuclear c-Rel or timing of translocation in the absence of Fyn. However, 
confocal microscopy is not quantitative enough to determine whether more c-Rel 
translocated to the nucleus in the absence of Fyn. Therefore to determine if the 
sustained phospho-Erk level shown in the previous experiments were responsible for 
the elevated IL-2 production in the absence of Fyn we used the Mek inhibitor 
PD90859 to inhibit Erk activation for specific windows of time during the period of 
antigen activation (Koike et al., 2003). We titrated the concentration of the inhibitor 
and found that 20 pM gave maximal inhibition of IL-2 production without affecting 
cell viability (data not shown). Figure 4.9A shows that treatment with 20 pM 
PD90859 for the entire culture period with peptide completely eliminated IL-2 
production in both groups, indicating that IL-2 production was ultimately dependent 
on Erk signals. In contrast inhibition between 0-4 hrs (the period that western 
blotting revealed Erk activity to be maximal) marginally reduced the percentage of 
cells producing IL-2 (Figure 4.9B) but had no affect on the level of production per- 
cell (Figure 4.9C) in both F5 WT and Fyn'7' cells compared to uninhibited controls. It 
should also be noted that cells exposed to PD90859 for 0-4 hrs had been treated for
189
30 min before stimulation to try and ensure that Erk activity was inhibited prior to 
activation. Administration of the Mek inhibitor from 4 to 6 hrs marginally reduced 
the % and MFI of IL-2 production in both groups. However when the inhibitor was 
administered between 6 to 10 hrs post activation there was a profound reduction in 
both the percentage of IL-2 producing cells and the MFI in both groups compared to 
untreated controls. Interestingly, while the percentage of cells producing IL-2 was 
comparable between the PD90859 treated cells, the MFI in the absence of Fyn, 
although reduced, remained above that of F5 WT cells (Figure 4.9C). Collectively 
these data suggested that although Erk activation between 6-10 hrs post activation 
and beyond, was essential to IL-2 production in both groups, it was not responsible 
for dictating the increase in IL-2 production by F5 Fyn'7" cells.
4.10 Jnk phosphorylation is detectable in the absence of Fyn
Considering the previous data and the fact that the ability of Fyn"7' cells to produce 
elevated IL-2 could be set up as early as 1 hour after stimulation (see Figure 4.3C) we 
wanted to look at signalling molecules that influence IL-2 transcription at an early 
phase of T cell activation. One such molecule is Jnk, which has been shown to play a 
role in the transcription of IL-2 (Ip and Davis, 1998). T cells express Jnkl and Jnk2, 
both of which exist in two different phospho-variants of p55 and p46 (Ip and Davis, 
1998). Upstream of Jnk are MKK4, MKK7 (Tournier et al., 2001; Yang et al., 1997; 
Derijard et al., 1995), which are in turn regulated by PKC0 and VAV (Moller et al., 
2001; Ghaffari-Tabrizi et al., 1999), which are also influenced by Src kinases (Liu et
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al., 2000) (Huang et al., 2000; Michel et al., 1998). Furthermore Flavell and 
colleagues have shown that while Jnkl'7' CD8 cells make less IL-2 after TCR 
stimulation, Jnk2 deficient CD8 T cells produce more IL-2 upon stimulation (Conze 
et al., 2002). To this end we stimulated cells as described for Figure 4.8, and lysed 
them for biochemical analysis of Jnk phosphorylation to determine if there were 
defects in phosphorylation of either of the two Jnk isoforms. Figure 4.10A shows 
that inducible phosphorylation of the Jnks was achieved after 5 and 30 min in both 
groups. We were able to resolve the p46 form of Jnkl and Jnk2, as well as a band at 
~54kD that was most likely the p54 form of Jnk 1/2. When these band intensities 
were quantified relative to loading controls, it was evident that the loss of Fyn had a 
minimal effect on induction of the Jnkl/2 p54 variant (Figure 4.10B), with the signal 
peaking after 30 min in both groups. There was possibly a slight increase in the 
duration of phosphorylation in the absence of Fyn with levels returning to that of WT 
by 9 hrs. In contrast, the phosphorylation of the p46 forms of Jnk2 (Figure 4 .10C) 
and Jnkl (Figure 4.10D) peaked at 5 min in WT cells, but were slightly more 
phosphorylated in the absence of Fyn, with maximal levels observed after 30 min of 
activation. Again there was also a possible increase in the duration of the 
phosphorylation of p46 Jnk2/1 in Fyn; cells compared to WT. Collectively, these 
data suggested that Fyn deficiency led to inducible levels of p46 Jnkl, p46Jnk2 and 
p54 Jnkl/2 phosphorylation. There may have been subtle differences but this would 
need confirming by replicate experiments.
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4.11 Activated Fyn'7' and WT F5 cells express differential mRNA levels of AP-1 
family members.
Jnk has been shown to influence IL-2 production through the activation of c-Jun, a 
component of the AP-1 transcription factor (Conze et al., 2002; Wang et al., 2000; 
Chen et al., 1994). The expression of c-Jun is regulated, in part, by the activation of 
pre-existing c-Jun in the resting T cell by Jnk (Derijard et al., 1994). In a resting T 
cell, c-Jun is bound as a hetero-dimer with ATF-2 to the c-Jun SRE (Rozek and 
Pfeifer, 1993; van Dam et al., 1993), and when phosphorylated by Jnk the complex is 
active and transcribes the c-Jun gene. As there was a suggestion that phosphorylation 
of certain Jnk isoforms was elevated in the absence of Fyn, we asked if the levels of 
steady state c-Jun mRNA were also increased as this could, in theory, contribute to 
the elevated IL-2 levels. To this end, we measured c-Jun mRNA levels by real time 
PCR. In activated F5 WT cells, levels of c-Jun mRNA (Figure 4.11 A) peaked after 
~15 min of stimulation. In contrast, we were unable to detect comparable levels of c- 
Jun mRNA in activated F5 Fyn'7' cells and there was a -4-fold reduction compared to 
WT cells at 15 min.
c-Jun is not the only component of the AP-1 complex that is transcribed de novo in an 
activated T cell. Transcription of other members of the AP-1 transcription family 
have also been shown to occur within one hour of T cell activation (Radler-Pohl et 
al., 1993; Holt, 1992). These components form homo and heterodimers that can bind 
and contribute to the activation the 112 gene (Glover and Harrison, 1995; Jain et al.,
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1992; Angel and Karin, 1991; Ryseck and Bravo, 1991)(Serfling et al., 1989). To 
address the impact that Fyn may have on the transcription of these other AP-1 
complex components we measured the kinetics of mRNA levels after activation using 
real time PCR. Figure 4.1 IB shows that maximal JunB mRNA was comparable 
between F5 WT and Fyn'7'samples, however peak mRNA levels were detected in 
activated F5 Fyn'7' after 45 min compared to 30 min in F5 WT cells. When analysing 
c-Fos (Figure 4.11C), F5 WT cells contained ~0.25-fold higher mRNA levels 
compared to F5 Fyn'7' cells at the maximal time point, which was 30 min for WT cells 
and 45 min for Fyn"7'. In contrast to c-Jun, FosB mRNA levels were elevated 3-fold 
in the absence of Fyn compared to WT cells. This was a pattern that we observed in 
two independent experiments. These data suggest that in Fyn deficient cells there 
may be a preferential bias toward AP-1 complexes consisting of FosB-Jun 
heterodimers as opposed to c-Jun homodimers, or c-Jun-c-Fos heterodimers.
4.12 Discussion
The aim of work presented in this chapter was to determine the cause of elevated IL-2 
production by F5 Fyn'7' cells after antigen stimulation. Although, there was not a 
detailed biochemical analysis conducted of every pathway downstream of the 
TCR/CD8 capable of modulating IL-2 production, a number of observation were 
made that could serve as a basis for explaining why F5 Fyn'7' cells were able to make 
more IL-2.
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Activation of F5 WT and Fyn'7' using optimal stimulation conditions showed that 
while we were able to induce the expression of activation markers in ~90% of all 
cells, only a proportion were also able to express IL-2. As shown in chapter 3, the 
percentage of activated F5 Fyn 7' cells making IL-2 was greater than F5 WT cells. IL- 
2 production required a duration of stimulation compared to CD69 expression. 
However, in the absence of Fyn, cells only required 1 hour of antigenic exposure to 
induce IL-2 production, whereas WT cells required at least 5 hrs. Collectively these 
data suggested that different signalling thresholds exist to control activation marker 
and IL-2 expression, and that Fyn deficiency improved the ability of F5 cells to cross 
the second threshold and produce IL-2. The use of the Src kinase inhibitor PP2 
revealed that, although 1 hour of antigen contact was enough to induce IL-2 
production by F5 Fyn'7' cells, they required Src kinase activity for longer than 3 hrs 
stimulation in order to produce IL-2. The elevated IL-2 production in the absence of 
Fyn was most likely not influenced by the efficiency of conjugate formation, as F5 
Fyn'7' cells did not show an improved ability to form stable conjugates with peptide 
pulsed APC compared to WT. When we looked at intracellular events, the induction 
and duration of Ca2+ mobilisation was also unaffected in the absence of Fyn, however 
we did find that Erk activation was prolonged compared to WT cells. Downstream 
of Erk, confocal analysis revealed that the kinetics of c-Rel nuclear translocation were 
comparable in both groups. Furthermore, administration of the Mek inhibitor 
PD90859 during the period of prolonged Erk phosphorylation was not able to 
eliminate the ability of F5 Fyn'7' to make more IL-2 than WT cells, suggesting that 
this was not the underlying cause of the phenotype. Analysis of Jnk activation
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revealed that phosphorylation was not defective in the absence of Fyn, however there 
may have been a subtle increase in the levels of p46 Jnkl/2. The expression of 
components of the AP-1 complex revealed that, in the absence of Fyn, there was 
increased levels of FosB mRNA and reduced levels of c-Jun and c-Fos mRNA 
compared to F5 WT cells. Collectively these data suggest that Fyn deficiency may 
lead to elevated IL-2 production by uncoupling the need for prolonged antigenic 
exposure to drive Src kinase activation and also possibly through the production of 
differential AP-1 family members.
In terms of the influence that Fyn deficiency had on the mRNA levels of AP-1 
members, studies have shown that c-Jun can form homodimers with itself and 
heterodimers with members of the Fos family (Kouzarides and Ziff, 1989; 
Kouzarides and Ziff, 1988). The stability of Jun-Fos heterodimers is greater than 
Jun-Jun homodimers (Smeal et al., 1989). Moreover, the binding affinity to AP-1 
sites of Jun-Fos complexes is greater than Jun-Jun homodimers (Ryseck and Bravo, 
1991; Ransone et al., 1990b; Ransone et al., 1990a; Halazonetis et al., 1988). This 
could be highly significant to the transcriptional control of the IL-2 gene as the AP-1 
sites within the promoter are relatively weak non-consensus sites (Hentsch et al., 
1992; Jain et al., 1992; Serfling et al., 1989). Therefore Jun-Fos heterodimers are 
able to bind with greater affinity than Jun-Jun homodimers to these sites and may be 
better transcriptional activators, thus the induction of Fos members may be essential 
to increasing IL-2 production in a T cell. There are several lines of evidence for this. 
Firstly, Fos members are transcribed de novo after T cell activation (Jain et al., 1992;
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Kovary and Bravo, 1991) and IL-2 gene transcription can be blocked by the use of 
protein synthesis inhibitors (Shaw et al., 1987). Secondly, FosB has been shown to 
specifically improve the binding of AP-1 complexes (Zerial et al., 1989). Also over­
expression of plasmid-encoded FosB was able to improve IL-2 reporter gene 
transcription in T cell lines and also in non-T cells (Hentsch et a l., 1992). 
Furthermore, transgenic over-expression of c-Fos in mice led to increased IL-2 
mRNA (Ochi et al., 1994). Also the use of dominant negative c-Jun lacking the DNA 
binding domain was able to reduce IL-2 promoter activity, possibly by sequestering 
Fos sub-units away from the AP-1 sites (Ransone et al., 1990b). The importance of 
AP-1 affinity to IL-2 induction was shown by the conversion of the non-consensus 
sites within the IL-2 minimal enhancer to consensus sequences that were able to bind 
the lower affinity Jun-Jun AP-1 complexes. This greatly improved AP-1 driven 
transcription of an IL-2 reporter gene (Hentsch et al., 1992). Furthermore, studies 
have suggested that different stimuli may induce differential expression of AP-1 
members changing the composition of the complex (Brooks et al., 1995; Chatta et al., 
1994; Rincon and Flavell, 1994; Ullman et al., 1993). It is also of interest that in 
anergic T cells that fail to make IL-2, there is a specific defect in the transcription of 
Fos members (Mondino et al., 1996). As outlined in chapter 3, Fyn has been 
implicated in anergy and may thus regulate the ability of a T cell to make IL-2 by 
reducing expression of FosB and increasing expression of c-Jun, because in the 
absence of Fyn we observed the complete opposite effect. Therefore the composition 
of AP-1 may be the decisive factor for the duration and level of IL-2 expression by an 
activated T cell.
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The effect that increased AP-1 binding would have on the 112 gene is not solely 
restricted to AP-1 sites. Work by E. Rothenburg’s group has shown that, if NFAT 
activation was blocked using CsA then the binding of all factors was inhibited, as 
measured by DNA foot-printing (Garrity et al., 1994). A similar result was obtained 
by blocking NF-kB activation using Forskolin (Chen and Rothenberg, 1994). 
Collectively, these data suggested that binding to the 112 promoter is an all or nothing 
event, whereby the loss of binding of one molecule will prevent the rest from 
assembling on the promoter. Furthermore, it is well established that binding of the 
respective factors to the distal Oct-1 site (de Grazia et al., 1994) and the proximal 
NFAT sites are regulated by the co-operative binding of AP-1 factors (Masuda et al., 
1995; Yaseen et al., 1994; Jain et al., 1993). Moreover, there is evidence that the 
specific composition of AP-1 will have an effect on the binding of factors to these 
sites (McCaffrey et al., 1993; Ullman et al., 1993; Ullman et al., 1991). Interestingly, 
the use of a dominant negative c-Jun molecule that retains the DNA binding motif, 
but lacks the transactivating motif was able to inhibit the binding of factors at the 
NFAT- AP-1 composite site but not the Oct-1-AP-1 site (Petrak et al., 1994). The c- 
Jun molecule lacking the transactivating domain would render Jun-Jun homodimers 
ineffective, but not Fos-Jun dimers suggesting that the co-operative nature of AP-1 at 
the Oct-1-AP-1 site is regulated by the specific composition of the AP-1 dimer. 
These data support the view that altering the AP-1 composition and the subsequent 
binding affinity can also influence the binding of other 112 transcriptional regulators 
due to the co-operative nature of AP-1.
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Interestingly a study by Greenberg and colleagues suggested that CD8 cells incapable 
of making IL-2 after antigenic stimulation had a specific block in the transactivation 
of the -150 non-consensus AP-1 site, downstream of the CD28RE (see Figure 4.1). 
They found that functional AP-1 complexes hade been formed in these cells as 
consensus AP-1 sites were transactivated. Furthermore, the mutation of the non­
consensus -150 AP-1 site to a consensus site was able to drive IL-2 expression in all 
cells (Finch et al., 2001). Collectively these data again suggest that the decision to 
make IL-2 is controlled, in part, by AP-1 factors that contain proteins such as FosB 
that can specifically bind to non-consensus sites, further suggesting that the formation 
of high affinity Fos containing complexes may be essential to IL-2 production.
The CD69 promoter also contains an AP-1 site that is essential to transcription 
(Castellanos et al., 1997), but this did not seem to be affected in the absence of Fyn. 
If the composition of AP-1 to higher affinity FosB containing complexes occurs in 
the absence of Fyn we may have also expected an increase in CD69 expression. 
However the AP-1 binding site in the promoter of the CD69 gene is a consensus site 
(Castellanos et al., 1997) and therefore may not be as sensitive to changes in AP-1 
composition.
There were two possible explanations for the increase in FosB mRNA in the absence 
of Fyn. First, is that the transcription of the FosB gene could be upregulated through 
the promoter. Transcription of Fos members is controlled by members of the Ets- 
family of transcription factors that include SAP-1, Elk-1 and Nets (Shipley et al.,
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1994). These have been shown to be pre-bound to the SRE in the promoter of Fos 
genes and when activated by phosphorylation drive transcription (Marais et al., 1993; 
Gille et al., 1992). The MAP kinases Erk, p38 and Jnk have been shown to regulate 
the functions of Elk-1 by phosphorylation (Cruzalegui et al., 1999; Enslen et al., 
1998; Cavigelli et al., 1995; Gille et al., 1995; Whitmarsh et al., 1995; Janknecht et 
al., 1994). In contrast, while p38 and Erk can phosphorylate SAP-1 (Janknecht and 
Hunter, 1997a; Whitmarsh et al., 1997; Price et al., 1996; Whitmarsh et al., 1995), it 
is thought to be a relatively poor substrate for the Jnks (Whitmarsh et al., 1997; 
Whitmarsh et al., 1995). Jnkl has been shown to be able to phosphorylate SAP-1, but 
only when its activity was increased by over-expression (Janknecht and Hunter, 
1997b). However Erk is considered to be the major MAPK responsible for driving 
Fos expression (Marshall, 1995). In the absence of Fyn, the pathway responsible for 
the increase in FosB mRNA is unclear. Transcription of FosB is a relatively early 
event (^45 min), therefore Erk activation may not be responsible for this process as it 
was actually reduced in the absence of Fyn at this time point compared to WT.
In contrast to Erk, at 30 min of stimulation, it was possible that the phosphorylation 
of p46 Jnkl and Jnk2 was increased compared to WT. Increased Jnk activity could 
lead to elevated Elk-1 activity and increase the transcriptional regulation of the FosB 
gene. However, activation of Elkl has also been shown to regulate transcription of c- 
Fos (Cavigelli et al., 1995), and as the steady state of c-Fos mRNA was actually 
decreased in the absence of Fyn, it would be unlikely that Elk-1 activity was 
responsible. It is possible that Jnk may be influencing other Ets family members as
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when Jnkl is over-expressed, it can activate SAP-1 (Janknecht and Hunter, 1997b). 
SAP-1 is also capable of controlling the expression of Fos family members 
(Janknecht and Hunter, 1997a), however the molecule(s) responsible for driving the 
increase in FosB expression would have to be distinct from those regulating c-Fos 
expression due to the different patterns we observed in the mRNA levels of these 
genes.
A second possible explanation for the increase in FosB mRNA in the absence of Fyn 
is through changes in the stability of the transcripts. Fos transcripts contain AU-rich 
elements (ARE) in the 3’ region of the gene (Wilson and Treisman, 1988). These 
make the transcripts unstable and prone to degradation (Wilson and Treisman, 1988). 
It is possible to classify transcripts containing ARE into three classes on the basis of 
the AUUUA repeat patterns (Chen and Shyu, 1995; Chen et al., 1995; Chen and 
Shyu, 1994; Stoecklin et al., 1994). There is also evidence that the mechanisms 
controlling the stability of these classes of transcripts may differ as mice lacking a 
protein known to interact with these ARE led to the selective increase in TNFa and 
GMCSF mRNA (Carballo et al., 2000; Taylor et al., 1996). Fos members are 
members of class I ARE (Chen et al., 1995) and thus the mechanisms regulating 
mRNA degradation are most likely shared between all the Fos members. Therefore, 
if it were simply a case of increased stability of the mRNA rather than increased 
transcription of the gene that was responsible for the elevated FosB levels in the 
absence of Fyn, it was interesting that c-Fos mRNA was actually reduced compare to 
WT. Our data also suggested that although FosB levels were increased in the absence
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of Fyn, the mRNA levels then rapidly decreased by 60 min compared to WT cells. A 
possible explanation for this result is that FosB has been shown to silence its own 
promoter (Lazo et al., 1992).
If increased Jnk activity in the absence of Fyn was responsible for the increase in 
FosB gene transcription, this would mean that there would have to be a pathway for 
regulating Fos levels that would be ultimately dependent on Src kinase activity. A 
study by Mustelin and colleagues highlighted a potential relationship between the 
regulation of Src kinase activity and transcription of Fos family members by Jnk 
proteins (Gjorloff-Wingren et al., 1999). They found that transfection of Jurkat cells 
with the phosphatase PEP, which regulates Lck/Fyn activity, led to a decrease in the 
phosphorylation of Tyr394 in Lck, a reduction in the activation and function of Jnk, 
reduced expression of a reporter gene linked to the Fos promoter and finally reduced 
IL-2 production (Gjorloff-Wingren et al., 1999). In relation to this, the use of a Csk 
siRNA was able to increase Lck activity and IL-2 production by spontaneous NF- 
AT/AP-1 activation (Vang et al., 2004). Furthermore, there is also evidence of Src 
kinase dependent pathways that lead to the preferential transcription and activation of 
FosB in B cells downstream of the BCR (Dickinson et al., 1995).
As well as increased FosB expression, we observed a reduction in c-Jun expression. 
Analysis of c-Jun7' T cells using the Rag complementation system revealed that, 
although IL-2 production was partially reduced, c-Jun was not essential to production 
of this cytokine (Chen et al., 1994). Similar to the increase in FosB mRNA, the
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decrease in c-Jun mRNA may be due to changes in the transcription of the gene, or 
due to alterations in the mRNA stability. In terms of the latter, it is possible that we 
could observe a selective decrease in c-Jun mRNA stability while observing increase 
in Fos member mRNA stability. Studies have suggested that Jun mRNA are class III 
ARE where as Fos mRNAs are class I ARE on the basis of the AUUUA patterns 
within these regions (Chen and Shyu, 1994) and therefore may be subject to different 
signals for stability. However, the same argument used for the Fos proteins applies to 
the Jun proteins, namely that c-Jun and JunB are in the same class of ARE, therefore 
it seems strange that we observed decreased c-Jun, but relatively normal JunB 
compared to WT cells in the absence of Fyn if the mechanisms controlling stability 
are shared.
With respect to transcriptional control of c-Jun, in resting cells, pre-existing c-Jun 
protein is found bound to the promoter of the c-Jun gene, along with the transcription 
factor ATF-2 (Rozek and Pfeifer, 1993). Phosphorylation of Ser-63 and Ser-73 
within the N-terminal activation domain of c-Jun by Jnk, and phosphorylation of 
ATF-2 by Jnk and p38 allows this transcription factor complex to become activated 
and drives transcription (van Dam et al., 1995; Wilhelm et al., 1995; Minden et al., 
1994). It was possible that we observed a degree of elevated Jnk activation so it was 
conflicting that this correlated with a decrease in c-Jun mRNA. There are a number 
of other possible explanations for the decrease in c-Jun mRNA levels that may not 
involve Jnk activation. For example ATF-2 activation is also important to drive c-Jun 
expression, although this is mediated in part by Jnks may be also controlled by p38
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MAPK (Derijard et al., 1995). We did not address the activation of p38 in the 
absence of Fyn, and defects in the activation of this molecule could translate to a 
decrease in c-Jun transcription.
MAPK kinases not only play a role in the transcription of the components of AP-1 
complexes, they are also able to control their transcriptional activity. For example 
Jnk can phosphorylate c-Jun and increase the transactivation potential of Jun-Jun 
homodimers and Jun-Fos heterodimers (Whitmarsh and Davis, 1996). Furthermore, 
Erk has been shown to phosphorylate a site near the basic region of c-Jun (Minden et 
al., 1994; Chou et al., 1992) that can inhibit the action of Jun-Jun homodimers, but 
not Jun-Fos heterodimers (Lin et al.y 1992; Boyle et al., 1991). In the absence of 
Fyn, we do not observe a complete loss of c-Jun mRNA. The c-Jun present is clearly 
functional as we have normal CD69 expression, and because Fos members cannot 
form functional homodimers (Smeal et al., 1989), we must assume that without 
functional c-Jun to form heterodimers with we would not observe any IL-2 
production. As we see some upregulation of c-Jun message, albeit reduced compared 
to WT, we cannot rule out that there are still some Jun-Jun homodimers formed in the 
absence of Fyn. However the prolonged Erk activity we observed may selectively 
impair the function of these complexes as they may be phosphorylated in the 
inhibitory regions. This would then influence the activity of the AP-1 dimers formed 
as the prolonged Erk activity would inhibit Jun-Jun homodimers, but not Fos-Jun 
heterodimers.
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It is also a possibility, that in the absence of Fyn, we primarily have AP-1 complexes 
containing JunB and FosB, as opposed to c-Jun and c-Fos as the latter both show a 
reduction in mRNA levels after activation. However, the function of JunB is unclear, 
and may even repress AP-1 transactivation when over expressed (Chiu et al., 1989). 
Furthermore, transfected JunB failed to increase the transcription of a reporter gene 
when expressed in EL-4 cells (Hentsch et al., 1992). More specifically, JunB has 
been shown to be able to down regulate expression of the c-Jun gene (Chiu et al., 
1989) and this may also contribute to the reduced levels of c-Jun in the absence of 
Fyn.
The idea that Erk, Jnk and possibly p38 mediated signals were controlling IL-2 
production in activated CD8 cells is an attractive idea in that CD8 cells that have 
undergone AINR (see Chapter 3) and no longer make IL-2 show defects in Erk, Jnk 
and p38 activation (Tham and Mescher, 2001). However, we will need to look in 
more detail at MAPK activity and activation using western blotting and also in vitro 
kinase assays to assess the function of these molecules in the absence of Fyn, and 
how this could influence the transcription and phosphorylation of AP-1 complexes. 
Also in terms of Jn k l and Jnk2 activity, it may be useful to look at the 
phosphorylation status of the downstream targets c-Jun and ATF-2. Studies in 
fibroblasts (Liu et al., 2004) and T cells (Conze et al., 2002) have suggested that the 
phosphorylation of c-Jun may be positively regulated by Jnkl but negatively 
regulated by Jnk2.
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In addition to the early signals that may be responsible for the changes in the mRNA 
of AP-1 members, Fyn may have also affected the function of late factors important 
to IL-2 transcription. This conclusion is based on two observations. Firstly, from the 
duration of stimulation experiment (Figure 4.3), 1 hour of antigen exposure was 
sufficient to induce IL-2 production in F5 Fyn ; cell but not in WT cells. Within this 
time frame, the putative high affinity AP-1 complexes would have been transcribed in 
the absence of Fyn but transcription and activation of distal factors, should not have 
been induced by such a short period of antigenic contact (Venkataraman et al., 1995; 
Northrop et al., 1994; Kang et al.9 1992), and therefore IL-2 production should not 
have been detected. Indeed, F5 WT cells required at least 4 hrs of antigenic contact 
in order to make IL-2. Collectively, these data suggested that in the absence of Fyn, 
either the cells had received signals that led to the premature activation of the late 
factors needed for IL-2 production in the 1 hr period, or that the putative changes in 
AP-1 composition overcame any requirement for the activation of late factors in IL-2 
transcription. Indeed c-Rel nuclear localisation could not be detected after 1 hour in 
the absence of Fyn, so it was unlikely that premature activation of this pathway had 
occurred. Furthermore, treatment of F5 Fyn'7' cells with the Src inhibitor PP2 after 3 
hrs of activation suggested that the signals generated after 1 hour were not enough to 
induce IL-2 production 24 hrs later, as we observed no cytokine by intracellular 
staining. If the signals delivered through Src kinases to the F5 Fyn'7' cells after just 1 
hour of activation had already dictated that they would be able to make IL-2 24 hrs 
later, then the administration of PP2 after 3 hrs should not have been able to prevent 
F5 Fyn'7' cells from making this cytokine. Collectively these data show that although
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the F5 Fyn 7' cells did not require continued antigenic exposure in order to achieve IL- 
2 production, they did require Src kinase activity for over 3 hrs, presumably to drive 
the signals responsible for c-Rel / Oct2 activation and translocation. Therefore after a 
relatively short period of stimulation, Fyn deficient cells may continue to signal 
through Src kinases and no longer required TCR/CD8 ligation to drive this. This 
would provide an explanation as to why after stimulation, a greater frequency of F5 
Fyn'7' cells were able to produce IL-2 as even relatively short periods of antigenic 
exposure would induce IL-2 production in the absence of Fyn.
It is well established that in the context of pMHC stimulations, T cell-APC 
interactions are extremely dynamic. So within a culture well the time a T cell spends 
in contact with the APC may influence the quality of signal delivered, regulating the 
ability to produce IL-2 (Hurez et al., 2003). As mentioned previously, several Fyn 
specific T cell substrates have been shown to link into pathways involved in 
rearrangement of the cytoskeleton, an important event controlling synapse and 
conjugate formation. Vav has been shown to be important in cytoskeletal 
rearrangement, furthermore it has suggested that Fyn is responsible for 
phosphorylating Vav (Michel et al., 1998), and that Fyn'7' cells are defective in their 
ability to form conjugates (Huang et al., 2000). Although we observed no gross 
difference when we addressed the stability of conjugate formation, we did not look at 
the duration of APC - T cell contact. If it is the case that Fyn deficiency reduces the 
duration of conjugate formation, then shorter periods of APC contact with Fyn7 T 
cells may not lead to activation defects, as our observations show that shorter periods
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of antigenic contact would still be sufficient to induce IL-2 production in the absence 
of Fyn.
Another Fyn substrate that has been shown to play a role in conjugate formation is 
ADAP (Wang et al., 2004). Expression of ADAP in a T cell line was able to greatly 
improve conjugate formation and LFA-1 clustering, however a mutant ADAP 
molecule that was unable to bind SLP-76 had the opposite effect. Moreover, not only 
was pSMAC formation and LFA-1 clustering affected by the dominant negative 
ADAP molecule, but also IL-2 production was reduced 2-fold. Interestingly, the 
interaction of SLP-76 with ADAP is thought to be mediated by the phosphorylation 
of ADAP by Fyn (Raab et al., 1999), therefore it was interesting that in our hands 
Fyn deficiency was able to upregulate IL-2 production. It would be interesting to 
look at the phosphorylation status of ADAP and the interaction with SLP-76 in our 
cells, and also to look at the duration of conjugate formation using microscopic 
techniques to determine if defects in these events could influence subsequent IL-2 
production.
From the data presented in this chapter, we propose the following model to explain 
the role of Fyn in CD8 T cell activation. Optimal stimulation of F5 WT cells via the 
TCR and CD8 would drive efficient signals capable of up regulating activation 
marker expression in 90% of cells, presumably through Lck. However Fyn would 
then serve to downregulate these signals, possibly through the action of the 
PAG/PEP/CSK complex. This would mean that only a subset of F5 WT cells would
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receive enough signal to cross the second threshold and be able to produce IL-2. 
However, in the absence of Fyn, while a 1 hour period of stimulation may induce 
differential expression of high affinity AP-1 complexes this is not sufficient to induce 
IL-2 expression without further Src kinase activity as the cells still remained sensitive 
to PP2 3 hrs later. Instead without Fyn, the activity of Src kinases may continue even 
after the removal of antigen, presumably leading to activation of distal IL-2 factors. 
This may be due to an inability or reduction in the efficiency to reform the 
PAG/CSK/PEP complex and downmodulate Src kinase activity (see Figure 4.12).
In terms of future work, we hope to confirm that the differences in Fos-Jun mRNA 
levels in the absence of Fyn translate into changes in the AP-1 complex at the protein 
level. We plan to do this with EMSA using both consensus and non-consensus AP-1 
sequences as bait, and confirm the identity of the complex using antibodies against 
specific Fos-Jun protein to look for super-shifts. We may expect to see the biggest 
differences in the composition of factors binding to the non-consensus sites in the 
absence of Fyn. Furthermore, we plan to transfect primary F5 T cells with or without 
Fyn with reporter constructs driven by either consensus or non-consensus AP-1 sites, 
and assay for changes in activity. This may provide an idea of the functional 
outcome of altering AP-1 composition.
Furthermore, to begin addressing if, after the removal of antigen, Fyn ; cells continue 
to signal through Lck we plan to stimulate cells for 1 hour, remove them from the 
antigen and look at the phosphorylation status of Lck substrates such as Zap-70 and
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She. In WT cells, we may expect to observe a decline in the phosphorylation of these 
molecules after removal of stimulation, however signal may persist over time in the 
absence of Fyn. To then provide a functional readout it may also be of interest to 
activate cells for 1 hour, remove again from the stimulus, and then look for c-Rel 
translocation into the nucleus 3 hrs later. We would expect that WT cells may 
contain no nuclear c-Rel after just 1 hour of antigen exposure, however if signalling 
continued in the absence of Fyn, then we may detect nuclear c-Rel. In terms of the 
PAG/CSK/PEP complex we also plan to look at the phosphorylation of Tyr317 of 
PAG using an antibody against this residue supplied by Dr J Lindquist (University of 
Magdeberg, Germany). We may expect to see that in the absence of Fyn, the 
rephosphorylation of this residue does occur, but with slower kinetics. We have 
conducted some preliminary experiments looking at the phosphorylation of the Tyr 
317 residue and found that we could detect it in WT cells 6-9 hrs after activation, but 
no band was present in the absence of Fyn (data not shown).
Although not addressed in this chapter, there are other molecules that may exert 
positive influence such as Spl-like (Skerka et al., 1995; Chen and Rothenberg, 1993) 
or negative influence such as Nil-2A (Williams et al., 1991) on the IL-2 minimal 
enhancer. It may also be of interest to look at the function of these molecules in 
future experiments. Furthermore, studies have suggested that regions of DNA 
upstream of the 112 minimal enhancer, while not able to drive transcription of linked 
reporter genes alone, may have modulatory effects on IL-2 production (Novak et al., 
1990; Serfling et al., 1989; Durand et al., 1988). To address if regions other than the
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112 minimal enhancer are responsible for the increase in IL-2 in the absence of Fyn, 
we plan to use a transgenic mouse line expressing the luciferase gene under the 
control of the 112 minimal enhancer. We are in the process of crossing these to the F5 
Rag-1'7' WT or Fyn'7'.background. If the 112 minimal enhancer is enough to drive 
increased IL-2 transcription in the absence of Fyn, we should expect to observe 
increased luciferase activity after activation of the F5 Fyn'7 cells with peptide.
It is also a possibility that without Fyn, there is some form of alteration at the 
chromatin level in terms of the accessibility of the IL-2 locus. Certainly the ability of 
Fyn'7' cells to still produce more IL-2 than WT after recall PdbU and ionomycin 
stimulation suggested that whatever difference set up by the initial TCR/CD8 
stimulus was transmitted to daughter cells, possibly at the level of chromatin 
modelling and locus accessibility. PdbU and ionomycin bypass TCR signalling but 
without restimulation, IL-2 production could not be detected, we can assume 
therefore that we are looking at the accessibility of the 112 locus, telling us what the 
cells have the ability to produce. Therefore it is interesting that even though IL-2 
production after TCR/CD8 stimulation has ceased before cell division, the resulting 
Fyn'7' daughter cells retained the ability to make more IL-2. Studies have shown that 
IL-2 is monoallelically expressed (Hollander et al., 1998) and therefore it could not 
be excluded that IL-2 production in the absence of Fyn may reflect changes in this 
phenomenon. It may be of interest to look at the accessibility of the IL-2 locus in 
Fyn'7' T cells.
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Figure 4.1: The 112 minimal enhancer contains binding sites for factors that 
regulate IL-2 production a t different stages of T cell activation
The 112 minimal enhancer (A) consists of a region of ~300bp upstream of the 112 
coding sequence that can confer inducible, tissue specific expression of linked 
reporter constructs. The regions that bind the various factors that can regulate IL-2 
production are shown. These factors have been implicated in controlling IL-2 
production at proximal and distal stages of T cell activation. The model (B) is based 
on the observation that activation of these factors occurs either early or late in T cell 
activation. While early factors can drive the expression of activation markers, IL-2 
production requires a more prolonged period of stimulation that may reflect the need 
for the late factors to be transcribed and become activated. A is adapted from Jain et 
al. (1995).
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Figure 4.2: The frequency of activated F5 cells able to secrete IL-2 is increased 
in the absence of Fyn
F5 WT and Fyn7' cells (as indicated) were activated on a layer of peptide pulsed 
MHC-class I dimer molecules. At the time points shown, cells were harvested and 
labelled with the IL-2 capture reagent, which consisted of pair of antibodies that were 
specific for CD45 and IL-2 fused with each other at the Fc regions. Cells were then 
returned to culture for a further hr and captured IL-2 protein was visualised with an 
anti-IL-2 PE conjugated antibody. Cells were also stained with anti-CD25 and anti- 
CD69 and analysed by FACS.
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Figure 4.3: F5 Fyn'7' cells require shorter periods of antigen exposure to commit 
to IL-2 production
The duration of antigenic contact required to commit F5 WT and Fyn'A cells (as 
indicated) to CD69 expression (A) and IL-2 production (B) was measured after a total 
of 24 hrss in culture. F5 cells were purified to deplete APC and activated on a layer 
of pMHC dimer molecules. After removal from the stimulus at the indicated time 
points, cells were washed extensively and placed into wells containing CFSE labelled 
naive F5 cells to control for any antigen carry over. FACS plots in A show how 
gating was applied to samples to measure CD69 expression and B IL-2 production in 
relation to CFSE positve and negative cells populations. These data were used to 
generate plot C. The broken line indicates the threshold of 50% of cells expressing a 
specific marker. Values are shown as the mean of triplicate samples and error bars ± 
SD.
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Figure 4.4: Prolonged Src kinase activity is required for IL-2 production in the 
absence of Fyn
The effect of the Src kinase inhibitor PP2 on peptide induced CD69 (A) and CD25 
expression (B), TCR down-modulation (C) and IL-2 production (D) was assessed in 
F5 WT and Fyn'7' cells (as indicated). PP2 or the negative control compound PP3 was 
added from the beginning of culture, or in some samples PP2 was added 3 hrss after 
stimulation (as indicated). TCR down-modulation (C) is expressed as the percentage 
of the unstimulated TCR MFI. The FACS plots in D were gated using unstimulated 
cells or isotype control antibodies.
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Figure 4.5: Fyn deficiency does not affect the formation of stable T cell -  APC 
conjugates
APC -  T cell conjugation was assessed using a FACS based method. Non-peptide 
pulsed APC centrifuged with T cells were used to set the gates to identify conjugates 
between peptide pulsed APC (A). Plot B shows the percentage of F5 WT and Fyn A T 
cells (as indicated) in conjugate with APC fluorescing in the FL-1 and FL-2 channels 
based on the gates shown in A. The values are the mean of triplicate samples and the 
error bars represent ± SD.
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Figure 4.6: Fyn deficiency does not alter intracellular Ca2+ mobilisation in 
response to pMHC
The ability of F5 WT (A) and Fyn7' cells (B) to flux Ca2+ in response to peptide 
pulsed APC (1 pM) was assesses using flow cytometry. Samples were acquired for 
30 seconds prior to conjugation with peptide pulsed APC to establish a baseline, and 
then for a total of 400 seconds thereafter. The arrows indicate the point of 
stimulation. The transcription of NFATcl was measured for antigen activated F5 
WT and Fyn'7' cells (as indicated). Levels of NFATcl are plotted relative to the 
house keeping gene HPRT (C). Calcium mobilisation by F5 WT (D) and Fyn'7' (E) T 
cells in response to anti-CD3, anti-CD8 or both (as indicated) was assessed. Samples 
were acquired for 30 seconds to establish baseline and the arrows indicate the point 
were avidin was added to induce a Ca2+ flux. In the case of Ca2+ mobilisation data, 
these are representative of two independent experiments each involving triplicated 
repeats.
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Figure 4.7: Erk phosphorylation is prolonged in the absence of Fyn
Erk phosphorylation was assessed in F5 WT and Fyn 7' cells (as indicated) in response 
to activation with plate bound pMHC dimers. Prior to lysis, the expression of CD69 
and CD25 was determined (A). Protein from equivalent cell numbers was run on 
10% SDS-PAGE and blotted for the presence of phospho-Erkl/2 (B, upper panel). 
The blot was stripped and reprobed for total Erk (B lower panel). The intensity of 
Erk-1 (C) and Erk-2 (E) phosphorylation and total protein was measured using 
densitometry. Phospho-values were corrected for differences in protein loading by 
division with those obtained for total Erk in each lane. These data are representative 
fo 3 independent experiments. To present the data obtained from the 3 independent 
experiments, the corrected values obtained for Erkl (D) and Erk2 (E) in the absence 
of Fyn were plotted as a percentage of the WT values for each time point and the 
mean ± SD was calculated.
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Figure 4.8: The kinetic of c-Rel nuclear translocation is unchanged in the 
absence of Fyn
Confocal microscopy (A) was used to address the nuclear translocation of c-Rel in F5 
WT and Fyn';‘ cells (as indicated) after antigen stimulation. The PMT for the green 
channel (Alexa 440) was set up using samples stained with PI and an isotype control 
for the c-Rel antibody, followed the secondary Alex-440 conjugated antibody (as 
indicated). Antigen induced transcription of c-Rel was measured in F5 WT and Fyn_/ 
cells (as indicated) by real time PCR (B). Values plotted are relative to the 
housekeeping gene HPRT.
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Figure 4.9: Elevated IL-2 production in the absence of Fyn is not solely due to 
prolonged Erk activity.
Activated F5 WT and Fyn';‘ cells were treated with the Mek inhibitor PD90859 for 
the windows of time indicated. Cells were washed thoroughly to remove any trace of 
inhibitor and placed into fresh culture wells with stimulus. The production of IL-2 
was measured after a total of 24 hrss of culture by intracellular staining. The FACS 
plots in A show the gates applied to the samples. These gates were set using 
unstimulated cells and isotype control antibodies. These data were used to generate a 
plot of the % of IL-2 positive cells (B) and the MFI of IL-2 production (C) after the 
indicated treatment with PD90859. These data are expressed as the mean of triplicate 
samples ± SD.
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Figure 4.10: Inducible Jnk phosphorylation can be detected in Fyn_/ cells 
following activation with pMHC
F5 WT and Fyn'7' cells were activated as described for Figure 4.8. Samples were run 
out on a 10% PAGE gel and the membrane blotted for the presence of phospho-Jnk 
1/2.(A, upper panel). This membrane was then stripped and reprobed for total Jnk 
protein (A, lower panel). Densitometry was then used to quantify the levels of p54 
Jnk 1/2 (B), p46 Jnk2 (C) and p46 Jnkl (D). As in Figure 4.7, the values obtained for 
the phospho Jnk bands were corrected for differences in loading by dividing by the 
numbers obtained for total Jnk in each lane.
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Figure 4.11: Fyn deficiency lowers the level of c-Jun mRNA while increasing 
levels of FosB mRNA
Antigen induced mRNA levels by activated F5 WT and Fyn'7' cells (as indicated) of 
c-Jun (A), JunB (B), c-Fos (C) and FosB (D) was assessed using real time PCR. The 
values plotted are corrected in relation to levels of the house-keeping gene HPRT. 
These data are representative of 2 independent experiments.
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Figure 4.12: A possible mechanism for how Fyn deficiency could be affecting the 
ability of F5 cells to produce IL-2
In terms of how Fyn deficiency could lead to increased IL-2 production, it is possible 
that 1 hr of antigen exposure was sufficient to commit F5 Fyn'7' cells to produce IL-2 
24 hrs later because the intensity of signalling during this period was elevated, 
leading to the premature activation of distal factors such as c-Rel and Oct-2 (A). 
However, due to that fact that c-Rel was not evident in either group at 1 hr, and that 
IL-2 production 24 hrs later remained sensitive to Src inhibition 3 hrs after activation, 
this first model may be unlikely. The second model suggest that upon removal of 
stimulus, F5 WT cells terminate signalling and never reach the required threshold for 
IL-2 production, however F5 Fyn7' cells continue to signal even in the absence of 
antigen and are able to produce IL-2 (B). In this model, IL-2 production does not 
occur more rapidly, however it has been uncoupled from the need for continual 
antigen exposure. We feel that the inability to rapidly terminate the signal may be 
due to the inefficient re-phosphorylation of Tyr317 of PAG, and a delay in the 
reformation of the PAG/Csk/PEP complex (C).
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Chapter 5: The role of Fyn in CD8 T cell effector generation and 
function
5.1 Introduction
Studies have shown that CTL generation may be intrinsically linked to the 
proliferative programme of CD8 cells (Oehen and Brduscha-Riem, 1998). From 
Chapter 3 it was evident that Fyn deficiency increased the proliferative capacity of 
the F5 CD8 cells by elevating IL-2 production. Significantly, IL-2 may play a role in 
the generation of CTL as IL-2'7' CD8 T cells have been shown to proliferate but not to 
acquire effector functions (Kramer et al.y 1994). Furthermore, IL-2'7 mice show 
defects in controlling certain viral infections (Cousens et al., 1995). Considering 
these data the aim of this chapter was to address the impact of Fyn deficiency on the 
generation of CTL responses in the F5 system both in vitro and in vivo. This was an 
interesting question as a role for IL-2 in CTL generation and function remains 
controversial, with some studies suggesting it can greatly improve a response 
(Cousens et al., 1995; Kundig et al., 1993), some concluding that it has no 
measurable effect (D'Souza and Lefrancois, 2004), and other reports stating that it 
may even negatively regulate T cells during the expansion phase in vivo (Blattman et 
al., 2003). Therefore studying CTL generation in F5 Fyn'7' cells presented an 
interesting scenario whereby we could examine the relationship between CD8 CTL 
generation and potentially increased autocrine IL-2 consumption.
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In a naive mouse, antigen-specific CD8 T cell clones are present at extremely low 
frequencies; however, on encountering antigen they undergo a rapid clonal expansion 
and differentiate into a CTL. The function of a CTL is to identify and then eliminate 
cells expressing specific antigen in the context of MHC-class I molecules. Lysis of a 
target cell by a CTL is achieved by mechanisms that require the de novo expression 
of molecules not present in a naive CD8 T cell (Kaech et al., 2002). These include 
IFNy (Billiau, 1996) and lytic granules such as Granzyme B and Perforin (Trapani et 
al., 2000; Kagi et al., 1996). Therefore, activation of naive CD8 T cells leads 
transcription of these effector molecules allowing for the elimination of viral 
infections to occur (Harty et al., 2000). There are two main pathways responsible for 
removal of a potentially infected cell by CTL. One involves the production and 
secretion of lytic molecules that include Perforin and Granzymes: the other involves 
the FasL pathway and the triggering of apoptosis through death receptors (Suda and 
Nagata, 1994). Interestingly, CTL are often termed as “serial killers”, as after 
releasing the primary store of lytic granules, they can resynthesis Perforin and 
Granzyme in order to then target further cells for lysis (Isaaz et al., 1995).
In terms of the lytic mechanisms, Perforin functions by undergoing a polymerisation 
reaction and inserting itself into the plasma membrane of a target cell to form pores, 
thus allow solutes and small ions to enter the cytoplasm (Podack and Konigsberg,
1984). CTL from mice deficient in Perforin are unable to carry out any granule- 
mediated killing (Kagi et al., 1994), and are therefore severely immuno­
compromised. Furthermore, studies have shown that the promoter of the Perforin
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gene contains at least two STAT5 binding sites (Yu et al., 1999; Zhang et al., 1999) 
making expression sensitive to IL-2 receptor signals.
As granule mediated cytolysis was also shown to be able to induce apoptosis, it was 
interesting that Perforin induced membrane damage but not DNA laddering (Duke et 
al.9 1983). This observation led to the discovery of further lytic molecules including 
Granzyme B (Lobe et al.y 1986) that could synergise with Perforin and pass through 
the pores to initiate apoptosis by activating Caspase 3 (Darmon et al., 1995). 
Granzyme B knockout cells are unable to mediate CTL driven DNA damage (Heusel 
et al.t 1994), however they are not as severely affected as Perforin deficient mice, 
highlighting the fact that Perforin expression is probably the rate-limiting step in a 
CTL response. As for Perforin gene regulation, there is evidence that IL-2 signalling 
is able to regulate the expression of Granzyme B in T cells and NK cells, however the 
direct mechanism for this at the transcriptional level is currently unknown (DeBlaker- 
Hohe et al., 1995; Manyak et al., 1989).
Activation of naive CD8 T cells also induces the expression of the cytokine IFNy, 
which can improve CTL responses by inducing the upregulating of MHC class I 
expression, increasing immune recognition of the target cell and by suppressing viral 
replication. IFNy may also be important for downmodulating an immune response as 
IFNy'7" mice possess increased CD8 cell numbers during the expansion and 
contraction phases following viral challenge (Badovinac et al., 2000). Furthermore, 
while IFNy'' mice show defects in dealing with Listeria monocytogenes and vaccinia
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virus, they are still able to mount a granule-mediated CTL response (Lu et al., 1998; 
H uang et al., 1993) suggesting that the lytic killing machinery can work 
independently of IFNy. Moreover, there is also evidence that IL-2 can regulate 
production of IFNy in a CTL response (Farrar et al., 1985; Reem and Yeh, 1984; 
Kasahara et al., 1983). However it is not known how this is achieved but may be 
due to the presence of a STAT5 binding element in the promoter of the IFNy  gene 
(Bream et al., 2004)
As well as granule mediated cytotoxicity, CD8 cells also induce apoptosis in target 
cells through the production of FasL (CD154). FasL is expressed in a membrane 
bound form after T cell activation (Anel et al., 1994; Vignaux and Golstein, 1994; 
Suda et al., 1993) and is then able to bind to the Fas receptor on the surface of other 
target cells and can induce apoptosis (Suda and Nagata, 1994). However, this 
mechanism is thought to be preferential for the removal of activated T cells by AICD, 
and may be less important to the killing of virally infected targets. There is also some 
evidence that IL-2 can influence the expression of FasL (Ye et al., 1996).
Using the F5 system it is possible to look at the generation and function of CTL both 
in vitro and in vivo. For in vitro studies, it is possible to activate F5 cells using the 
NP68 antigen and look at the expression of effector molecules. Furthermore, the 
ability of these in vitro generated CTL to lyse NP68 pulsed target cells can be 
addressed using the classical killing assay (Kramer et al., 1994). Mice expressing the 
F5 TCR transgene will also respond to administration of the A/NT/60-68 strain of
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influenza (Moskophidis and Kioussis, 1998) making it possible to look at CTL 
generation and function in vivo.
5.2 F5 and polyclonal Fyn'7* CD8 cells produce more IFNy than WT control cells
We began addressing the generation of CTL responses in the absence of Fyn by 
determining the ability of F5 cells to commit to IFNy production using intracellular 
staining. Figure 5.1A and 5 .IB show that 24 hrs after NP68 stimulation, and 
following a 4 hr recall stimulus with PdbU and ionomycin, both F5 Fyn 7 and F5 WT 
cells had identical potential to produce IFNy. At 48 and 72 hrs, F5 Fyn7' T cells 
continued to produce this cytokine at similar levels to that observed at 24 hrs, in 
comparison production by F5 WT cell declined by 4-fold at these times. Moreover, 
F5 Fyn 7' cells continued to produce elevated levels of IFNy compared to F5 WT cells 
at each round of division.
As previously mentioned with respect to IL-2 measurement, because intracellular 
cytokine staining is only visible after restimulation with PdbU and ionomycin it 
provides information on locus accessibility rather than what the cell is actually 
producing at that time. To determine the influence Fyn deficiency was having on 
IFNy production after primary activation we measured IFNy mRNA levels using real 
time PCR. From figure 5.1C it is evident that maximal IFNy mRNA was detected in 
WT F5 cells at 10 hrs whereas levels in activated F5 Fyn'7' cells peaked at 5 hrs. 
Moreover, maximal production of IFNy mRNA by Fyn deficient F5 T cells was ~7-
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fold higher than by WT F5 cells. At 24 hrs IFNy mRNA was still elevated 50-fold 
compared to the housekeeping gene HPRT, but it was undetectable in WT F5 cells at 
this time. Comparing these data to the data in Figure 5.1 A there is a striking 
difference. In F5 WT cells it is clear that intracellular IFNy could be measured at 24 
hrs after 4 hrs PdbU and ionomycin treatment, but this did not correlate with mRNA 
levels as they were undetectable in WT cells at this time. This difference was most 
probably due to the methods employed and the need for restimulation to detect 
intracellular IFNy protein.
In Chapter 3 we determined that polyclonal Fyn'7" cells behaved like antigen-activated 
F5 Fyn'7' cells after stimulation with anti-CD3 and anti-CD8 coated beads. Therefore 
we addressed the ability of purified naive polyclonal Fyn'7' CD8 cells to produce IFNy 
by intracellular cytokine staining after activation with anti-CD3/CD8 coated 
microbeads. Figure 5 .ID shows that at 72 hrs after stimulation, Fyn deficient cells 
were producing ~1.5-fold more IFNy on a per-cell basis than purified naive CD8 cells 
from WT polyclonal mice. Collectively these data suggest that IFNy production was 
elevated in the absence of Fyn in both monoclonal and polyclonal cells.
5.3 F5 Fyn'7’ cells show enhanced CTL activity in vitro
Next we wanted to measure the cytotoxic activity of the in vitro generated CTL using 
the classical killing assay. After the 3-day activation and culture period required to 
generate CTL, we phenotyped the cells before inclusion in the assay. Specifically we
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looked at cell size, and CD44 expression using FACS (figure 5.2A) to check that both 
groups of cells had activated comparably. It is clear from the data in figure 5.2A that 
after three days stimulation an equivalent number of cells had been activated as 
judged by increase in cell size (Fsc) and CD44 expression, however the MFI of CD44 
was reduced in the absence of Fyn. There were also equivalent frequencies of cells 
within the live gate (data not shown).
To further determine the efficiency of CTL generation after the 3-day culture period 
we measured intracellular Granzyme B levels. Unlike intracellular IFNy protein 
detection, this did not require any restimulation with PdbU and ionomycin. Figure 
5.2B shows that 100% of cells in both groups were expressing Granzyme B, however 
the level of production was elevated in the absence of Fyn on a per-cell basis (~2000 
MFI units in WT F5, compared to ~3000 MFI units in F5 Fyn'7' cells). Interestingly, 
CD5 expression, like CD44, was marginally reduced in the absence of Fyn compared 
to F5 WT cells.
Prior to inclusion in the CTL assay, cells were counted and adjusted so that equal 
numbers of blasting cells were incubated with a fixed number of target cells in each 
group. From the data presented in figure 5.2C it is clear that, at all but the highest 
effector to target ratios tested, F5 Fyn'7' CTL were ~27 times more efficient in 
antigen-specific killing than F5 WT CTL on a per-cell basis.
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5.4 The upregulation of CD44 and CD5 is reduced in the absence of Fyn
Having shown that the expression of CD5 and CD44 was reduced on in vitro 
generated Fyn'7' CTL after 3 days of culture, we wanted to look at the upregulation of 
these molecules over a range of antigen doses at 24 hrs. CD44 is thought to reflect 
the activation status of a T cell and also considered to be a marker of memory CD8 T 
cells (Kaech et al., 2002), whereas CD5 is considered to be a negative regulator of T 
cell activation (Tarakhovsky et al., 1995). Figures 5.3A and B shows that over the 
range NP68 concentrations used, the ability of F5 Fyn'7' cells to upregulate CD44 was 
consistently reduced compared to F5 WT cells as measured by the MFI of CD44 
expression. In contrast the overall percentage of CD44+ cells remained comparable. 
The same observation was made when CD5 upregulation was assessed (Figure 5.3C 
and D). Interestingly, as noted in Chapter 3, the expression of molecules such as 
CD69 and CD25 was comparable at 24 hrs in both groups (data not shown). The fact 
that CD44 expression and CD5 expression have been shown to increase during the 
transition of naive CD8 cells to a memory cell (Kaech et al., 2002) could reflect 
possible differences in the progression of F5 Fyn'7' cells along this developmental 
path.
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5.5 Elevated Granzyme B production by F5 Fyn'7' cells is driven by increased IL-
2 levels.
In F5 CD8 T cells lacking Fyn, activation using NP68 peptide led to increased IL-2 
production and increased effector generation / function. The next set of experiments 
was designed to ask whether the two observations were in fact linked, or whether 
they were distinct phenomena. IL-2 has been suggested to play a role in the 
generation of F5 CD8 effector function (Kramer et al., 1994); therefore interesting to 
assess the impact that the increased IL-2 production by Fyn'7' cells may have on the 
generation of CTL. To this end, the strategy of blocking IL-2 and spiking with IL-2 
was employed as described for Chapter 3, Figure 3.6.
Firstly, Granzyme B protein was measured in both groups after IL-2 manipulation in 
vitro. As previously mentioned, IL-2 can modulate the expression of the Granzyme 
B in T cells (DeBlaker-Hohe et al., 1995; Manyak et al., 1989). From Figure 5.4A it 
is clear that blocking IL-2 reduced the frequency of Granzyme B positive cells in the 
Fyn'7' group at 48 and 72 hrs to that of unmanipulated WT F5 cell levels. Blocking 
IL-2 with S4B6 lowered the percentage of Granzyme B expressing F5 WT cells also. 
Figure 5.4B shows that spiking cultures with IL-2 increased the frequency of 
Granzyme B positive cells in F5 WT samples to that of unmanipulated Fyn deficient 
samples, both at 48 and 72 hrs. IL-2 manipulation also influenced the MFI of 
Granzyme B expression in the same manner (data not shown). As described for 
CD25 expression (Chapter 3, Figure 3.6), addition of excess IL-2 to Fyn deficient
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cells was unable to elevate expression of Granzyme B compared to non-treated Fyn7 
cells suggesting that the response to IL-2 was already maximal.
Interestingly, while we could clearly influence Granzyme B expression at 48 and 72 
hrs, the addition of recombinant IL-2 had no effect on WT F5 cells at 24 hrs, neither 
did blocking antibody have an effect on F5 Fyn7 cells at this time. This suggests that 
either the various IL-2 treatments took time to exert an effect, or that Granzyme B 
expression at 24 hrs is IL-2 independent. If it was the latter reason, then this suggest 
that F5 Fyn'7' cells are able to make more Granzyme B at 24 hrs independently of IL-2 
levels. It is possible that the differences in the AP-1 members noted in Chapter 4 
could exert an effect on the Granzyme promoter as it contains an AP-1 site, however 
it is a consensus sequence (Babichuk et al., 1996) and may not be sensitive to 
changes in Fos-Jun components.
5.6 Elevated IFNy production by F5 Fyn'7’ is driven by increased IL-2 
production.
Next we assessed the impact of IL-2 availability on the ability of F5 Fyn'7' to produce 
more IFNy after activation. A number of studies have suggested that IL-2 can 
regulate IFNy expression (Farrar et a l , 1985; Reem and Yeh, 1984; Kasahara et al., 
1983). Figure 5.5A shows that blocking with S4B6 reduced production of this 
cytokine by F y n 7' cells to that of unmanipulated WT F5 cells at 72 hrs. The 
reciprocal experiment of spiking cultures with IL-2 was able to induce F5 WT cells to
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acquire the potential to produce ~2 fold more IFNy at 48 hrs than Fyn deficient cells 
without manipulation (Figure 5.5B). Therefore F5 WT cells had the capacity to 
produce large quantities of IFNy, however this was clearly dependent on IL-2 
availability. In both groups, the percentage of cells able to make IFNy was ~90% 
(data not shown). As noted previously for Granzyme B expression, addition of IL-2 
to Fyn7' cells did not elevate levels above untreated controls, again suggesting an 
already maximal response to this cytokine.
5.7 Activation of F5 Fyn'7' T cells in vivo leads to elevated IL-2 / IFNy production 
and increased cell recoveries.
Next we wanted to address whether the improved generation of CTL in the absence 
of Fyn would also occur in vivo. As mentioned previously, the F5 TCR is specific for 
the NP68 peptide derived from the nuclear coat protein of the A/NT/60-68 strain of 
the influenza virus (Mamalaki et al., 1993; Mamalaki et al., 1992; Townsend et al.,
1985), therefore, it was possible to use live virus to activate F5 cells. However we 
wanted to activate cells in vivo without allowing the virus to replicate in lung tissue, 
which could be fatal to the host. Instead we transferred 3 x 106 F5 T cells with virus 
i.v. into Rag-1'7" recipient mice, as the virus would not be pathogenic via this route. 
As shown in Figure 5.6A, F5 CD8 T cells transferred without virus did not show 
signs of activation after 7 days, as there was no upregulation of CD44. Therefore any 
proliferation could be solely attributed to activation by virus and not due to 
transferring cells into an empty host. From figure 5.6A it is clear that 7 days after
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transfer with virus 100% of the F5 CD8 T cells became activated and upregulated 
CD44 in both the F5 Fyn'7' and F5 WT groups. However, as shown in vitro, the level 
of CD44 was reduced on the surface of F5 Fyn'7' cells compared to F5 WT controls. 
Cell recoveries and frequencies after 7 days were also assessed in the different 
peripheral lymphoid organs to give an indication of cell expansion. From Figure 
5.6B and 5.6C it was clear that more F5 CD8 T cells were recovered from the lymph 
nodes and spleen of Rag-1'7' mice that had received flu virus and cells from F5 Fyn7' 
donors compared to F5 WT controls. Furthermore, the frequency of CD8 PBL in the 
blood of the mice was also elevated in the absence of Fyn compared to WT controls 
(Figure 5.6D) However it seemed that the percentage of CD8 cells in the PEC was 
not grossly different (Figure 5.6E). It appears that both in vitro and in vivo, F5 Fyn'7' 
T cell proliferation and/or survival was increased after peptide activation.
When cells from the LN and spleen were restimulated ex vivo with PdbU and 
ionomycin (Figure 5.6F), a greater frequency of Fyn deficient cells were able to 
produce IL-2 (54% F5 WT, 77.5% F5 Fyn'7') and the MFI was also elevated 
compared to WT cells (88.5 MFI units in F5 WT, compared to 137 MFI units in F5 
Fyn'7"). Furthermore, analysis of IFNy production by intracellular staining (Figure 
5.6G) revealed that a higher percentage of virally activated Fyn'7' cells were able to 
produce this cytokine after restimulation compared to WT cells (58.2% F5 WT 
compared to 76.6 F5 Fyn'7'). Collectively these data show that there was an increased 
potential to make IL-2 and IFNy after in vivo activation, and that this correlated with
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increased cell numbers recovered from the recipients of F5 Fyn'7' cells compared to 
WT controls.
4.8 Discussion
The aim of this chapter was to address the generation of CTL responses in the 
absence of Fyn, and determine if the increase in IL-2 production was affecting the 
differentiation programme of F5 Fyn'7' cells.
Production of IFNy by F5 Fyn'7' cells after antigen activation was elevated compared 
to WT F5 cells as measured at the protein level by intracellular staining and at the 
mRNA level by real time PCR. Furthermore levels of Granzyme B protein were also 
increased, however CD5 and CD44 upregulation was reduced in the absence of Fyn. 
The increase in effector molecule levels translated into an improved CTL response in 
vitro by F5 Fyn'7' cells compared to WT controls. Furthermore, the increase in 
effector molecule expression was shown to be mediated by IL-2 as the IL-2 blocking 
antibody S4B6 reduced expression of IFNy and Granzyme B by F5 Fyn'7' cells to that 
of untreated F5 WT cells. The reciprocal experiments of adding IL-2 was able to 
greatly improve the response of F5 WT cells. Finally, we showed that activation of 
F5 Fyn'7' cells in vivo using influenza virus also increased cell proliferation/survival 
and IL-2/IFNy production compared to F5 WT cells.
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Several studies have shown that CD8 CTL function is influenced by the presence of 
IL-2. For example infection of IL-27 mice using LCMV and vaccinia virus resulted 
in a 3-fold reduction in CTL activity (Cousens et al., 1995; Kundig et al., 1993). 
Also, in the F5 system, IL-2'7' CD8 cells did not become effector CTL (Kramer et al., 
1994). However, some studies have suggested that IL-2 has no effect on CTL 
generation. For example LeFrancois and colleagues infected WT or IL-27 mice with 
VSV and then addressed the CTL activity using an in vitro killing assay (D'Souza and 
Lefrancois, 2004). They observed no differences in the efficiency of killing peptide 
pulsed target cells by CTL generated in either WT or IL-2 7' mice, and concluded that 
IL-2 is not required for CTL function or generation. A possible reason for the 
differences between our data and that reported by LeFrancois and colleagues may be 
the nature of the experimental model used. For example, as mentioned in Chapter 3, 
the period of IL-2 production by CD8 cells is thought to be limited due to the 
manifestation of AINR (Tham et al., 2002). While CTL generated during this period 
of autocrine IL-2 consumption do not seem to be functionally impaired (Deeths and 
Mescher, 1997; Harding and Allison, 1993; Azuma et al., 1992) and would be able to 
control the acute phase of an infection, it is thought that effective CTL function 
beyond this period requires an exogenous source of IL-2 to control chronic infections. 
Studies have suggested that CD4 cells may act as the paracrine source of IL-2 for 
sustained CTL function. Certainly in models of chronic infection, such as viral 
challenge (Kalams and Walker, 1998; Cardin et al., 1996; Battegay et al., 1994; 
Matloubian et al., 1994; Kirberg et al., 1993) and tumours (Marzo et al., 2000; 
Shrikant et al., 1999; Ossendorp et al., 1998), the presence of CD4 cells were clearly
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important to a sustained CTL response. However, CD4 cells may also provide 
indirect assistance to CD8 CTL generation/function through CD40-CD40L 
interactions that occur between CD4 cells and APC (Bennett et al., 1998; Ridge et al., 
1998; Schoenberger et al., 1998). In the LeFrancois paper they used IL-2'/_ mice that 
had CD4 and CD8 cells, thus it is possible that in the absence of IL-2, CD40L 
interactions via the CD4 cells were able to compensate for the loss of IL-2. In our 
model, we do not have CD4 cells; therefore CTL generation may be more IL-2 
dependent in this circumstance. Certainly, previous work concerning CTL generation 
in F5 IL-2'/_ mice also lacking CD4 cells showed that IL-2 was essential to effector 
generation but not proliferation (Kramer et al., 1994). Furthermore, IL-15, IL-12, IL- 
18 and IL-21 have been implicated as having positive effect on CTL generation and 
function (Zeng et al., 2005; Salcedo et al., 2004; Chen et al., 2000; Okamura et al., 
1995; Zou et al., 1995) and research suggests that IL-15 is produced by dendritic cells 
after CD40-CD40L interactions (Kuniyoshi et al., 1999). In the polyclonal mice used 
by LeFrancois and colleagues, the presence of CD4 cells may also regulate the 
expression of these molecules by virtue of an effect on APC function, compensating 
for the loss of IL-2. Again, in our system, we may not be inducing efficient 
expression of these cytokines, possibly as an indirect consequence of the lack of CD4 
cells to condition the APC. Therefore, in a polyclonal setting, the loss of IL-2 may be 
less detrimental to CTL generation. However increasing the concentration of IL-2 
may still be beneficial in these circumstances as shown by Ahmed and colleagues 
who gave IL-2 to mice during the contraction phase of LCMV infection and noted 
that the subsequent frequency of viral-specific CD8 cells was increased compared to
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untreated control mice (Blattman et al., 2003). The real importance of IL-2 
availability to a CTL response may become evident in situations such as HIV 
infection where the immune system is unbalanced by a decline in CD4 numbers.
Although the role of IL-2 in CTL generation is dependent upon the experimental 
model, it is established that, with the exception of Granzyme B, the promoter 
elements of these genes all contain elements that can bind STAT5, which is itself 
regulated by IL-2 receptor derived signals (Nakajima et al., 1997). What 
distinguishes a CTL from a naive CD8 cell is the expression of effector molecules 
such as Perforin, Granzyme B and IFNy, therefore, one could argue that IL-2 must 
exert some effect on the expression of these molecules via their promoters, and thus 
influence the quality of CTL generated. Indeed our data supports this view, as we 
show a direct correlation between IL-2 exposure and effector generation/function in 
terms of the expression of key molecules both at the protein and mRNA levels.
It has been suggested that there is a linear developmental pathway from naive CD8 
cells to effector then on to memory cells (Kaech et al., 2002). This development has 
been tracked at the genetic level using microarrays and this identified a number of 
phenotypic changes that naive cells undergo during the transition to memory cells 
(Kaech et al., 2002). Expression of CD44 and CD5 is increased during the transition 
from a naive to a memory CD8 cell (Kaech et al., 2002). Furthermore, Kaech et al 
show that CD44 expression is lower on an effector cell in comparison to a resting 
memory cell. Therefore it was interesting that the upregulation of CD44 and CD5
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was reduced by our F5 Fyn'7' cells compared to F5 WT cells. This suggests subtle 
differences in the programme of CD8 differentiation in the absence of Fyn that may 
affect the CTL response.
One would expect that in order for an effector cell to become a memory cell it would 
have to first enter a resting state ready for reactivation on secondary antigen 
encounter. Certainly the hallmark of a CD8 memory cells is that they can mount a 
more vigorous response to antigen rechallenge in comparison to a primary effector 
cell (Kaech et al., 2002; Pihlgren et al., 1996). In the absence of Fyn, the period of 
naive CD8 cell activation seemed to be prolonged, possibly due to the inability of the 
PAG/Csk/PEP complex to downmodulate the signalling and this led to increased IL-2 
production by F5 Fyn'7' cells (see Chapters 3 and 4). Work by Manjunath and co- 
workers has suggested that in situations where IL-2 is absent or present in low 
concentrations, a proportion of partially differentiated CD8 cells may overlook the 
effector stage all together and directly become memory cells (Manjunath et al., 
2001). Therefore, while IL-2 may be able to prolong the effector state, it may 
concomitantly have a detrimental effect on the generation of memory cells in the 
absence of Fyn due to a decreased ability to become quiescent. In F5 WT cells, 
although not as efficient CTL after primary activation, there may be no such defects 
in generating memory cells as IL-2 production during the primary response was very 
low (see Chapter 3).
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We have begun to look at CD8 memory generation and the function of these cells in 
the absence of Fyn by conducting in vivo killing assays. In this system, we 
transferred F5 cells (WT or Fyn'7") with live flu virus into Rag-1'7' hosts. Then 28 
days later, we transferred in equal numbers of peptide pulsed target cells mixed 1:1 
with unpulsed targets in order to measure the memory response. Both populations 
were labelled with different concentrations of CFSE to distinguish one from another. 
Then 18 hrs after transfer, we sacrificed the mice and analysed the cells for 
disappearance of the peptide pulsed target cell peak. Interestingly by this system we 
noted that F5 Fyn'7' cells, although potent killers after 3 days in vitro, were now less 
efficient compared to WT F5 memory cells at 28 days following initial transfer (data 
not shown). Moreover, the frequency of CD8 cells in the blood and cell recoveries in 
the LN were reduced in mice that received F5 Fyn'7' cells compared to F5 WT cells 
(data not shown). After 7 days, it is likely that the F5 cells have already become 
resting memory cells as cell numbers are contracting by this time indicating that the 
peak of the proliferative phase is now over (data not shown). Upon rechallenge one 
would expect that these resting cells could mount a memory-like response to the 
antigen. It is possible that after 28 days of in vivo activation, while resting memory 
cells have been formed from the F5 WT cells activated with virus, the F5 Fyn'7' cells 
had not done so as efficiently. Certainly, memory cells are able to undergo 
homeostatic proliferation, whereas effector cells do not (Tuma and Pamer, 2002). 
This could explain why the numbers of F5 Fyn'7' cells were reduced compared to WT, 
as the more effector-like cells would be unable to expand and fill the empty space. 
The best way to resolve the question of memory formation in the absence of Fyn
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using the F5 system would be to do a detailed analysis of the kinetics of cell 
expansion and contraction after in vivo flu activation. It may also be informative to 
try and look at the in vivo killing capacity of these cells earlier than 7 days.
Although we have suggested that the modulatory role of Fyn in T cells signalling may 
be exerted through the PAG/Csk/PEP complex, it is possible that other molecules 
could be involved. Recently, Fyn has been implicated in the signal transduction of 
another T cell receptor called SLAM that may have an immunomodulatory role 
(Cannons et a l., 2004; Davidson et al., 2004; Chan et al., 2003). The Fyn mediated 
signal transduction through SLAM receptors requires the adapter molecule SAP 
(Latour et a l., 2001) and its SH2 domain been shown to associate with the SH3 
domain of Fyn (Latour et a l., 2003). Interestingly, ligation of SLAM with antibodies 
was originally thought to mimic physiological SLAM ligation, however studies have 
shown that it in fact blocks SLAM ligand associations (Mavaddat et al., 2000). 
Furthermore, constitutive engagement of SLAM by its natural ligand, SLAM itself, 
led to the abrogation of IFNy production in a cell line (Latour et al., 2001). This 
suggested that normal SLAM interactions serve to downregulate IFNy production by 
CD8 T cells. Furthermore, SAP7 mice exhibit elevated IFNy production upon 
activation via the TCR (Czar et al., 2001; Wu et al., 2001). Also, ligation of SLAM 
with the blocking antibody has also been shown to enhance cytotoxicity (Henning et 
al., 2001). Therefore it is possible that in the absence of Fyn, the increase in IFNy 
production and CTL function we observed might be due in part to defects in SLAM 
signalling that would normally dampen a CTL response. However, there are reasons
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as to why this may not be the case. Firstly, we have shown that the increase in IFNy 
production is sensitive to IL-2, in contrast a study by Aversa and colleagues 
suggested that SLAM mediated effects on T cell activation were IL-2 independent 
(Aversa et al., 1997). Secondly, we were able to see the maximal effect on IL-2 and 
IFNy mRNA production in the absence of Fyn at approximately 4-5 hrs after T cell 
activation (see Chapter 3 and Figure 5.1) however studies have suggested that SLAM 
expression is detectable at 6-8 hrs and peaks by 24 hrs (Aversa et al., 1997; Cocks et 
al., 1995), and that expression of SLAM is also IL-2 independent (Aversa et al., 
1997). Therefore SLAM signalling may be too distal an event to directly influence 
our phenotype, and is clearly not influenced by IL-2 levels. However, our data do not 
fully rule out that defective SLAM signalling is exerting some effect on the F5 CD8 
T cells in a more subtle way. Therefore it may be of interest to look at SLAM 
mediated signals in our cells.
For future experiments, another model that we could exploit to look at the in vivo 
CTL activity of Fyn'7' cells would be to infect mice intranasaly with the A/NT/60-68 
strain of influenza virus. This system has been used previously to ask what 
contribution virus-specific CD8 T cells have to the response against influenza 
(Moskophidis and Kioussis, 1998). They found that at relatively high doses of virus, 
the presence of antigen specific CD8 cells in combination with a lack of B cell- 
derived antibody responses, led to increased morbidity in mice due to vigorous CTL 
responses and immune pathology. However at lower doses of virus the presence of 
F5 cells actually had a protective influence. In our situation, we may expect that F5
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Fyn7 mice may show increased morbidity to high viral doses due to an increased 
CTL response that would cause immune pathology, but an increase in survival to low 
dose challenge compared to Fyn sufficient animals. This would give a physiological 
in vivo read out of CTL function in the absence of Fyn.
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Figure 5.1: Fyn '" cells produce more IFNy than WT cells after activation
CFSE labelled cells from Fyn'7' and WT F5 mice (as indicated) were activated using 
NP68 pMHC. IFNy production was assessed by intracellular cytokine staining (A 
and B). Gates were set as shown in A, and the MFI of IFNy production was plotted 
against time in culture (B). These data are representative of four independent 
experiments. The level of IFNy mRNA was also assessed using real time PCR and 
values are plotted relative to the housekeeping gene HPRT (C). These data are 
representative of two independent experiments. Finally, intracellular staining was 
used to measure IFNy production by purified naive CD8 cells from polyclonal Fyn7' 
and B6 mice after activation with anti-CD3/CD8 coated micro-beads for 72 hrs (D). 
The MFI of IFNy production is shown.
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Figure 5.2: CTL activity is elevated in the absence of Fyn
CTL were generated from Fyn'7' and WT F5 cells after a 3-day activation period with 
peptide. The CTL generated were phenotyped by FACS (A) for cell size (Fsc), 
Granzyme B expression, CD44 and CD5. These cells were then incubated with 1 x 
104 51Cr loaded, peptide pulsed EL-4 target cells and the CTL induced release 51Cr of 
was measured after 4 hours of culture (B). Peptide specific 51Cr release was 
calculated as outlined in the materials and methods, and values plotted are the mean 
of triplicate samples ± SD.
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Figure 5.3: Upregulation of CD5 and CD44 is reduced in the absence of Fyn 
Peptide activated Fyn7' and WT F5 cells (as indicated) were analysed by FACS for 
the expression of CD44 (A and B) and CD5 (C and D) at 24 hours. The comparative 
histograms in A and C are gated on CD8+ TCR+ cells. The graphs B and C show the 
MFI of CD44 and CD5 respectively. These data are representative of two 
independent experiments.
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Figure 5.4: Elevated Granzyme B expression by F5 Fyn'7' cells is IL-2 dependent
Peptide activated Fyn'7' and WT F5 cells were incubated with either the anti-IL-2 
antibody S4B6 (A), or recombinant IL-2 (B) and the ability to produce Granzyme B 
was assessed over time. The plots show the mean MFI of Granzyme B expression ± 
SD for triplicate samples.
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Figure 5.5: Elevated IFNy expression by F5 Fyn'7' cells is also IL-2 dependent
Peptide activated Fyn'7' and WT F5 cells were incubated with either the anti-IL-2 
antibody S4B6 (A), or recombinant IL-2 (B) and the ability to produce IFNy was 
assessed over time by intracellular cytokine staining after a 4 hr pulse with PdbU and 
ionomycin. The plots show the mean MFI of IFNy expression ± SD for triplicate 
samples.
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Figure 5.6: Activation of F5 Fyn'/_ cells in vivo leads to elevated IL-2 and IFNy 
production and increased cell recoveries.
A total of 3 x 106 cells from Fyn 7' and WT F5 mice were activated in vivo by the co­
transfer with A/NT/60-68 flu virus into Rag-1A mice. After 7 days mice were 
sacrificed and activation was assessed by measuring CD44 upregulation by FACS 
(A). As a control, F5 cells were transferred without virus (as indicated). The 
absolute number of CD8 cells in the LN (B) and spleen (C) was calculated as well as 
the frequency of these cells in the blood (D) and peritoneal cavity (E). Values plotted 
are the mean ± SD, where n = 5. The ability of LN cells to produce IL-2 (F) and 
IFNy (G) after recall stimulation and intracellular cytokine staining was determined. 
These data are representative of 3 independent mice. Statistical significance was 
determined using the t-test where * = p<0.05 and ** = p<0.01.
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Chapter 6: The role of Fyn in maintaining peripheral tolerance
6.1 Introduction
In the previous chapters, we have shown that Fyn may play a regulatory role in 
the activation of CD8 T cells by antigen, however it was evident that the response 
of Fyn'7' T cells did not continue ad infinitum. This suggested to us that Fyn'7' 
cells were still subject to regulation, and for reasons discussed in Chapter 4, 
possibly through the action of Lck and the PAG/Csk/PEP complex. There is 
accumulating evidence that the distinct functions of Fyn and Lck could be 
partially masked by the functional overlap that also exists between these two 
kinases. With this idea in mind, ablating Fyn expression but concomitantly 
reducing Lck levels may serve to distinguish the unique functions of Fyn in T 
cells. To this end we decided to follow up on an observation made in the lab that 
a transgenic mouse line expressing reduced peripheral Lck and no Fyn presented 
with a lymphoproliferative disorder.
The idea that the unique functions of Fyn and Lck may be partially masked by a 
degree of functional overlap is supported by a number of observations. Firstly, in 
terms of thymic development, Fyn'7' mice are normal, but Lck'7' mice have a 
profound block at the DN3 to DN4 stage (Molina et al., 1992). However, the 
cells able to traverse this checkpoint do so via Fyn as Fyn'7' Lck'7' mice are 
completely arrested at this stage (Groves et al., 1996; van Oers et al., 1996). 
Moreover, elevated Fyn expression has been shown to be able to rescue thymic 
development in Lck'7'mice (Groves et al., 1996). These studies suggest that one of
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the preferential functions of Lck is to transmit the signals required for p selection 
and that WT levels of Fyn can also do this but with a much lower efficiency that 
can be improved if Fyn is over expressed. Secondly, in terms of the in vitro 
activation of peripheral T cells, we have found in our lab that while Lck 
deficiency has a detrimental effect on the triggering of both CD4 (Lovatt et al., 
manuscript submitted) and CD8 cells (data not shown) into division, Fyn can 
compensate as proliferation is still be observed, albeit at a higher concentration of 
anti-TCR stimuli. Again, this is Fyn specific, as LckInd Fyn'7' cells in which Lck 
expression is turned off by the removal of Dox cannot be activated in response to 
TCR stimulation (unpublished observations). These data suggest that the 
preferential function of Lck in peripheral T cells is to promote activation, which 
Fyn may also do so but with reduced efficiency. Finally, in terms of in vivo 
peripheral function, our lab has shown that both Lck and Fyn can transmit TCR 
signals required for T cell survival (Seddon and Zamoyska, 2002b), but that Lck 
is required for driving TCR-mediated homeostatic proliferation as Fyn was unable 
to compensate in the absence of Lck (Seddon and Zamoyska, 2002a). Again these 
data suggest that the function of these two kinases has overlap, but that they may 
have preferential roles in T cell responses. Therefore, Lck seems more able than 
Fyn to drive a proliferative signal, but judging from our data, Fyn may be more 
required to efficiently downmodulate a response.
At the molecular level, there is also evidence for both distinct and overlapping 
functions. For example Fyn and Lck have been shown to interact with 
intracellular molecules such as Zap-70 (Fusaki et al., 1996; Duplay et al., 1994), 
PI-3 kinase (Susa et al., 1996), c-Cbl (Hawash et al., 2002; Tsygankov et al.,
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1996), and LIME (Brdickova et al., 2003; Hur et al., 2003). However, studies 
have also shown that there may be distinct substrates, as Fyn, but not Lck, has 
been shown to associate with ADAP (Marie-Cardine et al., 1999), SAM68 
(Feuillet et al., 2002) and SAP (Chan et al., 2003). In contrast work has 
suggested Lck uniquely associates with molecules such as LckBPl (Takemoto et 
al., 1995), and LAD (Choi et al., 1999). While the functional outcome of these 
interactions remain to be fully elucidated, again it suggests that both overlapping 
and distinctive function exist between Lck and Fyn.
As mentioned previously, T cell development is grossly defective in Lck7' mice 
(Molina et al., 1992), and completely blocked in Lck'7' Fyn 7' mice (Groves et al., 
1996; van Oers et al., 1996), therefore we have developed a system in which Lck 
expression can be regulated at the transcriptional level (LckInd mice) (Legname et 
al., 2000). This was achieved using the tetracycline-responsive gene induction 
system (see Figure 6.1 A) (Gossen et al., 1995; Furth et al., 1994). When the 
tetracycline derivative Doxycycline (Dox) is present the constitutively expressed 
“tet-on” transactivator domain (rtTA) under the control of the huCD2 expression 
casette (Zhumabekov et al., 1995) binds to the tetracycline response element 
upstream of the minimal CMV promoter. This drives expression of the 
downstream Lck transgene that can compensate for the absence of endogenous 
Lck protein in Lck'7' mice. Using this system we are able to generate a peripheral 
T cell population comparable to a WT mouse by administering Dox to pregnant 
mothers and also during weaning (Legname et al., 2000). We can then remove 
Dox from the diet of the offspring at any given time in order to analyse peripheral 
T cell function in the absence of this kinase and have shown that all detectable
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Lck is gone by 7 days (Seddon et al., 2000). However, one outcome of this 
system is that, while levels of Lck in transgenic mice are comparable to Lck in a 
WT thymus, in peripheral T cells expression from the LckInd system is ~20% of 
WT levels (see Figure 6.1B)(Seddon et al., 2000). While the reason for this is 
unclear, studies from our lab have shown that T cells generated using this system 
behave similarly to T cells from a Lck WT mouse in terms of thymic development 
and peripheral function (Seddon and Zamoyska, 2002a; Seddon and Zamoyska, 
2002b; Legname et al., 2000; Seddon et al., 2000). When we crossed the LckInd 
mice onto a Fyn'7' background, again thymic development proceeded normally, 
however there was a reduction in peripheral T cell numbers compared to Fyn 
sufficient controls (Seddon and Zamoyska, 2002b). Interestingly, we observed 
that the continual administration of Dox diet caused the animals to lose weight, 
necessitating the culling of the mice. This did not seem to be caused by the Dox 
diet per se, as B6  mice receiving this supplement remained healthy (see Figure 
6 .1C). In this chapter I will present the basic characterisation of this phenotype. 
For clarity, I will refer to the Lck7 mice with the rtTA inducible Lck transgene as 
LckInd mice, and those also lacking Fyn expression as LckInd Fyn'7' mice.
6.2 Mice expressing reduced Lck and no Fyn present with wasting disease 
and inflammation of the upper GI tract
To confirm that the manifestation of the wasting disease was specific to reduced 
Lck levels and ablated Fyn expression, and also to determine the time-scale of 
appearance, we monitored the weights of mice expressing all possible 
combinations of Fyn and Lck. From the data presented in Figure 6.2A it was
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clear that Dox fed Lck1®1 Fyn'7' mice were the only group that exhibited weight 
loss over time. Moreover, if mice with the same genotype were not fed Dox food, 
and thus did not express either Lck or Fyn, then no weight loss was observed. 
The disease was not caused by administration of Dox alone as B6  mice that were 
fed this diet remained healthy. Furthermore Dox fed LckInd mice that expressed 
Fyn also showed no sign of weight loss, indicating that Fyn expression was 
protective. When the weight of the mice presenting with wasting disease dropped 
to ~85% of the starting values they were euthanised for further analysis. As 
Figure 6.2A shows, this occurred between 8 and 24 weeks of age, with no sign of 
disease before 4 weeks of age.
We wanted to determine what could be the cause of the wasting disease, therefore 
mice were monitored daily for signs of diarrhoea or appetite loss. Mice from all 
groups fed comparably and showed no signs of watery stools in the cages. We 
then proceeded to remove the entire gastrointestinal (GI) tracts from sick animals 
for analysis. Figure 6.2B shows photos taken of the upper regions of the gut from 
a B6  mouse (left panel) and a Dox fed LckInd Fyn7 mouse presenting with weight 
loss (right panel). As shown in this example, the GI tract from sick mice showed 
regions of swelling marked on the photo with white arrows. In contrast these 
regions of swelling and thickening were not observed in the GI tract from the B6 . 
The thickening and swelling was restricted to the upper section and not in the 
colons of sick mice (data not shown), thus making the disease phenotypically 
distinct from other models of IBD that involve the colon (Leithauser et al., 2002).
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When sections were taken through the swollen areas of the upper GI tract from 
sick mice (Figure 6.2C), H & E staining revealed the presence of cellular infiltrate 
in the villi (marked with arrows). Furthermore swelling and the presence of cell 
infiltrate was not observed in the gut from Dox fed B6  mice, LckInd Fyn7 animals 
not presenting with weight loss and any of the other mice listed in Figure 6.2A 
(data not shown).
Figure 6.3 Dox fed LcklDd Fyn'7' mice exhibit enlarged LN and elevated T cell 
numbers.
As well as a wasting disease, further analysis of the sick Dox fed LckInd Fyn'7' 
mice revealed that they possessed enlarged lymph nodes compared to control 
mice (Figure 6.3A). Prior to disease manifestation (~ 4 weeks of age), the 
frequency (Figure 6.3B) and absolute number (Figure 6.3C) of T cells in the 
peripheral lymph nodes of Dox fed LckInd Fyn7 mice was 2-fold less than B6 
control mice. However, when disease was observed, the frequency of T cells 
increased to that of the B6  LN. This increase in frequency did not always 
translate into an increase in absolute T cell numbers, but in a proportion of the 
animals, numbers of T cells were substantially increased compared to B6  controls. 
It should also be mentioned that in some mice B cell numbers also increased.
As the mice presented with GI tract pathology, the mesenteric lymph nodes 
(MLN) were analysed separately. Again, Figure 6.3D shows that the frequency of 
T cells in the MLN of healthy LckInd Fyn'7' mice (4 weeks old) was ~2.5 fold less 
than the percentage in a B6  mouse. However, with age and once disease was
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manifested, the frequency of T cells increased compared to the frequency in the 
B6  mouse. Figure 6.3E shows that while the absolute T cell number in the MLN 
of B6  mice remained constant with age, in the sick mice there was a clear increase 
in cell number over time. A greater percentage of LckInd Fyn'7' mice exhibited T 
cell lymphoproliferation in the MLN than in the peripheral lymph nodes (PLN), 
indicating that the T cell proliferation was more profound at this site.
6.4 The expansion of CD4 cells is the main reason for the increase in T cells
We wanted to determine which T cell subset(s) was responsible for the increase in 
overall T cell numbers observed in sick mice. To this end we carried out 
extensive phenotyping of Dox fed Lck^  Fyn'7" mice presenting with disease. 
Figure 6.4A shows that before showing signs of sickness the frequency of CD4 
cells and CD8 cells was reduced by 2-fold and 7-fold respectively in the PLN 
compared to a B6  mouse. When presenting with disease the frequency of CD4 
cells increased 2-fold and, in the example shown in Figure 6.4A, the frequency of 
CD8 cells increased ~5-fold. In the FACS plots shown in Figure 6.4A and D the 
differences in the level of CD8 expression between healthy and sick LckInd Fyn"7' 
mice reflect the fact that staining was carried out on different days, to highlight 
this, age matched B6  stains are shown. When these frequencies were converted 
into total cell numbers (Figure 6.4B), CD4 cells increased with age in ~60% of 
LckInd Fyn'7 mice after 9 weeks of age. In contrast, Figure 6.4C shows that 
expansion of CD8 cell numbers with age was restricted to only ~20% of animals. 
CD4 and CD8 T cell numbers remained constant in B6  mice with age. It should
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also be noted that we only observed an increase in CD8 numbers when CD4 
numbers were also elevated.
As before, the MLN were analysed separately from the PLN. Figure 6.4D shows 
that a similar frequency of CD4 and CD8 T cells existed in the MLN of healthy 
LckInd Fyn7' mice compared to PLN. Again, upon disease manifestation, the 
frequencies of CD4 and CD8 cells increased, however the expansion of CD4 cells 
in the MLN was 3-fold compared to only 2-fold in the PLN. Furthermore, CD8 
expansion, although evident, was also not as great as was observed in other the 
lymph nodes. When the absolute numbers of CD4 cells (Figure 6.4E) and CD8 
cells (Figure 6.4F) were plotted with age it revealed that expansion of CD4 
numbers again occurred over time, and was evident in nearly every mouse 
analysed over 4 weeks of age. In contrast only 3 mice out of 17 showed increased 
CD8 cell numbers in the MLN. Collectively these data indicated that CD4 cells 
were the main population responsible for the increase in T cell numbers and the 
major lymphoid site where this occurred was in the mesenteric lymph nodes.
6.5 CD4 cell expansion occurs within the memory compartment
Having identified expansion of CD4 cell numbers as the major contributor to the 
increase in T cell numbers observed in sick mice, we wanted to determine the 
phenotype of these cells. CD4 cells can be subdivided into memory and naive 
based on the expression of the marker CD44 (Dutton et al., 1998). Upon 
activation by antigen, or in response to lymphopenia, a CD4 cell will upregulate 
CD44 and this is considered to be a marker of antigen-experienced cells (Zola,
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2000). To this end we looked at the frequency of CD4+ CD44+ cells within the 
PLN from healthy mice and compared these values to mice presenting with 
disease as well as with B6  animals. Figure 6.5A shows that before disease, CD4 
cells from LckInd Fyn'7' mice showed a reduced frequency of CD44W CD4 cells 
compared to a B6  control mouse. However, upon disease manifestation, the 
frequency of 0 0 4 4 “ cells increased ~3-fold compared to that seen in a B6  mouse. 
When the absolute number of naive CD44'° (Figure 6.5B) and CD44W memory 
(Figure 6.5C) CD4 cells were plotted against the age of the mouse it was evident 
that there was an expansion of CD4 memory cell numbers with age in the PLN of 
sick mice. In contrast naive CD4 cell numbers remained comparable to B6 
controls.
When the same analysis of the CD4 cells from the MLN was carried out, a similar 
pattern emerged to that observed in the PLN. Figure 6.5D shows that there was a 
reduced frequency of CD44W CD4 cells in the MLN of healthy LckInd Fyn'7' mice 
compared to B6  controls. As the mice became sick the frequency of CD44^ CD4 
cells increased 3-fold compared to B6  controls. When the absolute number of 
naive (Figure 6.5E) and memory (Figure 6.5F) CD4 cells was plotted against 
mouse age, again there was a striking expansion in the memory CD4 T cell pool 
over time within the MLN, also with no change in naive CD4 numbers. As was 
described previously for both total T cell numbers and CD4 cell numbers a greater 
frequency of sick LckInd Fyn'7' mice exhibited an elevation of memory CD4 cells 
in the MLN compared to other peripheral lymph node sites.
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6.6 CD4 cells from sick mice have an activated phenotype and remain 
polyclonal
Disregulation of Src family kinases has been shown to lead to T cell 
transformation (Majolini et al., 1999; Abraham et al., 1991), therefore we wanted 
to investigate if CD4 cell expansion in our sick mice was a result of the outgrowth 
of a specific T cell clone(s). To this end we used a panel of anti-TCR Vp chain 
antibodies and determined the frequency of CD4 cells expressing specific p 
chains by FACS. Figure 6 .6A shows the percentage of CD4 cells that expressed 
the indicated Vp chains from groups of B6  mice, 4 week old healthy LckInd Fyn7 
mice, and mice showing signs of disease. It is clear that similar frequencies of 
CD4 cells expressing the panel of Vp chains were observed in all mouse groups. 
There were however some subtle differences between the three groups of mice. 
For example healthy LckInd Fyn7 mice had a higher percentage of CD4 V p5+ and 
CD4 Vp6 + cells compared to both sick Lck1”*1 Fyn'7' and B6  control mice. 
Furthermore, no CD4 V p i l+ cells could be detected in the healthy LckInd Fyn"7' 
mice, whereas sick mice contained this population at a very small frequency. 
Collectively these data showed that CD4 T cell expansion was not due to the 
outgrowth of any of the Vp expressing clones tested, but that there may have been 
subtle changes in the Vp repertoire between groups of mice.
We next sought to further phenotype the CD4 cells from sick LckInd Fyn'7' mice. 
One hallmark of activated T cells is the ability to make cytokines upon ex vivo 
restimulation (Andersson et al., 1988). Furthermore the ability of these cells to 
produce cytokine could, in theory, contribute to disease pathogenesis. To this end
277
we decided to look at the ability of CD4 T cells from LckInd Fyn7 mice to produce 
IL-2 and IFNy upon ex vivo restimulation with PdbU and ionomycin. Figure 6 .6B 
shows that the percentage of CD44U CD4 cells isolated from the PLN and MLN 
able to make IL-2 was increased between 2 to 4-fold respectively compared to the 
same population from B6 mice. This was restricted to the CD44hi population in 
both groups as no IL-2 production was detected in the CD4410 CD4 cells. When 
we addressed IFNy production (Figure 6 .6C) the differences were even more 
striking. CD4 cells from the PLN and MLN of B6  mice made little IFNy upon 
restimulation. In contrast ~14% of CD4 CD44hi cells from the PLN and MLN of 
sick mice were able to produce IFNy. Again, no cytokine was detected in the 
naive CD4 population. Interestingly CD4 cells from healthy LckInd Fyn'7' mice did 
not shown an increased propensity to make IFNy (data not shown).
To further elucidate if the CD4 cells from the LN of sick mice had an activated 
phenotype we looked at the expression of CD45RB and CD62L. Expression of 
CD62L is high on the surface of naive CD4 cells, but is shed upon activation 
(Chen et al., 1995; Tedder et al., 1995b; Tedder et al., 1995a). Furthermore, 
CD45RB expression is also high on naive T cells and low on activated cells 
(Dutton et al., 1998). Analysis of the expression of these markers revealed that 
CD4 cells from sick mice were predominantly CD62L10, but could be equally 
subdivided into CD45RBwor CD45RB10 (Figure 6 .6D). In contrast the majority of 
CD4 cells from B6  mice were CD62LU and CD45RBhi, the same pattern was 
observed in healthy ^4-week-old LckInd Fyn 7 mice (data not shown).
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We also decided to look at the expression of CD5 on the surface of the CD4 cells, 
as CD5 has been shown to correlate with Src kinase levels (Seddon and 
Zamoyska, 2002b), and is thought to act as a negative regulator of T cell 
activation (Tarakhovsky et al., 1995). Figure 6 .6E shows that the MFI of CD5 
expression was reduced 2-fold on the surface of CD4 cells from sick mice 
compared to B6  controls, however this did seem to reflect the fact that there were 
populations of CD5U and CD5lD cells from the sick LckInd Fyn'7' mice. 
Furthermore, this reduction in CD5 MFI correlated with disease as healthy mice 
had comparable levels to a B6  and did not have two populations basewd on CD5 
expression (data not shown).
6.7 Sick mice have elevated numbers of CD4 CD25+cells
The fact that we observed a general lymphoproliferation of activated CD4 T cells 
combined with GI tract pathology suggested to us that there could be defects in 
mechanisms that control peripheral tolerance. Deletion of autoreactive T cells by 
negative selection relies on the presence of self-pMHC complex within the 
thymus. While self-antigens from sites such as the GI tract will be expressed in 
the thymus due to the function of the AIRE transcription factcor (Anderson et al., 
2002), T cell clones reactive to peptides produced by commensal gut bacteria will 
escape deletion as thesesantigens will not be presented in the thymus. To 
counteract this problem, there are mechanisms that regulate activation of these 
cells upon encountering self-antigen in peripheral sites. T regulatory cells (Treg) 
cells mediate one such mechanism. It is thought that these cells work by 
suppressing the activation of autoreactive T cells (Strober et al., 2002), by
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mechanisms yet to be fully elucidated. To this end we wanted to check that these 
cells were indeed present in the PLN and MLN of mice before and after 
presenting with sickness. Phenotypically, a major population of Trcg cells are 
generally regarded to be CD4 CD25\ furthermore, the expression of CD4 on the 
surface of these CD25+ cells is marginally lower than on CD25' CD4 cells 
(Sakaguchi et al., 1995). Figure 6.7A and C show the frequency of these putative 
Treg cells in the PLN and MLN respectively in all groups of mice. It should be 
noted that the expression of CD4 on the CD25+ cells in all groups was marginally 
reduced compared to CD25' cells. Also the frequency of these cells in the B6 
mouse was the same regardless of the peripheral location. Furthermore, the 
absolute number of these putative Treg cells in control mice remained unchanged 
in the PLN (Figure 6.7B) and MLN (Figure 6.7D) with age. Before disease onset, 
the frequency of these CD4 CD25+ cells from LckInd Fyn 7’ mice was comparable 
to B6  mice, as were the absolute numbers (Figures 6.7B and D). However when 
sickness presented the frequency of these cells increased dramatically in both the 
PLN and MLN of sick mice. Furthermore, the absolute numbers in the PLN 
(Figure 6 .8B) and MLN (Figure 6 .8D) increased with age and disease incidence. 
The percentage of sick mice showing elevated numbers of these cells in the MLN 
was higher than in the PLN (~50% in PLN, ~95% in MLN). Consistent with the 
memory CD4 expansion in the MLN, the expansion of CD4 CD25+ in the same 
site could indicate a response to bacterially derived antigens in the GI tract.
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6.8 Sick mice have elevated B cell numbers and ANA with age.
Although CD4 cell numbers were clearly elevated in the lymph nodes of sick 
mice, they did not account for the full increase in cellularity observed. Fyn and 
Lck are expressed in B cells and there is evidence that certain subsets may have a 
functional requirement for Lck (Dal Porto et al., 2004). Although we are unsure 
if the inducible Lck system is expressed in B cells it is a possibility. Furthermore 
T cell disregulation could influence B cell function possibly through CD40- 
CD40L interaction that regulate isotype switching (Bishop and Hostager, 2003). 
Therefore we wanted to assess whether B cell numbers were affected in sick mice. 
Figure 6 .8A, B and C shows the absolute numbers of B cells in the PLN, MLN 
and spleen respectively from sick mice and B6  controls. It is clear that there is B 
cell expansion in the PLN and MLN of Lck111*1 Fyn'7' mice with age however this 
trend is less pronounced in the PLN compared to the MLN. As the spleen is a 
major B cell site we also looked at the B cell numbers there. Figure 6 .8C shows 
that, although more variation within groups was observed, there was also some 
increase in B cell numbers in the spleens of sick Lck1®1 Fyn'7' mice.
Next we decided to address the production of antibodies by B cells by measuring 
serum Ig isotype levels by ELISA to see if there were any obvious differences. 
Figure 6 .8D shows that in the serum of all mice analysed, levels of IgGa, IgG2b, 
IgGl, IgG3 and IgM were comparable between B6 , and healthy or sick LckInd Fyn' 
7 mice. There was an increase in the level of IgG2a in the serum of LckInd Fyn7' 
mice compared to B6  controls, however this did not correlate with disease 
incidence as it was also elevated in healthy £ 4-week-old animals. This does not
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rule out the possibility that elevation of IgG2a is a very early indicator of disease 
induction. We also looked at levels of IgE in the serum of mice. Figure 6 .8E 
shows that there was an increase in IgE levels in the serum of sick mice with age. 
The one animal that exhibited very high IgE levels also presented with irritated 
and swollen ears in combination with skin lesions (data not shown).
As IgE levels have also been shown to correlate with autoimmune disorders such 
as Systemic lupus erythematosus (SLE) in humans (Nagpal et al., 1990) and also 
are detectable the lupus-like flaky skin mutant autoimmune mice (Withington et 
al., 2002), we decided to look for the presence of anti-nuclear antibodies (ANA). 
The presence of ANA is often indicative of autoimmunity as it reflects the 
presence of self reactive antibodies generated as a result of T cell activation 
(Shlomchik et al., 1990). From Figure 6 .8F it is clear that sera from B6  mice did 
not contain detectable levels of ANA as values were not greater than those 
obtained with negative control sera. Furthermore, sera from 4 week-old LckInd 
Fyn'7' mice also contained no detectable ANA, but with age and disease 
progression we were able to detect ANA in the sera of sick LckInd Fyn"7' mice.
6.9 Disease manifestation and duration can be controlled by switching Lck 
expression on or off
Having shown that the disease only became apparent in Dox fed LckInd Fyn'7' mice 
after 4 weeks and becoming fatal between 8 and 24 weeks of age we wanted to 
address the role that continual Lck expression had in influencing disease 
progression. To this end litters of LckInd Fyn7' mice were fed Dox up to 4 weeks
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of age to generate peripheral T cells. At 4 weeks these mice were taken off Dox 
and were left for a further 6  weeks during which no sign of disease was noted, as 
shown previously in Figure 6.2A. The mice were weighed at 10 weeks of age and 
put back on a Dox diet. Figure 6.9A shows that within 7 days of returning to Dox 
food and switching Lck expression back on the mice lost 15-20% of their original 
body weight and had to be culled. The littermate control that did not receive Dox 
remained healthy. Moreover, when CD4 T cell expansion was measured in the 
blood of these animals, the frequency of CD4+ PBL increased over time in the 
Dox fed mice, but not in the mouse kept free from Dox thus not expressing Lck 
(Figure 6.9B). These data indicated that the LckInd Fyn 7 mice required Lck 
expression for initiating the sickness.
Once the disease had manifested in the mice, we wanted to determine if 
pathogenesis required the continual expression of Lck. To this end a litter of 6 
LckInd Fyn 7 mice were fed Dox and the weights were monitored weekly. When an 
animal's body weight dropped to 90% of the original value we removed Dox and 
continued to monitor the body mass. Figure 6.9C shows that 5 out of the 6  mice 
began to show signs of disease around 7 weeks of age. When these animals were 
removed from Dox food having lost 10% of their original body weight, 3 animals 
recovered or stabilised their weight loss, and 2  mice which continued to lose 
weight had to be culled. Examination of the GI tract from the culled mice 
revealed extensive swelling of the upper regions (data not shown), but there was 
no sign of increased T cell numbers in the PLN or MLN. In contrast, the GI tract 
from mice that recovered body weight after being removed from Dox did not 
show the same extent of swelling and tissue damage (data not shown).
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Collectively these data show that disease progression, specifically memory CD4 T 
cell expansion, required continual Lck expression.
6.10 Transfer of LckInd Fyn'7' LN cells can induce wasting disease in Rag-1'7' 
recipient mice.
Having characterised the nature of the disease observed in Dox fed LckInd Fyn'7' 
mice we wanted to try and begin to understand what could be driving its 
manifestation. Analysing the disease in theses mice had a number of anomalies 
that needed to be resolved. For example, we were comparing the phenotype of 
activated cells from the Lck1"41 Fyn'7' mice with cells from B6  animals that were 
largely naive. Secondly, we did not know whether the disease was in fact being 
driven by the activation of auto-reactive T cells or whether it was being driven 
inpart by activation in response to lymphopenia. This could be significant as 
healthy LckInd Fyn'7' mice have a 2-fold fewer T cells compared to B6  mice (see 
Figure 6.3). Thirdly, although Dox fed LckInd mice expressing Fyn showed no 
signs of disease (see Figure 6.2A) these mice were reared on a diet containing 1 
mg/g of Dox food compared to Lck11141 Fyn'7' mice that received a 3 mg/g diet. The 
reason for this difference was that we observed poor thymic development in the 
LckInd Fyn'7' mice that had been fed 1 mg/g Dox diet (data not shown). Therefore 
the higher dose of Dox may have been contributing in some way to the disease. 
To try and answer all of these discrepencies we decided to use an in vivo transfer 
model. This involved the transfer total cells from the LN of healthy 4 week old 
LckInd Fyn'7' mice and from LckInd mice expressing Fyn into separate groups of 
Rag-1'7' hosts. Furthermore, using this model we could also determine if the
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disease was cell intrinsic and could be transferred to recipient mice, or whether 
the peripheral environment of the Lck1*1 Fyn'7' mice was also a contributing factor. 
Furthermore, we used LckInd mice expressing Fyn as controls, which would 
confirm that Fyn deficiency was essential to the manifestation of the disease.
Before injection, the total cell numbers were adjusted so that equal numbers of T 
cells (1 x 106 cells) were injected meaning that the initial degree of T cell 
lymphopenia would be comparable between hosts receiving cells from LckInd Fyn' 
7' and LckInd Fyn WT mice. Furthermore, induction of IBD in Rag-1'7' mice does 
not normally occur when transferring total LN preps as the presence of regulatory 
cells in the T cell memory pool provide disease protection in normal 
circumstances (Sakaguchi et al., 1995). To address the impact of Dox dose on the 
manifestation of the disease the recipients were split into a further two groups and 
fed either 1 mg/g or 3 mg/g Dox food. A further advantage of this system is that 
the transferred T cells will activate and proliferate in response to the lymphopenic 
environment of the Rag-1'7' mouse. Therefore we would be comparing cells that 
have been activated in exactly the same manner and environment the only 
difference being the presence or the absence of Fyn.
Regardless of the concentration of Dox food in the diet, Rag-1'7' mice that 
received LckIndFyn'7' cells lost weight over an 8 week period (Figure 6.10A). In 
contrast LckInd Fyn sufficient cells failed to induce any wasting disease in the 
recipient animals with either 1 mg/g or 3 mg/g Dox administration. After 24 
hours post cell transfer, mice were bled and the frequency of CD4+ PBL was 
determined (Figure 6.1 OB) in order to determine the success of the transfer and to
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provide an idea of initial T cell numbers. It is evident from Figure 6.10B that at 
this time T cell frequencies were comparable in the blood of the recipient animals. 
However, with time the frequency of CD4+ PBL increased in all mice, with a 
greater increase observed in animals that had received LckInd Fyn'7' cells.
When these mice were culled analysis of the periphery revealed that cells from 
LckInd Fyn'7' mice had expanded more than LckInd Fyn sufficient cells, again 
regardless of Dox dose (Figure 6 . IOC). This increase in T cell numbers was 
particularly evident in the spleens of these mice. Interestingly, the LckInd Fyn'7' 
mice fed 3 mg/g Dox food had elevated T cell numbers in the MLN, but not in the 
PLN, whereas animals on a 1 mg/g Dox diet showed increased numbers at both 
sites. Collectively these data show that whatever was driving the weight loss and 
T cell proliferation was cell intrinsic as it could be transferred to Rag-1'7' 
recipients. Also differences in initial T cell numbers or Dox diet were unlikely to 
be the driving factor behind the disease in LckIndFyn'7' mice.
As shown in Figure 6 .6 , a higher frequency of CD4 cells from LckInd Fyn'7' mice 
were able to make IL-2 and, especially, IFNy after ex vivo restimulation compared 
to B6  mice. Also there were differences in the pattern of CD62L and CD45RB 
expression and CD5 levels. As mentioned however, we were comparing two very 
different populations of cells, one activated and the other naive. In our transfer 
system we were activating both groups of cells in the same manner and thus 
making the cell populations more equivalent. To this end we assessed ex vivo 
cytokine production (Figure 6.10D upper panels), CD62L / CD45RB (middle 
panels), and CD5 (lower panels) expression. Figure 6.10D shows that cells
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expressing reduced Lck and WT levels of Fyn, when activated in response to 
lymphopenia, were mainly able to produce only IL-2 after restimulation with very 
few cells producing IFNy. In contrast to this, cells lacking Fyn produced both 
IFNy and IL-2  but there was a particularly striking bias toward cells only 
producing IFNy.
When CD62L and CD45RB expression was assessed it was evident that LckInd 
cells expressing Fyn had down modulated levels of both molecules in response to 
lymphopenic activation. In contrast LckInd Fyn'7' cells down-modulated CD62L 
levels but the majority maintained CD45RB expression. Furthermore, analysis of 
CD5 expression revealed that LckInd Fyn'7' cells had a 2.5-fold reduction in the 
CD5 MFI. In conclusion, these data showed that the phenotype of the LckInd Fyn7 
cells was not simply due to comparing activated with naive cells. It is also 
suggested that the activation induced differentiation programme of LckInd Fyn'7' 
cells was different from LckInd fyn sufficient cells. Interestingly, the phenotype of 
the CD4 cells from LckInd Fyn7 mice resembled effector-memory cells in that they 
are CD45RBhi, CD62L10 (Hasegawa et al., 2004) and mainly IFNy producers 
(Blander et al., 2003; Wang and Mosmann, 2001).
6.11 Transfer of CD44“ and CD44to CD4 LckInd Fyn'7' cells is capable of 
inducing disease
Having shown that the wasting disease was in fact cell intrinsic we wanted to 
determine exactly which cells were capable of conferring sickness. In the 
previous experiments total LN containing CD4 and CD8 T cells, as well as B cells
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was used as the source of material for the transfer into recipient mice. As sick 
mice showed expansion of all of these cell populations to various degrees we 
could not determine which cell types were required for disease induction. From 
previous data we reasoned that CD4 cell expansion and the phenotypic changes 
observed in this population from sick LckInd Fyn7' mice could be a major factor in 
the disease. To test this theory we purified CD4 T cells from the PLN of healthy 
4 week old LckInd Fyn7' mice and LckInd Fyn sufficient mice to ~ 96% purity in 
both groups (data not shown). It should be mentioned that all mice were weaned 
on a 3 mg/g Dox diet. Equal numbers of purified CD4 cells (1 x 106) were 
injected i.v into Rag-17' mice. Moreover, as well as total CD4, another two 
groups of mice received 1 x 106 of either naive (CD44‘°) or memory (CD44hi) 
purified CD4 cells from healthy LckInd Fyn7' donor mice. Purity in the memory 
group was ~99.9%, however there was ~10% CD44hi cells remaining in the naive 
group (data not shown). Again it should be stressed that transfer of comparatively 
large numbers of naive WT cells does not normally induce IBD in Rag-17' mice 
on a B6  background (data not shown). IBD is usually induced by transferring 1-5 
x 105 naive T cells (Sakaguchi et al.y 1995). In all cases mice were fed 3 mg/g 
Dox food to maintain transgene driven Lck expression. At 24 hours post transfer, 
recipient mice were bled and the frequency of CD4+ PBL was assessed. Figure 
6 .11A shows the CD44 profile of CD4+ PBL from all four groups of mice. From 
these data it was evident that there was an increased percentage of CD44hi cells in 
the recipients that received total CD4 cells from LckInd Fyn7' donors compared to 
LckInd Fyn sufficient mice. As expected there was no CD44lQ cells evident in the 
blood of mice that received memory CD4 cells, however there was a percentage 
of CD44*“ cells evident in the blood of recipients injected with naive LckInd Fyn7'
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cells. In all groups the initial frequency of total CD4 T cells was comparable 
(data not shown).
When the weights of the recipient mice were monitored it became evident that the 
wasting disease manifested 8-12 weeks post transfer (Figure 6.1 IB) only in 
animals that received either total CD4 cells or memory CD4 cells from LckInd Fyn 
7' donor mice. Within this time frame, mice that received naive CD4 cells from 
LckInd Fyn'7' mice remained healthy and actually increased in weight, as did mice 
that received total CD4 from LckInd Fyn WT donors. However, after 15 weeks 
post transfer, animals that received the naive CD4 cells from LckInd Fyn'7' animals 
began to rapidly lose weight and were culled.
We next sought to determine the phenotype of the CD4 cells from the four groups 
of mice. In all mice 100% of CD4 cells became due to lymphopenic
activation (data not shown). Figure 6.11C (upper panel) shows that the majority 
of CD4 cells from LckInd Fyn sufficient controls converted to a CD62L10 
CD45RB10 phenotype after transfer. In contrast CD4 LckInd Fyn'7' cells again lost 
CD62L expression but the majority remained CD45RBhi. This phenotype was 
observed regardless of the starting population of LckInd Fyn'7' cells transferred. 
CD5 expression was also assessed and found to be reduced on the surface of CD4 
cells in all groups of LckInd Fyn'7' cells transferred compared to LckInd Fyn 
sufficient cells. As noted in figure 6 .6 , the decrease in MFI seemed to be due to 
the appearance of a distinctive CD5lD cell population.
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CD44 CD4 cells can be subdivided into two separate groups depending on the 
expression of CD62L and CD45RB. CD44hi CD62L10, CD45RB10 CD4 cells are 
considered to be central memory cells and CD44W CD62L10 CD45RBW cells are 
thought to be effector-memory cells (Hasegawa et al., 2004; Dutton et al., 1998). 
In the sick mice we seemed to have an accumulation of effector-memory type 
CD4 cells as a large proportion expressed CD45RB (Figure 6 .6 D. Furthermore, 
when we transferred the LckInd Fyn'7' cells in vivo they seem to preferentially 
becom e effector-m em ory type cells (Figure 6.10D). Another factor that 
distinguishes central memory from effector memory is that effector memory cells 
can produce IFNy upon recall stimulation. From the data in Figure 6 .6B/C it was 
clear that CD44W cells were able to make IFNy upon recall stimulation, also when 
the cells from LcklDd Fyn'7' mice were activated in vivo they preferentially secreted 
only IFNy and very little IL-2 (Figure 6.10D). Therefore we wanted to determine 
if the major cell population able to make IFNy from LckInd Fyn7 mice were also 
CD62L'°, CD45RBw, and thus effector-memory-like. Figure 6.1 ID shows the IL- 
2/ IFNy staining profile of CD45RB10 (left panels) and CD45RB111 (right panels) 
CD4 CD44hi cells from LckInd F yn7 (lower panels) and LckInd mice expressing Fyn 
(upper panel) after transfer into Rag-17 recipients. It is evident that LckInd Fyn7 
CD45RBhi CD4 cells were mainly producing IFNy, with very few cells only able 
to make IL-2 within this population. In contrast, a percentage of the CD45RB10 
population was able to make just IL-2, although there were cells able to make 
IFNy. In the Fyn sufficient group, the CD45RBW cells also had a higher 
percentage o f IFNy single-producer cells compared to the CD45RB10 cells, 
however the majority were able to produce IL-2 only. Collectively these data 
support the idea that activation of cells from LckInd Fyn7 mice leads to the
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accumulation of effector-memory like CD62Ll°, CD45RBhi cells that are 
preferentially able to only make IFNy.
6.12 Discussion
The aim of this chapter was to characterise the wasting disease observed in mice 
expressing reduced Lck and no Fyn. By monitoring the weights of cohorts of 
mice representing all possible combinations of Lck and Fyn, we confirmed that 
sickness was only evident in Dox fed LckInd Fyn'* mice. When 20% of initial 
body mass was lost, mice were culled for analysis, this occurred anywhere 
between 4-12 weeks of age. Analysis of the GI tract revealed swelling of the 
upper regions and cellular infiltrate within the lumen of the villi. The PLN, MLN 
and spleens of these mice were enlarged due to an accumulation of 
effector/memory type CD4 cells that had lowered CD5 expression and could 
make IFNy upon recall stimulation. There was also a degree of B cell 
disregulation that led to increased B cell numbers in the MLN and PLN. 
Moreover, there were indications of autoimmunity as we could detect both ANA 
and IgE in serum of sick mice. We were able to regulate disease initiation and 
progression by administering or removing Dox from the diet of the mice, showing 
that the expression of Lck was essential to the disease state. The disorder was not 
driven by the LckInd Fyn'7' mice being more lymphopenic than Fyn sufficient LckInd 
mice, nor was it due to differences in the dosage of Dox administered to the 
groups of mice. This was shown in transfer experiments using equal numbers of 
T cells from LckInd Fyn'7' or LckInd Fyn WT mice into Rag-1'7' hosts. We were able 
to induce wasting disease only in Rag-1'7 hosts that received LckInd Fyn7 cells, 
and this occurred with either Dox dosage. Furthermore, we showed that the
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wasting disease could be conferred specifically by transferring either CD4 naive 
or memory-like cells from Lck1”41 Fyn'7' mice. Activation of Lck111*1 Fyn'7' CD4 cells 
in response to lymphopenia led to the accumulation of effector/memory type cells, 
whereas Lck,nd cells seemed to become more resting memory-like. This 
observation was based on the fact that LckInd Fyn'7' cells became CD44hi CD62L'° 
CEHSRB111 and were able to produce IFNy. In contrast LckInd cells also became 
CD44U CD62Ll°, but were CD45RB10 and produced mainly IL-2.
The reason for the drastic weight loss observed in the LckInd Fyn'7' mice seemed to 
result from inflammation of the regions of the GI tract. In more classical models 
of IBD, the inflammation is normally restricted to the colon (Strober et al., 2002), 
and not the upper regions. When we have induced IBD in Rag-1'7' mice by 
transferring small numbers of naive CD4 cells from WT mice, as expected 
animals lost weight due to diarrhoea and colonic inflammation (data not shown). 
However, when we fed these recipient mice Dox food, we still observed IBD, but 
the site of swelling resembled that seen in LckInd Fyn'7 mice. We feel that 
although phenotypically distinct, the disease observed in the LckInd Fyn7 mice 
may still be related to classical IBD as the site of inflammation may differ simply 
due to the administration of Dox. IBD-like disorders in general are a direct result 
of mucosal inflammation in response to commensal gut antigens (Strober et al., 
2002). As Dox is antibiotic, it could change the nature of the disease and the site 
of inflammation by altering the balance of bacteria in the GI tract.
IBD can be subdivided into two categories depending on the level of immune 
disregulation responsible for causing it. Type I disorders arise from autoagression
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of gut T cells that lead to a loss of tolerance to commensal gut antigens (Strober et 
al., 2002). An example of a Type I disorder is IBD induced by the transfer of 
cells from mice expressing a STAT4 transgene into SCID recipients. The over 
expression of STAT4 renders the T cells hyper-responsive to IL-12 signalling, 
breaking tolerance to gut antigens (Wirtz et al., 1999). Furthermore, Type I 
disorders are in general associated with T hl responses (Strober et al., 2002). This 
is most likely because the bacterial agents that include superantigens, such as 
SEA, and mitogens like LPS or CpGs will induce IL-12 production, leading to a 
preference for T hl responses (Strober et al., 2002). In contrast, a Type II disorder 
is thought to arise from a failure in the regulatory mechanisms that would usually 
control an otherwise normal effector response (Strober et al., 2002). Transferring 
naive CD4 cells into SCID mice is an example of a type II disorder as IBD is 
induced because there are no regulatory cells normally present in the memory 
population (Powrie et al., 1994), allowing the cells to proliferate unchecked.
There is evidence to suggest our model of IBD has elements of a Type I mucosal 
inflammation disorder. Firstly, it was interesting that such a comparatively high 
number of naive CD4 cells from the LckInd Fyn'7' mice could induce the IBD-like 
syndrome upon transfer. In typical SCID IBD models involving B6  mice that are 
driven by type II immunological defects (an absence of appropriate regulatory 
mechanimsms), there is a direct correlation between the degree of lymphopenic 
expansion and the severity of IBD induction. Transferring small numbers (1-2 
xlO5) of naive CD4 cells normally induces rapid disease as these relatively few T 
cells undergo significant proliferation in order to fill the space in the lymphopenic 
host. This proliferation and activation is normally controlled by Trcg cells within
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the memory population (Sakaguchi et al., 1995; Powrie et al., 1994). In contrast, 
larger numbers of transferred naive CD4 cells do not undergo the same degree of 
expansion and fail to induce IBD in empty hosts. Therefore we may have 
expected that disease progression should not have occurred after the transfer of 
such a comparatively high number of naive CD4 T cells. The fact that we did 
observe disease suggested that there was something intrinsically autoagressive 
about the naive T cells derived from the Lck1" 1 Fyn'7' mice that was not simply due 
to an absence of Treg populations. It is also evident from our data that the CD4 
CD44hi cells that also contain the putative regulatory cell populations seemed to 
induce more rapid disease in the mice instead of conferring protection. This result 
suggested that the rate-limiting step for disease induction could have been the 
activation and conversion of naive CD4 cells to 0044^  cells, but also that the Treg 
cells were unable to suppress.
Evidence that the CD4 cells from Lck1"1 Fyn'7 mice were somehow disregulated 
came from the observation that when we restimulated them ex vivo, we were able 
to detect the potential to produce IFNy. This was not observed in cells from LckInd 
mice. The major IFNy producing cell population was CD44hi CD62L‘° CD45RBhi, 
suggesting that these are effector/memory type CD4 cells (Hasegawa et al., 2004; 
Dutton et al., 1998). Moreover, we could transfer the disease to Rag-1 '7' recipients 
by virtue of these cells alone. IFNy has been shown to increases the severity of 
colitis in SCID models. There is also evidence that the deletion of CD4 cells in 
vivo can ameliorate mucosal inflammation (Okamoto et al., 1999). Moreover, in 
SCID models of IBD, it is generally CEHSRB1*1 CD4 cells that are transferred in 
order to induce disease (Claesson et al., 1999). These facts highlight the
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important contribution that disregulated CD4 function could have to mucosal 
inflammation in the LcklDd Fyn7' mice. Furthermore work by Stein et al suggested 
that there may have been defects in the deletion of autoreactive T cells in Fyn'A 
mice (Stein et al.y 1992). This could have been exacerbated by reducing Lck 
levels leading to the escape of autoreactive T cells from deletion in the thymus. 
Collectively these data suggested that disease manifestation was intrinsic to the 
CD4 cell population and therefore had elements resembling a Type 1 model of 
mucosal inflammation.
As discussed in Chapter 5, in the absence of Fyn, CD8 cells may mount a more 
prolonged primary response by virtue of their inability to efficiently 
downmodulate TCR signals. In the LckInd Fyn'' mice, we may be observing a 
more severe manifestation of the same phenomenon where disregulated T cell 
activation in response to self-antigens led to an accumulation of CD4 
effector/memory phase of differentiation. Certainly, when we transferred Fyn WT 
and Fyn'A LckInd cells into empty hosts, both groups became activated and 
underwent lymphopenic expansion. However, while Lck1" 1 Fyn WT cells became 
central memory-like cells, the LckInd Fyn'/_ cells seemed to remain in a state of 
continued activation.
From our data it was clear that low levels of Lck expression in the absence of Fyn 
was an absolute requirement for disease induction. However, when we removed 
sick mice from Dox it was possible to ameliorate the disease and even halt the 
weight loss. Therefore, we could conclude from these data that we needed 
continual Lck expression to maintain the disease state. This suggested to us that
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the reduced Lck levels were able to transmit activation signals, but were unable to 
regulate the response without Fyn. To try and explain these data we propose the 
model shown in Figure 6.12. At WT levels of expression, Fyn and Lck seem to 
contribute to the proliferative and regulatory signals, but Lck may be better suited 
to driving proliferative signals, and Fyn may be better at downregulating the 
response (see Figure 6.12A and B). This conclusion is based on the phenotype of 
the respective knockout mice, where the loss of Lck leads to inefficient activation 
whereas the loss of Fyn leads to inefficient regulation of the response. In the 
LckInd system, the reduced Lck expression does not seem to compromise the 
ability of the cells to become activated, nor to terminate the response if Fyn is also 
present. However, the low level of Lck seems to be unable to compensate for the 
loss of Fyn in terms of downregulating a response (see Figure 6.12C). This is an 
interesting model, as it suggests that Lck and Fyn may not have unique functions 
in the true sense of the word, but instead possess preferential roles in controlling T 
cell responses.
There is one conflicting observation to this model as we have observed 
upregulation of Lck levels in activated Lcklnd Fyn7 cells following ~72 of in vitro 
activation (Lovatt et al manuscript submitted). Therefore it is also a possibility 
that the activation-induced upregulation of Lck in these cells is responsible for 
breaking tolerance as the activation threshold of LckInd Fyn7' cells may have been 
set with respect to the low Lck levels present in a resting state. However it should 
also be noted that although significantly upregulated, the level of Lck is still lower 
than in a WT cell (~75%). When the LckInd Fyn'7' cells are developing in the 
thymus, they express Lck levels comparable to WT (see Figure 6 . IB). However
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we have not established whether Lck trangene levels are downregulated upon 
export to the periphery, or if this occurs in the transition from DP to SP. SP cells 
are still thought to undergo proliferation and alterations in surface marker 
expression in medullary areas of the thymus for ~2 weeks (Gabor et al., 1997; 
Ernst et al., 1995). Therefore it is possible that the activation threshold of a T cell 
is set in some way during this period of SP thymocyte development. 
Interestingly, Fyn expression has been shown to significantly upregulate between 
the DP and SP stages (Olszowy et al.y 1995), and if Fyn is important in regulating 
a T cell response, this may be important to the activation threshold of the T cell.
As mentioned previusoly Fyn may regulate the formation of the PAG/Csk/PEP 
inhibitory complex but there is also evidence that Lck may be able to 
phosphorylate PAG also (Brdicka et al., 2000). Therefore it is possible that the 
reason for the disrgeulation of the Lck1"*1 Fyn'7' T cells is due to a failure to 
assemble the PAG/Csk/PEP complex as there is no Fyn and reduced Lck levels. 
Interestingly an increase of effector/memory CD4 cells has also been reported in 
mice that lack the phosphatase PEP (Hasegawa et al., 2004). This suggests there 
could be some common mechanism between the defect in PEP deficient mice and 
our LckInd Fyn'7' mice. However, there are differences between the phenotype of 
the LckInd Fyn'7' mice and PER7' mice as there was no evidence of IBD or ANA 
reported by Hasegawa and colleagues. One reason for this lack of autoimmune 
phenotype is that in PEP7'mice, PAG Tyr 317 phosphorylation would presumably 
be unaffected meaning that Csk could still associate with PAG and phosphorylate 
the C-termini residues on Lck and Fyn. Moreover, in the PER7" mice, the presence 
of other phosphatases such as PTP-PEST may be able to compensate for the loss
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of PEP (Davidson and Veillette, 2001) rendering the immune disregulation less 
severe. In our LckInd Fyn'7' mice, this whole complex may be completely absent 
due to no Tyr 317 phosphorylation leading to the inappropriate and disregulated 
activation of T cells in these animals. We are planning to look at the status of 
PAG Tyr 317 in the cells from LckInd Fyn'7' mice to address this question. 
However it should also be noted that PAG'7' mice remain healthy (Dr Lindquist, 
personal communication), therefore the disregulation of PAG is presumably not 
the only molecule possibly affected in Lcklnd Fyn"7' mice.
As the phenotype of both PAG'7' and PEP7' mice differ from what we see it is also 
possible that other immunomodulatory mechanisms may be defective in the Lcklnd 
Fyn'7' mice. As discussed in Chapter 3, Lck and Fyn have been implicated in the 
signalling of CTLA-4 (Hu et al., 2001). Furthermore, CTLA-4'7' mice also suffer 
from a lymphoproliferative disorder (Khattri et al., 1999; Shrikant et al., 1999). 
However there are differences wherby the CD4 cells generated by this response 
are Th2-like, and secrete IL-4 and IL-5 upon ex vivo restimulation (Khattri et al., 
1999). In contrast, a major proportion of CD4 cells from LcklDd Fyn'7' mice were 
more Thl-like by virtue of their ability to produce IFNy. However we could not 
exclude that some Th2 cells were present as we were able to detect IgE in the 
serum of the LckInd Fyn'7' mice. Furthermore, as discussed in Chapter 5, Fyn has 
been shown to mediate signalling downstream of the immunoinhibitory receptor 
SLAM (Chan et al., 2003) through the linker molecules SAP. It is possible that 
the disease observed in the LcklDd Fyn'7' mice is influenced, in part, by defects in 
SLAM mediated signalling as SAP7' cells show increased ability to produce IFNy 
(Czar et al., 2001). However, recent work has shown that these cells are not
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predisposed to become Thl cells, rather that the production of Th2 cytokines is 
defective in these mice (C annons et al., 2004; Davidson et al., 2004). 
Furthermore SAP7' mice show no evidence of autoimmune disease (Czar et al., 
2001), suggesting that it is unlikely that disregulated SLAM signalling is the sole 
cause of the autoimmune disorder in LcklDd Fyn 7' mice. We cannot rule out that 
the reduction in Lck levels combined with ablated Fyn expression is altering the 
function of T cell signalling receptors other than the TCR, and that disregulation 
of multiple pathways is responsible for the disease. We plan to address these 
question in future experiments. For example, if disregulated TCR signals were 
solely responsible for disease induction, then we may not expect CD4 cells from 
Lck1" 1 Fyn'7' mice to induce disease in MHC-class II deficient hosts.
As well as an effect on T cell function, we also noted that B cell numbers were 
often increased in LckInd Fyn'7' mice. Furthermore, we also noted that we could 
detect both IgE and ANA in the serum of LckInd Fyn'7' mice, correlating with 
disease incidence. From the transfer experiments, it was evident that B cells were 
not required for disease induction, as the purified CD4 T cells conferred weight 
loss alone. Interestingly however, when B and T cells were co-transferred into 
recipient mice, disease induction occurred on average at 9 weeks, but when T 
cells were injected alone, disease manifestation was evident between 10-12 
weeks. Although ANA have been reported in IBD models, it is thought that B 
cells are generally not important to the disorder (Strober et al., 2002). However, 
it is possible that the presence of B cells was able to accelerate the disease, 
however this would need to be confirmed by further experiments as the difference 
in induction time is subtle.
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As the CD4 cells seemed to be the driving factor behind the disease, it seemed 
likely that the B cells changes were a secondary effect. Certainly, CD4 cells can 
influence B cell function through the action of secreted cytokines including IL-4 
and IL-13 that can induce immunoglobulin (Ig) class switching (Vercelli, 1995). 
Furthermore, CD40L on CD4 T cells can interact with CD40 on the surface of the 
B cell and induce proliferation, Ig production and Ig class switching (Bishop and 
Hostager, 2003). The interaction of activated CD4 T cells with B cells are thought 
to occur in specialised structures within the B cell follicles of secondary lymphoid 
tissue. These areas are termed germinal centres (GC). Moreover, the spontaneous 
formation of GC has been reported in the spleens of mice that suffer from 
autoimmune disorders such as type I diabetes and a lupus like syndrome (Luzina 
et al.y 2001). Considering these data it may be of interest to look for the 
spontaneous formation of GC in the spleens LckInd Fyn 7' mice. B cells within 
these areas are generally B220+ PNA+ GL-7+ (Luzina et al., 2001) and can be 
visualised using immunohistochemistry (Hasegawa et al., 2004). Furthermore, it 
may be informative to transfer CD4 cells from LckInd Fyn'7' mice into TC R a'7' 
mice and look at the influence these transferred T cells have on B cell function. 
Conversley, we could also transfer B cells from LckInd Fyn’7' mice into pMT mice 
that lack B cells and see if we can induce disease. These experiments would 
answer if B cell disregulation in the LckInd Fyn'7' mice was a direct result of altered 
T cell function. Lastly, it may be informative to look at the expression of CD40L 
on the CD4 cells from Lcklnd Fyn7' mice. If CD40L levels are increased in LckInd 
Fyn'7' mice it may explain why the B cell population is disregulated.
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Although data showing phenotypic differences in the CD4 population may 
suggest that the IBD-like disorder we observe in LckInd Fyn'7' mice is a Type I 
model of mucosal inflammation, it is also possible that it could be a class II 
disorder, or even a composite of both. We could see the presence of putative CD4 
CD25+ Treg cells in our healthy LckInd Fyn'7' mice at similar frequencies to B6 
controls. However, what is not clear is whether the IBD was caused by a lack of 
suppressive function, or because the CD4 cell expansion overwhelms their ability 
to regulate. In terms of the former idea, studies have shown that these cells may 
exert effects by cell-cell contacts (Nakamura et al., 2001; Thornton and Shevach, 
1998) that would presumably involve some form of receptor engagement that 
could require Fyn and Lck functions. Therefore, the loss of Fyn, and the 
reduction in Lck levels may prevent the CD4 CD25+ Treg cells from suppressing. 
Although our data shows that the number of CD4 CD25+ cells expanded with 
disease, it was not clear if these cells represented newly activated CD4 cells, or 
whether they were infact Treg cells. In any case, it is clear that these cells fail to 
control the immune response in the Lck1*1 Fyn'7' mice. We are currently addressing 
the phenotype and function of Treg cells from LckInd Fyn'7' mice to determine of 
they possess suppressive capabilities. Furthermore, it may be interesting to 
transfer Treg cells from WT mice into LckInd Fyn'7' mice showing signs of sickness 
to determine if disease could be ameliorated.
It is possible that the accumulation of these activated effector/memory type 
CD44hi CD62L10 CD45RBhi CD4 cells in sick mice is influenced by defective 
AICD mechanisms that would normally facilitate the removal these cells (Green 
et al., 2003). For example, studies suggest that Lck is essential to the induction of
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AICD in cycling T cells after ligation of the TCR (Yu et al., 2004). Furthermore, 
as mentioned in Chapter 3, Fyn has been shown to physically associate with the 
cytoplasmic tail of Fas (Atkinson et al., 1996), and there is a report suggesting 
Fyn7' cells are resistant to Fas-mediated AICD (Ricci et al., 2001). Certainly, 
Ipr/lpr mice that have non-functional Fas, and gldJgld mice with a FasL mutation 
both suffer from autoimmunity and lymphoproliferation (Lynch et al., 1994; 
Takahashi et al., 1994; Watanabe-Fukunaga et al., 1992). Therefore, it may be of 
interest to induce AICD in these cells ex vivo with antibodies against the Fas 
receptor, or using anti-CD3 stimulation of pre-activated T cells.
Finally, another intruiging pehonotype that requires further analysis is the 
observation that Lck1"1 Fyn 7' mice often presented with a constant shaking of the 
head, and also the manifestation of varying degrees of hind leg paralysis (data not 
shown). This suggested that there may also be a neurological component to the 
disease that resembles experimental autoimmune encephalomyelitis (EAE). As 
EAE is though to be caused by infiltrating CD4 cells (Segal, 2003), it will be of 
interest to assess the presence of CD4 cells in brain sections of symptomatic 
LckInd Fyn'7' mice using immunohistochemistry.
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Figure 6.1: Overview of the Lck1*1 system and protein expression patterns
Lck expression is regulated in the lymphoid system of our mice by the tetracycline- 
responsive gene induction system. Briefly, when the tetracycline derivative 
Doxycycline is present, the constitutively expressed rtTA protein is able to bind to the 
tet-response element upstream of the minimal CMV promoter and drive expression of 
the Lck transgene (A). While expression of Lck using this system is comparable to 
WT Lck levels in the thymus (B, left panels), peripheral expression is reduced to 
~20% of WT (B, right panels). When Lck1"1 Fyn 7' mice were fed 3 mg/g Dox food, 
they had to be culled due to rapid weight loss (C). However, Dox food did not affect 
the weight of mice of any other genetic background. Figures A and B are adapted 
from data supplied by Dr Ben Seddon and Dr Matthew Lovatt.
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Figure 6.2: Wasting disease is only evident in mice with reduced Lck expression 
and no Fyn
Groups of 4-week-old mice (as indicated) were weighed and then monitored for signs 
of weight loss over a period of 24 weeks. Graph A shows the weight changes in the 
mice expressed as the percentage of the starting weight, when this value dropped to 
~85%, mice were culled for analysis. The GI tract was removed and photographed
(B) under lOx magnification through a standard light microscope with digital camera 
attachment Regions of swelling are marked with a white arrow. The gut was fixed in 
Bouins solution, embedded in paraffin, sectioned, and subjected to H & E staining
(C). Areas containing cell infiltrate are marked with white arrows.
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Figure 6.3: Sick mice possess enlarged LN and increased T cell numbers
The cervical lymph nodes (A) from individual mice (as indicated) are shown. Cells 
from the PLN (B and C), and the MLN (D and E) were then analysed by FACS for 
the expression of the TCR (B and D). The frequencies obtained by FACS are 
indicated and were used to calculate the total number of T cells present in the PLN
(C) and MLN (D) and are expressed as a function of age. For the LckInd Fyn ;" mice n 
= 24; for the B6  mice, n = 14.
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Figure 6.4: Sick mice exhibit an increase in CD4 cell numbers
FACS analysis was used to determine the frequency of CD4 and CD8 T cells in the 
PLN (A) and MLN (D) of the indicated mice, the percentages of cells within the gates 
are shown. These frequencies were used to calculate the total numbers of CD4 cells 
in the PLN (B) and MLN (E), as well as the number of CD8 cells in the PLN (C) and 
MLN (F), are shown as a function of mouse age. For the LckInd Fyn'7' mice, n = 24; for 
the B6  mice, n = 14.
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Figure 6.5: There is an expansion of memory CD4 cells in the LN of sick mice
FACS analysis was used to determine the frequencies of naive (CD44‘°) and memory 
(CD44hi) CD4 cells in the PLN (A) and MLN (D) of the indicated groups of mice. 
The frequencies are indicated on the plots. These values were then used to calculate 
the total number of naive (B and E) CD4 cells and memory CD4 cells (C and F) in 
the PLN (B and C) and MLN (E and F) plotted against the age of the mice. For the 
LckInd Fyn 7 mice, n = 24; for the B6  mice, n = 14.
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Figure 6.6: Sick mice show no clonal outgrowth, but cells have an activated 
phenotype
FACS analysis was used to determine the % of TCR+ CD4+ cells that were expressing 
a given Vp TCR chain (A). The values plotted are the mean ± SD where n = 6  for all 
the groups of mice. The ability of TCR+ CD4+ cells to make IL-2 (B) and IFNy (C) 
upon ex vivo restimulation with PdbU and ionomycin was assessed using intracellular 
staining and FACS analysis. Gate were set using isotype matched control antibodies. 
The expression of CD62L and CD45RB was determined by FACS (D), gates were set 
using naive cell from a B6  mouse (as indicated). The percentages of cells within each 
quadrant is shown. Finally, expression of CD5 was also measured by FACS and the 
MFI of CD5 expression is indicated in the top left of the plot (E). All plots are 
representative of 10 individual mice per group.
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Figure 6.7: Sick mice possess increased numbers of CD4 CD25* cells in the LN
Cells from the PLN (A) and MLN (C) were analysed by FACS for the expression of 
CD4 and CD25. The FACS plots shown are gated on TCR+ CD4+ cells and the 
frequencies of CD25+ cells are indicated. These values were then used to calculate 
the total number of CD4 CD25+ cells in the PLN (B) and MLN (C) and plotted 
against the age of the indicated mice. For the LckInd Fyn'7' mice, n = 24; for the B6 
mice, n = 14.
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Figure 6.8: Sick mice show increased B cell numbers, IgE levels and ANA with
age
The total number of B cells from the PLN (A), MLN (B) and spleen (C) was 
calculated by determining the frequency of B2207CD19+ cells by FACS. For this 
analysis, n = 24 for the LckInd Fyn'7' mice, and n = 14 for the B6  mice. Serum was 
collected from the indicated mice and analysed by ELISA for Ig levels (D). OD 
values were converted to pg/ml using a standard curve for each isotype measured. 
Values are expressed as the mean ± SD, where n = 8 for the B6  and LckInd Fyn 7' mice 
greater than 4 weeks of age. For LckInd Fyn'7' mice less than 4 weeks, n = 3. The 
level of serum IgE was also determined by ELISA (E) and plotted as the OD 450nm 
versus the age of the mouse. In this experiment n = 3 for the B6  mice, and n = 16 for 
the Lck1*1 Fyn'7' mice. Lastly, the level of ANA (OD 405nm) was determined in the 
sera of LckInd Fyn'7' mice (n = 16) and B6  mice (n = 3) and plotted versus age (F), 
values for positive and negative control sera are shown on the left of the plot.
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Figure 6.9 Continual Lck expression is required for disease pathogenesis
A litter of LckInd Fyn 7' mice (n = 6 ) were kept on Dox up to 4 weeks of age then taken 
off Dox for 6  weeks. Mice were weighed the day prior to Dox re-exposure and every 
other day subsequently (A). Any weight changes were expressed as the % of the 
starting weight. Mice were also bled and the frequency of CD4+ CD44+ PBL was 
determined by FACS (B). To determine if the removal of Dox could induce recovery 
after disease manifestation, Lck1*1 Fyn'A mice (n = 6 ) were fed Dox till the body 
weight was ~90% of the initial value (indicated by broken line) and then were 
switched to regular diet and subsequently weighed (C).
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Figure 6.10 Lcklnd Fyn'7' cells are able to transfer disease to Rag-1'7' hosts
Cells from the LN of LckInd Fyn7' or LckInd Fyn WT mice (as indicated) were 
transferred to Rag-1'7' recipients and the weight (A) and frequency of CD4+ PBL (B) 
was determined over time. At the end of the time course, mice were sacrificed and 
the total number of TCR+ cells was determined in the PLN, MLN and spleen (C) 
using FACS analysis. These cells were then phenotyped using FACS analysis (D) for 
the ability to produce cytokines after restimulation (upper panels), CD45RB/CD62L 
expression (middle panels) and CD5 levels (lower panels). The frequencies for IL- 
2/IFNyand CD62L/CD45RB expression are shown, as well as the MFI of CD5 
levels. These plots are representative of the three animals per treatment group.
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Figure 6.11: The disease can be transferred by memory and naive CD4 Lck,nd 
Fyn"7' cells into Rag-1'7' hosts.
CD4 cells from LckInd Fyn WT and Lcklnd Fyn7 mice were purified from animals 
showing no signs of disease. Total CD4 cells from both groups were injected into 
Rag-1'7' recipients. In addition, CD4 cells from LckInd Fyn'7' mice were also divided 
into naive and memory subsets on the basis of CD44 expression and injected into 
recipients. After 24 hours, recipient mice were bled and the PBL were analysed by 
FACS for the expression of CD4 and CD44 (A). The weights of the recipient mice 
were monitored over time (B) and expressed as a percentage of the initial weight. Ex 
vivo cells from the indicated mice were analysed by FACS for the expression of 
CD62L/CD45RB (upper panels, the percentage of cells within each quadrant are 
shown ) and CD5 (lower panels, the MFI of CD5 expression is indicated). These 
cells were also restimulated with PdbU and ionomycin for the detection of 
intracellular IL-2/IFNy by FACS (D). Plot are gated on CD4+ CD45RB‘° (left 
panels) or CD4+ CD45RBU (right panels). These plots are representative of the three 
mice per group.
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Figure 6.12: A model of how Lck and Fyn could affect signal initiation 
and regulation in T cells
The work presented in this thesis and that of others suggest that Lck and Fyn can both 
contribute to both the initiation and termination of a response (A). This observation 
stems from the activation of Lck'7' and Fyn'7' cells. In the absence of Fyn, activation is 
not compromised, however the response is prolonged, in contrast the loss of Lck 
affects the activation signal (B). In the LckInd system, we feel that the reduced Lck 
level is unable to downregulate the response, however this is masked by the presence 
of Fyn. If Fyn is removed, then the reduced Lck levels can drive an activation signal, 
but the inability to regulate the response is now revealed.
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Chapter 7: Concluding remarks
The overall aim of this thesis was to determine the role of Fyn in T cell activation in 
response to antigen. The data presented here has revealed a unique and as yet 
unappreciated role for Fyn in the regulation of T cell responses, both in vitro and in 
vivo. Our data suggests that the ability of Fyn'7' CD8 cells to regulate the activation 
signal is disregulated in comparison to when Fyn is present. This manifests itself as 
an increased ability to produce IL-2, as production of this cytokine has been shown to 
require a more prolonged period of activation than the expression of activation 
markers. However the activation of Fyn'7' cells did not seem to continue ad finitum  
after triggering because not every CD8 cell was subsequently able to become an IL-2 
producer. This suggested to us that the signal was still being terminated in the 
absence of Fyn, but possibly not with the same rapidity or efficiency.
The main question remaining from the work presented here is to determine the 
molecular mechanism of how this could be occurring. As discussed in Chapter 3, 
Lck and Fyn are regulated in part by their phosphorylation status via the 
PAG/Csk/PEP protein complex found within GEMS. The importance of PAG 
phosphorylation is underscored by the fact that in its absence, both Csk and PEP are 
released from the GEMS, where the majority of Src kinase activity is also found 
(Torgersen et al., 2001). Yasuda et al showed that while Fyn'7' cells had defective 
PAG Tyr317 phosphorylation compared to WT cells, it was still detectable (Yasuda 
et al., 2002). This suggests that another kinase is capable of carrying out this action,
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but with less efficiency than Fyn itself. Lck has also been shown to phosphorylate 
PAG using in vitro kinase assays, whereas Syk and ZAP-70 could not (Brdicka et al., 
2000). Considering all these data, it is possible that the reason for the increase in IL- 
2 production in the absence of Fyn is due to an increase in the period of Lck 
activation leading to a more prolonged period of signalling. In this model (Figure 
4.12), activation of Fyn‘;' T cells would lead to the loss of the weak Tyr 317 
phosphorylation of PAG, allowing Lck to become activated and transduce a 
stimulatory signal. However, without Fyn present, Lck activity would continue for 
an expanded window of time due to the inefficient rephosphorylation and assembly of 
the PAG/Csk/PEP complex, possibly by Lck itself. Indeed work by Fillip et al has 
suggested that the majority of Lck is found outside the GEM in a resting T cell but 
that Fyn is found within theses lipid domains. This presumably acts to maintain PAG 
Tyr 317 phosphorylation and keep the T cell inactive, as it is possible to detect 
residual Fyn kinase activity in resting T cells (Filipp et al., 2003; Yasuda et al., 2002; 
Haughn et al., 1998). Upon stimulation Lck rapidly translocates into GEMS and may 
be responsible directly or indirectly for increasing Fyn activity (Filipp et al., 2004; 
Filipp et al., 2003). This is interesting as it supports the idea that Fyn may act as part 
of a negative feedback loop to control Lck activity, that is only required when and if 
Lck is also activated. It is possible that in the absence of Fyn, Lck can phosphorylate 
Tyr 317 of PAG, but less efficiently than Fyn, as it has to translocate to the GEM in 
order to encounter PAG. In contrast Fyn is already present there regardless of the T 
cell activation status. It is also possible that the movement of Lck in an out of the 
GEM is an extremely dynamic process, explaining why PAG Tyr 317
phosphorylation is reduced, as Lck may only access PAG intermittently. 
Furthermore, this reduction in efficiency may also be due to the fact that the SH3 
domain of Fyn seems to preferentially associate with a proline rich region of PAG 
(Marie-Cardine et al., 1999), and may reflect differences in substrate specificity 
between the SH3 domains of Lck and Fyn. Certainly, the SH3 domain of Fyn has 
been shown to be able to recognise atypical motifs in target proteins including SAP 
(Latour et al., 2003) and SKAP55 (Kang et al., 2000). It would be interesting to 
determine if Lck can interact with PAG in the absence of Fyn, and whether the 
interaction is indeed less efficient.
This model of defective PAG phosphorylation could also offer an explanation for the 
lymphoproliferative phenotype observed in mice that express no Fyn and reduced 
Lck (Chapter 6 ). The reduced level of Lck, while clearly sufficient to transduce 
activation signals, may not be able to mediate the rephosphorylation of PAG Tyr 317. 
In a WT mouse, not all Lck is co-receptor associated (Bonnard et al., 1997), however 
the functional roles of co-receptor and free pools of Lck have not been elucidated. 
Work form our lab has shown that the Lck protein expressed in the Lcklnd mice is 
CD4 associated (Lovatt et al., manuscript submitted) and this may mean that the non- 
co-receptor pool is reduced. It is possible that the absence of non-coreceptor 
associated Lck in the LckInd Fyn'7' mice may contribute to the inability of Lck to 
effectively substitute for the loss of Fyn in downmodulating a response. The free Lck 
may be more able to associate with PAG and phosphorylate Tyr 317, mediating 
assembly of the PAG/Csk/PEP complex. The remaining Lck in the LckInd Fyn7 T
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cells could subsequently be disregulated and not subject to the same stringent 
regulation. This could lead to the conversion of a survival signal delivered by self- 
pMHC interactions into a proliferative one. In this model, one would expect to be 
unable to detect any PAG Tyr 317 phosphorylation in a resting naive T cell from the 
Lck1*1 Fyn '" mice. Furthermore, one may expect that the small amount of Lck present 
would be in a state of disregulation, as judged by a lack of Tyr 505 phosphorylation 
and an increase in Tyr 394 phosphorylation. We plan to look at this in future 
experiments.
It is unlikely that the putative absence of PAG Tyr 317 phosphorylation in the sick 
mice is solely responsible for this phenotype because PAG '7 mice are reported to 
remain healthy (Dr J Lindquist, personal communication). However, PAG also 
contains 10 Tyr residues that can be phosphorylated, 6  of which are arranged into an 
atypical ITAM motif (Lindquist et a l , 2003). Therefore it is possible that some 
residues may mediate different functions, some positive and some negative with 
respect to T cell activation. Interestingly, when we IP PAG from CD4 cells of the 
sick LckInd Fyn 7' mice and probe for total phosphotyrosine using the 4G10 mAb, we 
observed an increase in the total phosphorylation of PAG compared to controls that 
include Lcklnd, B6  and Fyn7 CD4 cells (data not shown). However, there were more 
CD44hi cells in the CD4 population isolated from LckInd Fyn'7' mice and this may have 
contributed to the differences observed. It is possible that there is a defect in the 
phosphorylation of Tyr 317 that would be masked by an increase in the signal from 
other Tyr residues, and that the increase in phosphorylation of other Tyr residues may
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play some inductive role in the T cell lymphoproliferation explaining why PAG'7' 
mice remain healthy. We plan to look at this directly using a pTyr 317-specific 
antibody.
Another explanation as to why PAG'7' mice remain healthy is the fact that the adapter 
molecule LIME has also been shown to bind Csk/PEP complexes (Brdickova et al., 
2003). Furthermore, it is thought that LIME phosphorylation is mediated by Lck, and 
in the absence of PAG, LIME may also be able to also regulate Src kinase signalling. 
Interestingly, when LIME is phosphorylated, the SH2 domain of Lck can bind to it. 
The result of this interaction is that even though Csk can phosphorylate Tyr505 on 
Lck, the kinase domain remains open as the SH2 domain is bound to phospho-LIME. 
Therefore, LIME may only be able to allow PEP to dephosphorylate the kinase 
promoting Tyr394 of Lck, but prevents molecular closure from occurring. The net 
result of this may be some residual Lck kinase activity. From these data, one could 
hypothesis that the ability of LIME/Csk/PEP complex to regulate a signal may not be 
as effective as the PAG/Csk/PEP complex. Considering these data it may be of 
interest to look at the role of LIME in both the F5 CD8 Fyn'7' and CD4 cells from the 
L c k 1* 1 p y j j - / -  systems. This model is further complicated by the fact that LAT also 
binds Csk/PEP complexes and also Lck within the GEMs (Kabouridis, 2003).
The data presented in this thesis shows that Fyn deficiency has two very different 
outcomes depending on the level of Lck also present. In one situation where we have 
no Fyn but WT Lck levels, it could be argued that Fyn deficiency is beneficial to the
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generation of a CTL response by virtue of the increase in autocrine IL-2 production 
(Chapter 5). This is an interesting observation as IL-2 therapy has been used as a 
treatment for cancer to improve the activity of CTL responses against tumour cells in 
mouse models and human clinical trials (Radny et al., 2003; Shrikant and Mescher, 
2002; Rosenberg et al.y 1985). The success has been variable, as large does 
administration of recombinant IL-2 has led to life threatening disorders in patients 
such as capillary leakage syndrome (Rosenstein et al., 1986). It is thought that this 
may be due to the fact that the administration of IL-2 is far from localised and will 
not only influence CD8 cells. In terms of the use of mouse models, situations where 
the tumour has been engineered to secrete localised IL-2 has led to improved CTL 
activity and clearance of the tumour (Schweighoffer et al., 1996; Boyer et al., 1995). 
Furthermore, studies have attempted to transfect the tumour infiltrating T cells 
themselves with an IL-2 transgene to overcome localisation problems (Liu and 
Rosenberg, 2003). If we could look in future at the ability of F5 Fyn ; mice to deal 
with persistent antigens such as tumour cells expressing the NP68 peptide, we may 
expect that in the absence of Fyn, survival and control of tumour growth may be 
improved compared to Fyn sufficient controls.
IL-2 therapy has also been used in clinical trial to treat HIV infection in conjunction 
with HAART (Martinez-Marino et al., 2004a; Martinez-Marino et al., 2004b; Kovacs 
et al., 2001; Kovacs et al., 1996). With HIV infection, although the immune system 
is considered to be in a perpetual state of chronic activation, CTL function may be 
impaired as HIV specific CD8 cells possess very little Perforin (Andersson et al.,
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1999) and cytolytic activity (Appay et al., 2000; Shankar et al., 2000; Gray et al., 
1999; Trimble and Lieberman, 1998). As discussed in Chapter 5, the production of 
IL-2 by CD8 cells and the subsequent expression of Perforin could be the limiting 
factor in terms of the duration and effectiveness of a CTL response. While autocrine 
IL-2 consumption is able to generate CTL, sustained responses against persistent 
infections such as HIV may require CD4 help in the form either paracrine IL-2 or 
indirectly via CD40-CD40L interactions (Schoenberger et al., 1998). In HIV 
patients, CD4 numbers decline over time, therefore the help that sustained CTL 
function would need may also be diminished. As our data has shown in the F5 
system that in the absence of CD4 cells, IL-2 plays a significant part in the 
generation/function of CTL. Therefore, the administration of exogenous IL-2 is 
thought to act to sustain CTL function by regulating Perforin expression in HIV 
treatment
Interestingly, elevated Fyn activity has been reported in CD8 T cells from HIV 
infected individuals (Phipps et al., 1997; Phipps et al., 1996). Although primarily 
thought to infect CD4 cells, there is accumulating evidence that HIV can also infect 
CD8 cells (Saha et al., 2001; Flamand et al., 1998; Yang et al., 1998; Livingstone et 
al., 19%; Mercure et al., 1993), furthermore the NEF protein of HIV can interact 
with the SH3 domain of Src kinases (Collette et al., 1996), including Fyn (Arold et 
al., 1997). There could be functional significance to this interaction because, as well 
as the intramolecular association of the C-termini Tyr residue with the SH2 domain, it 
has also been shown that the SH2-CD linker region between the SH2 and kinase
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domains can associate with the SH3 domain and stabilise the closed molecular 
conformation that interferes with kinase activity (Gonfloni et al., 1997). While the 
mechanisms controlling this are unclear (Briggs et al., 2000), it is interesting that the 
NEF protein has been shown to displace this interaction in vitro, due to the presence 
of a PxxP motif (Moarefi et al., 1997). Therefore binding of the NEF protein to the 
SH3 domain of Fyn may reflect a mechanism by which the virus elevates Fyn activity 
by preventing the SH3 domain from interfering with catalytic site. Certainly, the 
recently described activator of Lck and Fyn, Uncl99, has been shown to act in a 
similar manner (Gorska et al., 2004). In terms of our findings, this would presumably 
reduce IL-2 production and affect CD4 independent CTL function. Therefore the 
combination of putative increased Fyn kinase activity coupled with the loss of CD4 
cell numbers may contribute to a failure to generate long lasting CTL activity, 
making the ability to boost IL-2 production by CD8 cells especially relevant in CD4 
depleted environments. However, it should also be noted that the role of Src kinases 
in HIV pathogenesis still remains to be fully elucidated as there are also reports 
suggesting that the activity of these molecules are in fact reduced in HIV infected 
individuals (Guntermann et al., 1997; Morio et al., 1997).
Considering that an increase in CTL activity could be beneficial in HIV and cancer 
treatments, it may be of interest to consider situations where Fyn activity could be 
inhibited by a pharmacological reagent. This could possibly both increase and 
prolong a CTL response by elevating IL-2 production, mimicking the effect of IL-2 
therapy. However, it would have certain advantages over the administration of IL-2
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to patients. For example as the increase in IL-2 production would in theory be CD8 
cell specific and highly localised, therefore it may overcome any potential toxicity 
problems resulting from high doses of IL-2. Furthermore, there are studies that 
suggest that the period of IL-2 administration during an immune response is critical 
as it may even have a detrimental effect on memory T cell survival (Dai et al., 2000; 
Ku et al., 2000 ), and may be most beneficial during the contraction phase of a 
response (Blattman et al., 2003). Inhibition of Fyn in CD8 cells may overcome this 
problem as the window of IL-2 production would not be grossly different from Fyn 
sufficient cells and thus the period of IL-2 exposure for the CD8 cells should not be 
changed.
As discussed in Chapters 3 and 4, Fyn may regulate the induction of anergy in CD8 T 
cells (Welke and Zavazava, 2002; Utting et al., 2001; Utting et al., 2000; Gajewski et 
al., 1994). In situations where antigen persists, studies have suggested CD8 cells 
become anergic (Ehl et al., 1998), and this may contribute to the failure of CTL 
responses in HIV and cancer. Therefore, selective inhibition of Fyn may be able to 
break this anergic state and allow CTL function to continue indefinitely; something 
that would be especially beneficial to HIV treatment. Moreover, the pharmacological 
targeting of a host cellular protein such as Fyn, as opposed to a viral protein that is 
subject to high rate mutation may overcome the problems with drug resistance that 
has become so prevalent in HIV infection management.
335
There are however a number of caveats to this idea. Firstly, inhibition of Fyn would 
presumably also affect other cell types that require this kinase to be active. Mast cells 
also express Fyn, however it seems to be important for transducing degranulation 
signals (Parravicini et al., 2002), and therefore inhibition may not be detrimental in 
terms of an anti-viral response. In CD4 cells, Fyn seems to play a role in regulating 
the production of Th2 cytokines (Cannons et al., 2004; Davidson et al., 2004). 
Again, in terms of viral clearance there may be a preferential skewing to Thl type 
CD4 cells and the loss of Fyn did not seem to affect IFNy production by these cells 
after Thl polarisation (Cannons et al., 2004; Davidson et al., 2004). The role of Fyn 
in B-cells has not been fully elucidated, however Fyn deficiency does not seem to 
lead to any overt phenotype (Horikawa et al., 1999). The splice variant FynB is also 
expressed in the brain, in a form that utilises exon 7A of the Fyn gene leading to 
alterations in the kinase domains of FynT and FynB (Davidson et al., 1994). FynB 
deficient mice have been shown to have defects in the myelination of 
oligodendricytes (Sperber et al., 2001; Osterhout et al., 1999; Umemori et al., 1999) 
and also exhibit a number of behavioural defects such as increased fear responses 
(Miyakawa et al., 1994). While it could, in theory, be possible to develop an 
inhibitor that would only exert an effect of FynT, the blood/brain barrier may prevent 
any compound from being able to target FynB. However, one major obstacle to the 
use of Fyn inhibitors to boost CTL function may be the need for specific cell type 
delivery to CD8 cells.
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In any case, it may be beneficial to use a Fyn inhibitor for short periods. For 
example, current IL-2 therapy for the treatment of HIV involves the administration of 
this cytokine during an STI (structured antiviral therapy interruption) of HAART 
(Smith et a/., 2000). In this case, viral replication is no longer pharmacologically 
suppressed and viral loads begin to peak again. However, the magnitude of this peak 
was inversely proportional to the CTL response mounted by the patient during the 
STL Therefore IL-2 treatment during this period is thought to boost CTL function 
eventually leading to a lower, stabilised viral load. It may be possible to use an 
inhibitor of Fyn in the same manner and assess the impact on CTL function by virtue 
of the steady state viral load achieved. However, there are suggestions from our data, 
that while primary effector function may be increased, memory CD8 generation could 
be compromised in our system in the absence of Fyn. This would also need to be 
considered in terms of disease management
The major caveat to the use of pharmacological Fyn inhibitors would be the degree of 
Src kinase specificity. While Fyn deficiency could be argued as beneficial to CTL 
responses, if Lck expression / activity was also reduced by the inhibitor we may then 
generate a situation resembling the LckInd Fyn'7' mouse disease model. Therefore, any 
Fyn inhibitor would have to have a high degree of specificity and not interfere with 
the actions of Lck. There are structural differences between Fyn and Lck that could 
be exploited to produce a compound that may inhibit action of one and not the other. 
For example the primary sequence of the SH2-CD linker places these two kinases 
into two different phylogenetic groups (Williams et al., 1998). Furthermore this
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linker region may mediate the specific interaction of Fyn with the molecule SAM68 
(Feuillet et al., 2002). If the binding of NEF to this region is responsible for 
increasing Fyn kinase activity and rendering CD8 cells anergic, then designing a 
small molecule inhibitor that could prevent NEF binding to the SH-2-CD linker of 
Fyn without affecting molecular conformation may be a possible strategy. 
Alternatively, it may also be possible to target Fyn specifically by virtue of the 
unique region, as this would presumably not affect Lck function, as there is no 
sequence similarity within these domains.
There are two possible ways to look at the use of Fyn inhibitors as a way of boosting 
an immune response. As mentioned previously, in terms of a response against a virus 
or cancer cell it may prove beneficial to boost a CTL response. However, in 
situations of autoimmunity where the focus of the immune system is turned toward 
self, the loss of Fyn may prove detrimental to the host. Certainly, this was the case 
when we introduced Fyn deficiency into mice that expressed reduced Lck levels. We 
are currently planning to look at the role of Fyn in a number of experimental 
autoimmune models to see if a deficiency in this kinase will exacerbate the disease.
Considering the potential positive and negative effects that Fyn could have on an 
immune response it will be essential to determine the downstream targets of Fyn, and 
furthermore, what the contributions of the SH2, SH3, SH4 and kinase domains are to 
these processes.
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